Association between Cancer and the Detection and Management of Comorbid Health Conditions among Elderly Men with Prostate Cancer in the United States by Yeh, Wei-Shi
 i 
ASSOCIATION BETWEEN CANCER AND THE DETECTION AND MANAGEMENT OF 
COMORBID HEALTH CONDITIONS AMONG ELDERLY MEN WITH PROSTATE 






A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 














Andrea K. Biddle 
William R. Carpenter 
Paul A. Godley 
Stephen W. Marshall 













































ALL RIGHTS RESERVED 
 iii 
ABSTRACT 
Association between Cancer and the Detection and Management of Comorbid Health 
Conditions among Elderly Men with Prostate Cancer in the United States 
(Under the direction of Andrea K. Biddle) 
 
Using the data from the Surveillance, Epidemiology, and End Results registry 
(SEER)-Medicare Program, this dissertation analyzed the longitudinal relationship between 
prostate cancer and comorbid conditions. This study examined the detection and use of 
care for comorbidities among patients who were diagnosed with prostate cancer in 2000. 
The study also assessed racial disparity in survival among the survivors after controlling for 
use of care for non-cancer comorbidities, which have never been controlled for in previous 
cancer survival analyses. 
Prostate cancer survivors not only were more likely to be diagnosed with 
comorbidities, but also received more necessary care for non-cancer conditions after 2000. 
The prevalence rates of chronic obstructive pulmonary disease, diabetes, depression, 
hypercholesterolemia, and hypertension and the overall severity of comorbidities increased 
more among the prostate cancer group than the non-cancer comparison group across time. 
After 2000, prostate cancer survivors were more likely to receive necessary care, especially 
clinical assessment and management of chronic conditions, than individuals without cancer.  
Although these findings did not differ by race, the magnitudes of changes after cancer 
diagnosis were larger among black survivors. 
Black prostate cancer survivors had higher overall, cancer-specific, and non-cancer 
mortality rates than white survivors. Although racial disparities in survival were largely 
explained by racial differences in socioeconomic status and cancer disease information, the 
 iv 
disparities were no longer statistically significant after controlling for comorbidities and use of 
care for non-cancer conditions.  
In conclusion, cancer diagnosis may represent an important opportunity for prostate 
cancer survivors, especially black survivors, to be more aware of their health and to receive 
more necessary care. Efforts to increase early diagnosis, appropriate treatment, and post-
diagnosis use of care among black survivors may be necessary to improve their survival and 
to further eliminate racial disparities in prostate cancer survival. 
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CHAPTER 1. INTRODUCTION 
 
Cancer is a prevalent disease affecting the elderly population in the United States. 
With early detection and effective treatment, cancer is no longer considered a fatal disease. 
Since many cancer survivors eventually die from causes other than cancer, issues related to 
other health conditions also are very important for this population. Comorbidities are 
commonly observed in cancer survivors, especially among elderly survivors (1). The 
presence of other comorbidities not only complicates cancer management decisions, it also 
affects a cancer survivor’s health-related quality of life and survival (2-6). However, previous 
studies have focused on the association between comorbidities at cancer diagnosis and 
patients’ cancer-related outcomes (3-6). The longitudinal effect of cancer on comorbidities 
remains unclear. 
This study analyzed the longitudinal relationship between cancer and comorbidities. 
Specifically, we focused on prostate cancer survivors who comprise the second largest 
cancer population in the United States. Since the majority of prostate cancer patients are at 
least 65 years of age, the co-occurrence of chronic conditions represents an important 
health issue for this population because the majority of them die from causes other than 
cancer (7). The following sections first describe prostate cancer in the United States, racial 
disparity among prostate cancer survivors, and then describe the policy significance, 




1.1 Prostate Cancer in the United States 
Prostate cancer is the most frequently diagnosed cancer among men in the United 
States. It is estimated that more than two million American men have a history of prostate 
cancer (8, 9). A man has an one-in-six chance to develop prostate cancer during his lifetime 
(8). Previous epidemiological studies have concluded that age, race, and a positive family 
disease history are the strongest risk factors for prostate cancer (8, 10-12). Evidence about 
the influence of other factors including hormone level, diary habit, obesity, and physical 
exercise is inconclusive (12). Currently, more than 80 percent of prostate cancer survivors 
are at least 65 years of age (8). Although prostate cancer is the second leading cause of 
cancer-related death (only after lung cancer), the overall 5-year relative survival rate (as 
compared with non-cancer population) is approximately 99 percent (9).  
The prostate specific antigen (PSA) blood test is the most commonly used method to 
detect prostate cancer. The American Cancer Society suggests that PSA test should be 
offered annually beginning at age 50 years to men who have a life expectancy of at least ten 
years (13). The incidence of prostate cancer has increased dramatically as a result of PSA 
testing, the use of which has substantially increased since the mid-1990s (14). However, the 
use of the PSA screening is controversial and equivocal (15-17). At present, more than 90% 
of prostate cancer patients are diagnosed with localized or regional stage cancer, which are 
highly survivable (9). Results from the randomized Prostate, Lung, Colorectal, and Ovarian  
Cancer Screening Trial demonstrated that the mortality rates from prostate cancer did not 
differ between patients who received annual PSA screening or usual care (18). Also, the 
benefits of prostate cancer treatments for localized or regional prostate cancer are 
controversial. At present, radiation therapy or surgery has not resulted in an overall survival 
benefit over watchful waiting (16, 19, 20). However, previous studies found potential 
psychological harms by prostate screening (15, 21) and adverse effects, such as 
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incontinence and erectile dysfunction, caused by cancer treatments (15, 22, 23). Therefore, 
researchers have questioned whether it is necessary to diagnose and treat patients with 
early stage prostate cancer (15-17). 
Since prostate cancer is predominantly survivable, the majority of its survivors die 
from causes other than cancer (9). For many survivors, prostate cancer and its treatment 
may constitute only a fraction of medical history. Other comorbid conditions may play a more 
important role in a survivor’s health, longevity, and physical function. However, the 
comorbidities among prostate cancer survivors have not been the focus of previous cancer 
survivorship research. It is unclear whether comorbidities are more likely to be diagnosis 
after prostate cancer diagnosis. It also is unclear whether survivors receive more necessary 
care for their comorbidities after their prostate cancer diagnosis. 
1.2 Racial Disparity among Prostate Cancer Survivors 
Racial disparity in health outcomes of prostate cancer survivors has been observed 
in many previous studies (8, 9, 24-33). Prostate cancer incidence and mortality rates for 
black men are approximately twice the rates for white men (9). In addition, black men are 
more likely to be diagnosed with advanced prostate cancer than white men and to have 
worse prognosis (31). In North Carolina, one recent study surveyed black and white patients 
within six months of prostate cancer diagnosis to investigate potential explanatory factors 
that might be associated with racial disparity (28). Compared with white patients, black 
patients indicated that they have less access to appropriate care and expressed less trust in 
physicians, both of which may create barriers to timely diagnosis of prostate cancer. 
Racial disparity in survival among prostate cancer survivors has consistently been 
reported in current literature (26, 27, 29-33). Various studies have tried to identify the factors 
that may explain the racial differences in overall and cancer mortality rates. A previous study 
 4 
 
found that the difference in survival between black and white patients is associated with pre-
existing comorbidities (32). However, another study found that even after controlling for 
treatment options and comorbidities, black patients diagnosed with localized prostate cancer 
still have worse overall and prostate cancer-specific survival rates than those rates observed 
in white men (27). A study using California cancer registry data found that racial disparity in 
survival was completely explained by treatment option, stage, grade, year of diagnosis, and 
socioeconomic status (SES) (30). However, other studies using data from national registries 
found that even after controlling for SES, treatment options, and pre-existing comorbidities, 
black survivors diagnosed with localized prostate cancer still had worse overall and prostate 
cancer survival rates than those observed in white men (27, 29). A meta-analysis found that 
black survivors had higher cancer recurrence, prostate cancer mortality and overall mortality 
than white survivors (33). After controlling for comorbidity, type of prostate cancer screening, 
and access to health care, racial differences diminished for overall mortality but remained for 
cancer recurrence and prostate cancer mortality. 
1.3 Policy Significance 
Chronic diseases are prevalent in elderly cancer survivors in the United States. The 
existence of comorbidities may not only influence the choice of cancer treatment, but also 
may affect the health-related quality of life and mortality of cancer survivors. The issues 
related to comorbidities become more important for elderly cancer survivors because the 
majority of them die from causes other than cancer. Understanding the longitudinal 
relationship between comorbidities and cancer is crucial to providing appropriate care for 
cancer survivors. However, although the number of elderly cancer survivors has been 




This dissertation first attempted to assess the influence of prostate cancer on the 
diagnosis of manageable chronic conditions. The results can inform policy makers and 
health care providers about whether cancer diagnosis provides an opportunity for previously 
underdiagnosed comorbidities to be found. In addition, we compared the number of office 
visits by physician specialty and examined whether the new comorbidities are more likely to 
be diagnosed by certain physician specialties. These findings provide information about 
which physician specialty tend to be the main health care provider for prostate cancer 
survivors. 
In the next step, this study examined the use of necessary care for non-cancer 
comorbidities among prostate cancer survivors. We identified the type of necessary care 
that cancer survivors tend to underuse for their non-cancer comorbid conditions. We also 
evaluated the risk factors that are associated with less use of necessary care. The results of 
our analyses can provide policy makers and health care providers information about 
vulnerable cancer survivors who tend to underuse appropriate medical services. By 
examining the relationship between type of health provider and use of care, we may identify 
more effective ways to deliver care to cancer survivors, thus representing the first step to 
figuring out what care is needed and how best to provide it. Our findings provide a reference 
for other researchers to develop prospective studies that examine more effective ways to 
deliver care for cancer survivors.  
Black patients are traditionally a vulnerable population experiencing poor quality of 
care (34-36). Effective control of comorbidity in black cancer patients may help improve life 
expectancy and lead to a reduction in survival disparities (37). However, the use of 
necessary care for non-cancer comorbidities has never been controlled for in previous 
cancer survivorship studies. In this dissertation, we examined not only whether use of 
necessary care is associated with longer survival but also whether racial disparity decreased 
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after controlling for use of necessary care. Since use of necessary care is a potentially 
modifiable factor, the results of this study inform policy makers and health care providers 
whether increasing use of necessary care is an effective way to improve survival and further 
eliminate racial disparity among prostate cancer survivors.  
1.4 Purpose of this Dissertation 
The purpose of this dissertation was to examine the longitudinal relationship between 
prostate cancer and comorbidities. We first analyzed whether comorbidities are more likely 
to be diagnosed after prostate cancer diagnosis. We then evaluated the relationship 
between cancer and the proportion of necessary care that is received across time. We also 
conducted subgroup analyses to evaluate whether the findings from these analyses differ by 
race. Finally, we examined whether racial disparity in mortality remains after controlling for 
time-varying comorbidities, use of necessary care, and other relevant factors. The data were 
obtained from Surveillance, Epidemiology, and End Results registry (SEER)-Medicare 
program.  The specific aims of this study were: 
Aim 1: To evaluate whether the comorbidities are more likely to be diagnosed after 
prostate cancer diagnosis and whether the finding is different by race 
The prevalence of chronic obstructive pulmonary disease (COPD), diabetes, 
depression, hypercholesterolemia, and hypertension was compared before and after the 
cancer diagnosis. Early detection of these comorbidities may lead to better disease control 
by appropriate medical treatments. In addition, we used the Charlson Comorbidity Index 
(CCI) (38, 39) and National Cancer Institute Combined Index (NCICI) (40) to assess the 
severity of comorbidities at different time points. To indentify the main health care provider 
for prostate cancer survivors, we examined the number of office visits by physician specialty. 
We further examined whether the new chronic conditions (i.e., those conditions diagnosed 
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after the cancer diagnosis) tend to be identified by prostate cancer specialists or by primary 
care physicians (PCPs). Finally, we conducted subgroup analyses to examine whether the 
findings from above analyses are different by race.  
Aim 2: To evaluate the longitudinal relationship between prostate cancer and use of 
necessary care and to evaluate whether the finding is different by race   
After cancer diagnosis, survivors may receive more medical services because 
cancer follow-up may provide regular contact with the health care system, increasing the 
chance of receiving appropriate medical care (35). We used the refined Access to Care for 
the Elderly Project (ACE-PRO) indicators to examine the receipt of care for non-cancer 
comorbidities for a maximum of ten years. The use of necessary care for each indicator was 
measured in every two years. We also calculated a composite score that indicates the 
overall use of necessary care during each time period. We examined whether prostate 
cancer survivors used more necessary care after cancer diagnosis. Subgroup analyses 
were conducted to examine whether the findings differ by race. Finally, we used regression 
analyses to identify the risk factors for less use of necessary care. Specifically, we examined 
the relationship between type of care provider (i.e., oncologist or primary care physician) 
and use of necessary care. 
Aim 3: To investigate whether racial disparity in mortality remains after controlling for 
time-varying comorbidities and use of necessary care 
Racial disparity in survival has been observed among prostate cancer survivors.  We 
conducted a survival analysis to examine whether racial disparity in mortality rate remains 
after controlling for time-varying comorbidities (from Aim 1) and use of necessary care (from 
Aim 2), neither of which have been controlled in previous studies. A Cox proportional 
hazards (PH) model was used to evaluate whether black survivors have a higher overall 
mortality rate than the white survivors after controlling for other factors. Since prostate 
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cancer and other causes are competing risks for death, competing-risk models were 
conducted to examine racial disparity in cancer and non-cancer mortality.  
1.5 Structure of this Dissertation 
Chapter 2 first reviews current literature defining cancer survivorship. It also reviews 
approaches to measure comorbidity and use of care for non-cancer health conditions. A 
literature review of behavioral changes after cancer diagnosis and comorbidities among 
cancer survivors also is presented in Chapter 2. These sections are intended to provide 
background on and justification for this dissertation. Finally, a comparison of previous 
studies and the current study is provided at the end of Chapter 2. Chapter 3 describes the 
data source, study sample, and variable definitions of this dissertation. This chapter also 
contains a detailed description of study hypotheses and the analysis plans. Chapters 4-6 are 
individual manuscripts, each of them accomplishing one of the three study aims of this 
dissertation described in Section 1.4. These manuscripts take the place of a single results 
chapter, and each is intended for submission for independent publication. The references for 
the manuscript are combined with other general references in a single bibliography. Chapter 
7 summarizes the findings and limitations of this dissertation and provides recommendations 




CHAPTER 2. LITERATURE REVIEW 
 
2.1 Cancer and American Seniors 
Cancer is a prevalent disease affecting the elderly population. At present, persons 
older than 65 account for approximately two-thirds of newly diagnosed malignancies in the 
United States (9). The availability of effective treatment has significantly extended the life 
expectancy among cancer patients, with approximately 66% of cancer patients surviving 
more than five years beyond the initial cancer diagnosis (9). It is estimated that there are 
more than 10 million cancer survivors in the United States, which represents 3.5% of the 
entire population (9). The number of cancer survivors is expected to continue to grow with 
more early detection, effective treatments, and the aging of the population. From 2000 to 
2050, the absolute number of patients aged 65 and older diagnosed with cancer is expected 




2.2 Cancer Survivorship 
2.2.1 Survivors 
With early detection and effective treatments, cancer survival has improved 
dramatically over the past three decades (9, 23). As a result, the definition of cancer survivor 
has evolved over time. Before 1986, the general medical definition of a cancer survivor was 
a patient who remains disease free for a minimum of five years (23, 42, 43). At present, the 
NCI Office of Cancer Survivorship gives a very broad definition of cancer survivor: “An 
individual is considered a cancer survivor from the time of cancer diagnosis, through the 
balance of his or her life. Family members, friends and caregivers are also impacted by the 
survivorship experience and are therefore included in this definition (44).” In the current 
study, we define patients as cancer survivors from the time of cancer diagnosis. For those 
who survive for more than five years, we measure their health outcomes separately because 
they are considered long-term survivors by the old definition (23). 
2.2.2 Survivorship 
Dr. Fitzhugh Mullan, a physician who was diagnosed with cancer at 32, described 
the survivorship experience as the seasons of the year (45). He depicted three seasons of 
cancer survival: acute, extended, and permanent survival. The acute phase of survival 
proceeds from cancer diagnosis through the completion of primary treatment. The primary 
issues of this phase are cancer treatment and its side effects. The extended phase of 
survival of cancer survivorship begins at the completion of primary cancer treatment, and is 
dominated by watchful waiting, regular follow-up examinations, and intermittent therapy. The 
permanent phase of survival does not represent a single moment but evolves from extended 
disease-free survival when the likelihood of recurrence is sufficiently low. 
2.2.3 Survivorship Research 
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The NCI Office of Cancer Survivorship provides the following definitions for cancer 
survivorship research:  
 
Survivorship research encompasses the physical, psychosocial, and 
economic sequelae of cancer diagnosis and its treatment among both 
pediatric and adult survivors of cancer.  It also includes within its domain, 
issues related to health care delivery, access, and follow up care, as they 
relate to survivors.  Survivorship research focuses on the health and life of a 
person with a history of cancer beyond the acute diagnosis and treatment 
phase.  It seeks to both prevent and control adverse cancer diagnosis and 
treatment-related outcomes such as late effects of treatment, second cancers, 
and poor quality of life, to provide a knowledge base regarding optimal follow-
up care and surveillance of cancers, and to optimize health after cancer 
treatment (44). 
 
Dr. Noreen Aziz, the Senior Program Director of NCI Office of Cancer Survivorship, 
recently reviewed the studies investigating adverse medical outcomes and post-treatment 
follow-up care among long-term cancer survivors (22). She also examined definitional issues, 
research paradigms, and methodological concerns about cancer survivorship research. Dr. 
Aziz found that long-term or late adverse treatment effects commonly are observed in 
pediatric survivors. However, the issues remain relatively understudied among those who 
were diagnosed as adults. She also found that follow-up care relevant to survivorship 
outcomes is neither standardized nor guideline- or evidence-based for most adult cancers, 
and optimal practices have yet to be defined. To date, few studies have compared survivors’ 
health outcomes pre- and post- cancer diagnosis (22). Most of the current literature relevant 
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to this domain is derived from cross-sectional studies and it remains unclear whether the 
adverse symptoms began during treatment or immediately after treatment (22, 43). Dr. Aziz 
recommends that more prospective research be conducted to provide more knowledge 
about symptoms that persist after cancer treatment or arise as late effects and interventions 
that are effective in preventing or controlling them (22). She also emphasizes the 
importance of conducting studies of vulnerable population including older or long-term 
survivors. 
2.3 Comorbidities among Cancer Survivors 
The co-occurrence of comorbidities is an important health issue for cancer survivors, 
especially for the elderly population. At present, most patients who are diagnosed with 
cancer will not die from it (9). Previous studies have found that cancer survivors are at a 
greater risk for other comorbidities than the non-cancer population (6, 46, 47). These 
increased risks may be the results of the side effects or late effects of cancer treatment, 
genetic predisposition, or common lifestyle factors. A population-based study found that 69% 
of cancer patients aged 40 to 84 have at least one chronic condition other than cancer (1). 
Several studies also indicated that the presence of other chronic health conditions may not 
only complicate treatment management, but may negatively affect prognosis and post-
treatment health-related quality of life (3-6). Another study reported that prostate cancer 
patients are more likely to die from non-cancer causes than from cancer itself (32), 
demonstrating the influence of comorbidities and other factors on overall mortality rate and 
cancer-related death. However, the authors did not report the risk factors for death due to 
causes other than cancer (32). 
2.4 Behavioral Changes after Cancer Diagnosis 
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A cancer diagnosis has the potential to have mixed effects on the diagnosis or 
management of other comorbidities. On the one hand, cancer diagnosis may represent “a 
teachable moment” for risk factor reduction because patients tend to be more aware of their 
other health problems after cancer diagnosis (48-50). To prevent cancer recurrence and to 
increase the likelihood of survival, cancer survivors often attempt to quit smoking, to eat 
healthier, and to engage in regular exercise (48-56). Previous studies have found a positive 
effect of these lifestyle changes on health-related outcomes (51, 57, 58). In addition, 
patients may receive more medical services after diagnosis because cancer follow-up may 
provide regular contact with the health care system, increasing the chance of receiving 
appropriate medical care (35). Health care providers also may identify some chronic 
conditions that were underdiagnosed prior to the cancer diagnosis. Therefore, it is possible 
that comorbidities would be better controlled after cancer diagnosis.  
On the other hand, comorbidities may worsen after cancer diagnosis. Long-term and 
late effects of cancer treatments are commonly observed among cancer survivors. For 
example, chemotherapy and radiation therapy may have negative effects on erectile 
function, cardiovascular disease, or mental health (22, 23, 59). In addition, cancer patients 
may not think that the continued management of other comorbidities is as important after 
their cancer diagnosis. Survivors may receive less care for comorbidities because their care 
may consist primarily of specialty care provided by specialist physicians, with little attention 
to primary care needs (36). Insufficient primary care may lead to development of other 
comorbidities or the worsening of existing comorbidities. 
2.5 Risk Adjustment for Comorbidities in Cancer Patients 
The Charlson Comorbidity Index (CCI) is a commonly used measure of comorbidity 
in epidemiologic and outcomes research (38, 39). The measure was originally developed in 
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1987 using 1-year mortality data from internal medicine patients admitted to a single New 
York hospital. The index provides an overall score based on a composite of values assigned 
to 19 medical conditions. Each condition is assigned a score of 1, 2, 3 or 6 depending on the 
risk of dying associated with this condition, and the total score ranges from 0 to 37 with 
higher scores representing increased risk of death. The CCI estimates 1-year risk of 
mortality from specific medical conditions among hospitalized patients and has been 
validated in an evaluation of breast cancer patients (38, 60). The original CCI was designed 
for use with medical records rather than medical claims. Deyo and colleagues adapted the 
index for use with administrative databases by matching the conditions in the CCI to their 
corresponding International Classification of Diseases, 9th Revision, Clinical Modification 
(ICD-9-CM) codes (39). The authors validated the performance of the CCI (Deyo 
modification) in predicting health outcomes in Medicare beneficiaries who underwent lumbar 
spine surgery. 
One of the limitations of the original CCI is that the calculation of index score 
depends solely on the codes obtained from inpatient claims. Therefore, cancer patients who 
have chronic conditions but have not been hospitalized for them during the study period may 
be mistakenly classified as having no comorbidities. To incorporate the medical diagnoses 
from outpatient visits, Klabunde and colleagues developed a new measure (NCI Index) to 
estimate mortality risk of comorbidities specifically using SEER-Medicare data (61). The NCI 
Index adapts the chronic conditions identified by Charlson and colleagues (38) and 
calculates two separate comorbidity scores from inpatient and physician (Medicare Part B) 
claims. Klabunde and her colleagues demonstrated that the NCI Index has better 
performance than the CCI in predicting 2-year, non-cancer mortality among elderly prostate 
and breast cancer patients (61). In addition, the NCI Index weights comorbid conditions 
differently than the CCI, and the conditions weights vary by cancer site. In a subsequent 
study, Baldwin and colleagues demonstrated that the NCI Index has predictive ability similar 
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or equivalent to receipt of chemotherapy and non-cancer mortality for colorectal cancer 
patients when compared to other comorbidity measures (62). 
Based on their previous work, the researchers at the NCI recently developed a new 
measure of comorbidity severity (40). Unlike the NCI Index, which results in two separate 
scores, the NCICI combines comorbid conditions identified from Medicare inpatient and 
physician claims into a single comorbidity index. Researchers can sum the weighted 
conditions to establish a single index and to compare the severity of comorbidities across 
patients. A higher comorbidity score represents a more severe health problem. Klabunde 
and her colleagues compared the performance of the new weighted and un-weighted 
indices with the estimated comorbidity measures in predicting non-cancer mortality (40). 
Compared with the Charlson and un-weighted NCI Combined indices, the NCI Index and 
weighted NCICI showed the best model fits in predicting non-cancer mortality. The NCICI is 
easier to implement and statistically more efficient than the NCI Index because only a single 
comorbidity score is calculated. Different chronic condition weights are estimated for breast, 
colorectal, lung, and prostate cancer patients. To date, most previous studies used the CCI 
to adjust the risk for non-cancer mortality for their cancer survivors (27, 32, 63). To our 
knowledge, none of the published studies has used the NCICI to control for the comorbidity 
severity for cancer survivors. 
2.6 Quality of Care for Comorbidities of Cancer Patients 
Asch and colleagues (34) from the RAND Corporation have developed a 
comprehensive system for measuring underuse of necessary care among elderly patients 
using inpatient and outpatient Medicare claims. A multi-specialty physician panel developed 
46 indicators of necessary care and avoidable outcomes for 15 medical conditions: 1) with a 
high prevalence or incidence among the elderly population, 2) for which effective treatment 
is available, and 3) are identifiable from diagnoses coded on claim data.  Medical conditions 
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include acute myocardial infarction, anemia, angina, breast cancer, cerebrovascular 
accident, cholelithiasis, chronic obstructive pulmonary disease, congestive heart failure, 
depression, diabetes, gastrointestinal bleeding, hip fracture, hypertension, pneumonia, and 
transient ischemic attack.  Necessary care is defined as care for which: 1) the benefits of the 
care outweigh the risks, 2) the benefits to the patients are likely and substantial, and 3) 
physicians have judged that not recommending the care would be inappropriate. Asch and 
colleagues found that among 16 of 40 necessary indicators, Medicare beneficiaries received 
indicated care less than two-thirds of the time.  In addition, blacks were less likely to receive 
adequate necessary care as indicated by 16 of the indicators. 
The ACE-PRO indicators were updated in 2006 to reflect changes in performance 
measurement and clinical practice. The refined ACE-PRO indicators have been tested and 
validated on Medicare claims by Medicare Payment Advisory Commission (MedPAC) (64). 
The refined ACE-PRO consists of 40 indicators for medical conditions covering anemia, 
angina, breast cancer, colorectal cancer, chronic obstructive pulmonary disease, congestive 
heart failure, coronary artery disease, depression, diabetes, gastrointestinal bleeding, 
hypertension, and stroke or transient ischemic attack. Based on the type of care, these 
indicators can be grouped into clinical assessment in chronic condition, management of 
chronic condition, follow-up after hospitalization, possible adverse outcomes avoided, and 
work-up at initial diagnosis. 
Earle and colleagues evaluated the quality of health care of Medicare beneficiaries 
and found that elderly breast cancer survivors received more preventive care than the non-
cancer controls (35), suggesting that breast cancer patients’ enhanced participation in the 
health care system may explain better quality of care. The study used the SEER-Medicare 
data and followed 5-year breast cancer survivors for two years. Compared with matched 
controls, breast cancer survivors were more likely to receive influenza vaccination, lipid 
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testing, cervical and colon screening, and bone densitometry. Elder age, black race, lower 
socioeconomic status, and residing in a rural area were cited as risk factors for underuse of 
preventive care. In addition, seeing both oncology specialists and primary care physicians 
was associated with the use of more preventive care. 
Different findings were reported in colorectal cancer patients. Despite the higher 
prevalence of comorbidities, colorectal cancer survivors tended to underuse adequate 
treatment for their chronic conditions. Earle and Neville adopted the method developed by 
Asch and colleagues to evaluate underuse of necessary care among colorectal cancer 
survivors (36). This study followed 5-year colorectal cancer survivors for two years and 
found that colorectal cancer survivors were less likely to receive preventive care and acute 
interventions for their comorbidities than the non-cancer controls. The study also examined 
other factors that are associated with underuse of care. Patients who received care from 
both oncologists and primary care providers are more likely to use adequate care. Black 
race also was a strong predictor for underuse of care. However, the findings of this study 
may not apply to other types of cancer survivors, such as those with prostate cancer. As well, 
the study only focuses on the use of care for a 2-year period after patients have survived 
their invasive colorectal cancers for five years and colorectal cancer survivors generally do 
not have severe long-term consequences from the cancer or its treatment. Despite this 
research, little is known about whether patients receive adequate care before a cancer 
diagnosis and right after the cancer treatment, or whether underuse of necessary care is 
associated with poor health outcomes in cancer survivors. 
2.7 Comparison between Previous Studies and the Current Study 
The dissertation can expand our knowledge of comorbidities among elderly cancer 
survivors. Our study design has several advantages over previous studies. A comparison 
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between previous studies and the current study is listed in Table 1. Previous studies usually 
measure the prevalence or severity of comorbidities cross-sectionally, either at the time of 
cancer diagnosis or at a certain time point after cancer diagnosis. Our study measured and 
compared the prevalence and severity of comorbidities pre- and post-cancer diagnosis. The 
longitudinal follow-up allowed us to evaluate the influence of cancer diagnosis on 
comorbidities.  Other studies typically use the CCI to control for the severity of comorbidities 
for cancer survivors. Our study measured comorbidity severity using the NCICI, which was 
developed specifically for use with Medicare claims. As well, by including a non-cancer 
comparison group, we were able to control for the effect of aging on comorbidities.   
Table 1. Comparison between previous studies and current study 
Topic Previous studies Current study  
Comorbidities  Cross-sectional 
-  At cancer diagnosis  
-  A time-point after cancer diagnosis 
 Use CCI 
 Examine only cancer survivors 
 Longitudinal 
- Pre- and post-cancer diagnosis 
- Long-term follow-up 
 Use both CCI and NCICI 
 Also includes individuals without  
     cancer 
Use of care  Cross-sectional 
 Breast or colorectal cancer survivors 
 Use the original ACE-PRO indicators 
 Include matched non-cancer controls 
 Longitudinal 
 Prostate cancer survivors 
 Use the refined ACE-PRO indicators 
 Include individuals without cancer 
Racial 
disparity 
 Focus on overall and cancer mortality 
 Use Cox proportional hazards model  
     only 
 Control comorbidity severity at the 
index date with CCI 
 Use of care is not controlled 
 Also focus on non-cancer mortality 
 Use both Cox proportional hazards 
and competing-risk survival models 
 Control time-varying comorbidity 
severity with NCICI 
 Control for use of necessary care 
CCI: Charlson Comorbidity Index; NCICI: National Cancer Institute Combined Index 
 
Previous studies have investigated the level of adequate care among long-term 
breast and colorectal cancer survivors cross-sectionally (i.e., for a 2-year time period) but 
did not analyze the association between use of necessary care and a survivor’s health 
outcomes (35, 36). The original ACE-PRO indicators were used in one of the previous 
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cancer survivorship study (36). In our study, we used the refined ACE-PRO indicators to 
evaluate the receipt of adequate care among prostate cancer survivors and follow them 
longitudinally for a maximum of ten years. We also investigated the risk factors for less use 
of necessary care among prostate cancer patients. Specifically, we examined the 
longitudinal influence of types of care provider on use of care. 
Previous studies, using cross-sectional study design, have observed racial 
differences in prostate cancer patients’ initial comorbidities, access to care, and survival 
rates (27, 31, 32, 65, 66). Our study examined these racial differences in all of our 
longitudinal analyses. We first evaluated the changes in comorbidity severity pre- and post- 
cancer diagnoses and estimate the differences by race. We then examined the racial 
difference in use of necessary care and analyzed whether the difference changed after 
prostate cancer diagnosis. Finally, we investigated whether racial disparity in survival rate 






CHAPTER 3. RESEARCH DESIGN AND METHODS 
 
3.1 Overview 
This dissertation employed data from the SEER-Medicare Program to investigate the 
longitudinal relationship between prostate cancer and comorbidities among elderly prostate 
cancer survivors. We examined the data of prostate cancer survivor and individuals without 
cancer for up to ten years, beginning from 1998 through 2007. Table 2 provides a summary 
of methods used to address the three aims in this dissertation. In Aim 1, we first analyzed 
the unadjusted change in prevalence and severity of comorbidities pre- and post-cancer 
diagnosis. We then conducted Poisson regressions and GEE models to examine the 
changes controlling for other confounders. In Aim 2, we examined how prostate cancer 
survivors use necessary care for their comorbidities and whether this pattern of use 
precedes the cancer diagnosis. Similar to Aim 1, we first evaluated unadjusted use of 
necessary care and then adjusted for other confounders by GEE models. In Aim 3, we 
examined the potential racial disparity in survival among prostate cancer survivors. We first 
compared unadjusted Kaplan Meier survival curves by race. We then evaluated racial 
difference in overall, cancer, and non-cancer mortality after controlling for time-varying 







Table 2. Summary of study designs, methods, and analytical models by study aim 





Cancer and non-cancer groups 
- Is the prevalence of chronic conditions 
higher after cancer diagnosis? 
- Is the severity of comorbidities greater 
after cancer diagnosis? 
- Do cancer survivors make more visits to 
health care providers after diagnosis? 
- Are the new chronic conditions diagnosed 
by prostate cancer specialists or primary 
care physician? 
- Are the findings from the above analyses 
different between black and white men? 
 Unadjusted 
- Chi square test 
- Student’s t test 
 
 Adjusted 
- Poisson regression 
- GEE model 











Use of care for 
comorbidities 
Cancer and non-cancer groups 
- Are cancer survivors more likely to 
receive necessary care for their 
comorbidities? 
- What is the effect of prostate cancer on 
the proportion of necessary care that is 
received? 
- Does the above relationship vary by 
race? 
 Unadjusted 
- Chi square test 
- Student’s t test 
 
 Adjusted 
- GEE model 
 Proportion of patients 
receiving each type of 
necessary care 
 A composite score 
combining similar type 
of care 
 A composite score 
indicating the overall 








Cancer group only 
- Do racial differences in mortality remain 
after controlling for severity of 
comorbidities (from Aim 1) and underuse 
of care (from Aim 2)? 
- What are other risk factors for mortality 
among prostate cancer survivors? 
 Unadjusted  
- Kaplan-Meier survival 
curves 
- Log rank test 
 
 Adjusted 
- Cox proportional 
hazards model 
- Competing-risk model 
 Overall mortality 
 Cancer mortality 
 Non-cancer mortality 
 Race 
 Comorbidity 
 Use of care 
   GEE: General generalized estimating equations; NCICI: National Cancer Institute Combined Index; CCI: Charlson Comorbidity Index
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3.2 Research Hypotheses 
In Aim 1, we examined the longitudinal relationship between prostate cancer and 
diagnosis of other comorbidities. We first examined whether the prevalence and severity of 
comorbidities change differently between cancer and comparison groups after 2000. Since 
patients tend to have more contact with the health care system after cancer diagnosis (35), 
we expected some previously underdiagnosed chronic conditions to be identified. We then 
conducted subgroup analyses to examine whether the findings from these analyses were 
different by race. Previous studies reported that black patients generally have more 
comorbidities (32) but the comorbid conditions are more likely to be underdiagnosed than 
white patients (67). Therefore, we expected the increases in diagnosis comorbid conditions 
were more in black survivors. Finally, we compared the number of office visits by specialty 
among cancer survivors. We expected prostate cancer specialists to become the main 
health care providers for survivors after cancer diagnosis and to provide some primary care. 
In Aim 1, our hypotheses were: 
H1: After 2000, the prevalence and severity of comorbidities increase more among cancer 
survivors than among individuals without cancer 
H2: After cancer diagnosis, the prevalence and severity of comorbidities increase more 
among black survivors than among white survivors 
H3: Survivors make more visits to prostate cancer specialists but fewer visits to PCPs after 
cancer diagnosis 
H4: New comorbidities identified after cancer diagnosis are more likely to be diagnosed by 
prostate cancer specialists than by PCPs. 
 
In Aim 2, we examined the longitudinal relationship between prostate cancer and use 
of necessary care for other comorbid conditions. We compared the proportion of necessary 
care that was received by cancer and non-cancer comparison groups. We expected 
prostate cancer survivors to receive more necessary care because they may have more 
contact with the health care system (35). In subgroup analysis, we expected the black 
survivors to use less necessary care than the white survivors based on the findings from 
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previous literature (34-36). However, we expected the racial difference in use of necessary 
care among cancer survivors decreases after prostate cancer diagnosis. Finally, we 
examined the relationship between type of care provider and use of necessary care. Based 
on the findings from previous literature (35, 36), we expected survivors seeking care from 
both prostate cancer specialists and PCPs to receive more necessary care than those who 
visit prostate cancer specialists only, PCPs only, and neither of them. Our hypotheses were: 
H1: Before 2000, the use of necessary care is not different between cancer and non-cancer 
comparison groups. 
H2: After 2000, cancer group uses more necessary care more than the non-cancer 
comparison group does. 
H3: Black survivors consistently use less necessary care than white survivors 
H4: Racial difference in use of necessary care decreases after cancer diagnosis 
H5: Survivors who visit both prostate cancer specialists and PCPs after cancer diagnosis 
receive more necessary care than those who visit either or neither of them. 
 
 
In Aim 3, we examined the racial disparity in survival among prostate cancer 
survivors after controlling for time-varying comorbidity (from Aim 1) and use of necessary 
care (from Aim 2). We expected that racial differences in overall and cancer mortality would 
remain, but the racial difference in non-cancer mortality would disappear after we control for 
other variables. The hypotheses of Aim 3 were: 
H1: The magnitude of racial disparity in overall mortality decreases after controlling for time-
varying comorbidities and use of necessary care. However, the disparity is still 
statistically significant. 
H2: The magnitude of racial disparity in cancer mortality decreases after controlling for time-
varying comorbidities and use of necessary care. However, the disparity is still 
statistically significant. 
H3: No racial disparity is observed in non-cancer mortality after controlling for time-varying 




3.3 Conceptual Framework 
 
Figure 1. Conceptual model 
 
Figure 1 represents a conceptual model describing the relationship between prostate 
cancer, comorbidities, and use of care. Based on previous literature, patients’ characteristics 
including age, black race, and family disease history are the primary risk factors for prostate 
cancer and also are associated with the prevalence of other comorbidities (8, 10, 11). In 
addition, socioeconomic status (SES), insurance status, and marital status are associated 
with time until diagnosis and the use of care for other comorbidities (25, 28, 31). The 
correlation between cancer treatment and comorbidities are bidirectional. The existence of 
comorbidities will influence the choice of cancer treatment, and the side effects of cancer 
treatment will affect the prevalence and severity of comorbidities (3-6).  
The relationship between cancer and use of necessary care for comorbidities 
remains unclear. Researchers have found that breast cancer survivors are more likely to 











Use of care 
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receive preventive medical care whereas colorectal cancer survivors tend to receive less 
medical services (35, 36). However, the relationship between prostate cancer and the use of 
necessary care remains unstudied. In addition, patients’ age, race, SES, and comorbidities 
have all been shown to be correlated with the underuse of care among cancer survivors (36). 
In previous studies, the type of care provider is shown to be associated with use of 
necessary care (35, 36). 
3.4 Data Source 
3.4.1 SEER Registry 
The Surveillance, Epidemiology, and End Results (SEER) Program of the National 
Cancer Institute (NCI) is an authoritative program collecting information on cancer incidence 
and survival statistics, serving as the only comprehensive source of population-based 
cancer information in the United States (68). After the most recent expansion in 2000, the 
SEER Program reports cancer incidence and survival data from 17 population-based cancer 
registries covering approximately 26 percent of the population. Residents in current SEER 
regions include 23 percent of whites, 23 percent of blacks, 40 percent of Hispanics, 42 
percent of American Indians and Alaska Natives, 53 percent of Asians, and 70 percent of 
Hawaiian/Pacific Islanders in the United States. The SEER Program is considered the 
standard for quality among cancer registries around the world. It routinely collects data on 
patient demographics, primary tumor site, stage at diagnosis, primary course of treatment, 
and cause of death. The SEER Program collects SES information including median 
household economic and educational status (69, 70). These SES variables are aggregate 
measures from the US Census Bureau that reflect the characteristics of census tracts and 
zip codes in which patients resided during the year of their first diagnosis (69). 
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This dissertation used the data from the SEER-17 registries, which cover Arizona 
native Americans, Alaska Natives, nine states (California, Connecticut, Hawaii, Iowa, 
Kentucky, Louisiana, New Jersey, New Mexico, and Utah), and seven regions (Atlanta, 
Detroit, rural Georgia, Los Angeles, San Francisco, San Jose, and Seattle). Data are 
available for all cases diagnosed from 2000 through 2005. 
3.4.2 Medicare Enrollment and Claims Files 
Medicare is the primary health insurer for 97% of the US population ages 65 years 
and older (70). All Medicare beneficiaries receive Part A benefits, which are generally paid 
for by payroll taxes for workers. Approximately 99 percent of Medicare beneficiaries pay no 
premium for Part A services because they have at least 40 quarters of Medicare-covered 
employment (71). Medicare Part A benefits cover inpatient care in hospitals, including critical 
access hospitals, and skilled nursing facilities (but not custodial or long-term care), hospice 
care and some home health care services. Among Medicare Part A beneficiaries, 95% of 
them also pay a monthly premium for the Part B benefits (70). Medicare beneficiaries pay 
premiums for Part B benefits, which cover physician services, outpatient care, durable 
medical equipment, some of the services of physical and occupational therapists, and home 
health in some cases. Medicare claims provide information about comorbidities and use of 
medical services that are the outcomes of interests in this study. 
3.4.3 SEER-Medicare Data 
The SEER-Medicare data are population-based data that combine SEER cancer 
registry information with Medicare enrollment and claims files (70, 72). The linkage of SEER 
program data and Medicare claims was initially completed in 1991 as the result of 
collaboration between the National Cancer Institute, the SEER registries, and Centers of 
Medicare and Medicaid Services (CMS). The current SEER-Medicare data include all 
Medicare-eligible beneficiaries appearing in the SEER registry through December 31, 2005, 
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and their Medicare claims through December 31, 2007 (72). The linkage of SEER and 
Medicare data is relatively complete, with 93% of elderly SEER registrants linked to the 
Medicare enrollment file (70). A beneficiary’s disease diagnoses, treatments, and services 
received are available in the Medicare claims.  However, data are missing for health 
maintenance organization (HMO) enrollees, services not covered by Medicare (i.e., 
outpatient prescription drugs and long term care), services provided  by Veterans Affairs or 
Medicaid, or by Medicare supplement programs (i.e., Medigap) (70).  
At present, the SEER-Medicare data include more than 3.3 million individuals with 
cancer; of whom, approximately 40,000 were diagnosed with prostate cancer in 2000 (72). 
In addition to beneficiaries with cancer, the SEER-Medicare data also include a sample of 
Medicare beneficiaries who do not have cancer. The non-cancer group is drawn from a 
random, 5-percent sample of Medicare beneficiaries living in the SEER regions and 
comprises approximately 400,000 cancer-free individuals. Compared with the overall elderly 
population, elderly adults living in the SEER regions are less likely to be white, to live in 
poverty, and to reside in rural areas (70). In addition, elderly persons in the SEER regions 
also have higher rates of HMO enrollment and lower rates of cancer mortality.   
3.5 Study Sample 
The same study sample was used for both Aims 1 and 2. We included only patients 
who were diagnosed with localized or regional prostate cancer (i.e., Stage I, II, and III) in 
2000 to evaluate the long-term effect of prostate cancer on comorbidities. These patients 
are not likely to die from prostate cancer because their five-year relative survival rate is 
approximately 100% as compared with the non-cancer population (73). Approximately 5% 
prostate cancer patients were excluded from our analysis because of distant prostate cancer, 
which has a five-year relative survival rate of only 32% (73) and because the presence of 
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some comorbidities (e.g., cardiovascular diseases) may be associated with hormonal 
treatment for distant prostate cancer (59). Another 5% of patients were excluded because 
their prostate cancer stage was either missing or unknown. The data of each cancer patient 
were examined for up to ten years, beginning from January 1, 1998, through December 31, 
2007. To be eligible for inclusion in the study, patients must have been enrolled continuously 
in Medicare Part A and Part B during the study period. To observe the presence of 
comorbidities before cancer diagnosis, we included only patients who were diagnosed with 
prostate cancer at age 67 or older as of January 1, 2000, thus allowing for two years of 
observation prior to diagnosis. Medicare beneficiaries who are eligible for Medicare because 
of disability or the presence of end-stage renal disease before age 65 were excluded from 
the analyses. HMO enrollees also were excluded, as services provided by HMOs are not 
included in the SEER–Medicare data. Other exclusion criteria included: prior cancer history, 
diagnosis with a second cancer within six months, noninvasive tumors (i.e., carcinoma in 
situ), unstaged prostate cancer, diagnosis after age 84, diagnosis at death or via autopsy, 
and missing income and education information. Finally, patients of races other than black 
and white were excluded from the analyses because of the small sample size and unreliable 
classification of the race groups (69). 
To adjust for the potential effect of aging, we also included a non-cancer comparison 
group from the 5-percent random sample of individuals without cancer included in the 
SEER-Medicare data. Inclusion criteria for the non-cancer comparison group were: male 
gender, black or white race, qualified for Medicare benefit because of age, continuously 
enrolled in Medicare Part A and Part B and never enrolled in the HMO program during the 
study period, and living in the SEER-17 regions. 
Table 3 compares the variables available for the cancer and comparison groups. 
Demographic information, including age, race, SEER region, median income and education 
 29 
 
level in residential areas, is available for both groups. We were able to assess the severity 
of comorbidities and the use of necessary care from the Medicare claims for both groups. 
However, some variables such as marital status, cancer stage, tumor grade, primary cancer 
treatment, and type of care provider were available only for the cancer cases in our study. 
Therefore, when we identified the factors associated with higher comorbidity scores and 
more use of necessary care, we focused only on the prostate cancer group. 
 
Table 3. Comparison of available variables for cancer cases and non-cancer controls 
Variables Cancer-cases Non-cancer controls 
Age Yes Yes 
Race Yes Yes 
SEER registry site Yes Yes 
Median income in residential area Yes Yes 
Median education level in residential area Yes Yes 
Comorbidity severity Yes Yes 
Use of care for comorbidities Yes Yes 
Marital status Yes No 
Cancer stage Yes N/A 
Tumor grade Yes N/A 
Cancer treatment Yes N/A 
Type of care provider Yes N/A 
N/A: not applicable 
 
Similar inclusion and exclusion criteria were adopted for the study sample in Aim 3. 
However, we also included survivors who were diagnosed with distant prostate cancer in the 
survival analyses. Individuals without cancer were excluded because we only focused on 
racial disparity in survival among prostate cancer survivors. In addition, we only included 
survivors from registries with at least 11 black prostate cancer cases in 2000. Survivors from 
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Hawaii, Iowa, New Mexico, Utah, rural Georgia, San Jose, and Seattle were excluded 
because black race only consists of a very small proportion of their populations. 
3.6 Variable Definitions 
3.6.1 Socio-demographic information 
A cancer patient’s age, race, and date of death are available from both SEER and 
Medicare data. Demographic information from these two sources is highly consistent (69). 
Since the demographic data for the comparison group are available only in the Medicare 
enrollment file, we employed Medicare’s Enrollment Database as our primary source to 
identify age, race, and vital status for both groups. Empirically, data aggregated at the 
census tract level are more likely to reflect a patient’s SES than are zip code level data (69). 
However, the SES information for the comparison group is available only at the zip code 
level; hence, we controlled for median household income and percentage of residents with 
less than a high school degree at zip code level from the 2000 Census for both cancer and 
comparison group in Aims 1 and 2. 
In Aim 3, since the non-cancer comparison group was excluded, we adopted median 
household income, percentage of residents living below poverty level, percentage of 
residents with less than a high school degree at census tract level in the analyses.  
3.6.2 The date and cause of death 
The date of death is available in both Medicare and SEER data, but is derived from 
different sources covering different time periods. The Medicare death date was obtained 
from Medicare Enrollment Database, which is updated nightly by the Social Security 
Administration, and includes death data through December, 2007. The SEER death date is 
primarily derived from state death certificates, but it is sometimes acquired from the 
Medicare Enrollment Database when state data are unavailable, whereas SEER Program 
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has this information only until December, 2005. We used Medicare as the primary source to 
identify time of death for overall mortality because it allows us to have a longer follow-up 
timeframe (i.e., up to eight years). For analyses disaggregating mortality by causes, we 
employed data from the SEER Program which has information for cause of death. These 
analyses were limited to deaths prior to 2005. 
3.6.3 Primary cancer treatment 
We used definitions similar to those used in previous studies examining racial 
differences in the outcomes of localized prostate cancer patients (27, 63). The type of 
primary treatment for prostate cancer was identified from the SEER data and Medicare 
claims within six months of cancer diagnosis. Surgery is defined as procedures performed 
with curative intent or in anticipation of a subsequent curative procedure (27). To identify 
radical prostatectomy and procedures performed on regional lymph nodes, we used: (1) the 
SEER indicator for whether a cancer-directed surgery was performed; (2) procedure codes 
from Medicare claims (International Classification of Diseases, 9th Revision, [ICD-9] 60.5 
and 60.6; Current Procedural Terminology [CPT] codes 55810, 55812, 55815, 55840, 55842, 
55845, 55866); and (3) site-specific surgery codes 30–90 from the SEER data. Radiation 
therapy (XRT) is defined as external beam therapy, brachytherapy, or therapeutic isotope 
radiation therapy as listed in the SEER data (63). Specifically, we used: (1) the SEER 
indicator for whether a cancer-directed XRT was performed; (2) ICD-9 procedure codes 
92.2x, V58.0, V66.1, V67.1, CPT codes 77301, 77400–77499; revenue center codes 0330–
0339 from Medicare claims; and (3) site-specific radiation codes 1–5 from the SEER data to 
identify XRT. Men who receive both surgery and XRT will be classified as having surgery 
because some patients may receive XRT after an incomplete or unsuccessful surgery (27, 
63). 
3.6.4 Type of care provider 
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The type of care provider was classified based on the specialty information in the 
Medicare Carrier Claims (36). Prostate cancer specialists were defined as sub-specialists in 
urology (code 34), hematology oncology (code 83), medical oncology (code 90), surgical 
oncology (code 91), or radiation oncology (code 92). Primary care physician (PCPs) were 
defined as physicians in general practice (code 01), family practice (code 08), internal 
medicine (code 11), geriatric medicine (code 38), or multi-specialty group practices (code 
70). 
3.7 Risk Adjustments for Comorbidities 
We used the CCI and the NCICI to assess the severity of comorbidities at different 
time points. The CCI is a commonly used measure of comorbidity in epidemiologic and 
outcomes research (27, 38, 39, 63, 74). Researchers can accumulate the weighted 
comorbidities to establish a single index and to compare the severity of comorbidities across 
patients. A higher comorbidity score represents more severe health problems. The NCICI 
was developed specifically for the use with SEER-Medicare data to adjust for the risk of 
dying from causes other than cancer (40). The NCICI adapts the comorbid conditions from 
the CCI but weights them differently, and allows the comorbidity weights vary by cancer site. 
Compared with the CCI, the NCICI performed better in predicting non-cancer mortality 
among cancer survivors (40). The CCI and NCICI are described in detail in Section 2.5. The 




Table 4. Chronic conditions and their weights in NCICI and CCI index 
Chronic conditions ICD-9 Codes NCICI  CCI 
AIDS 042-044.9 N/A 6 
Cerebrovascular disease 430-438 0.266 1 
Chronic pulmonary disease 490-496, 500-505, 506.4 0.725 1 
Congestive heart failure 428-428.9 0.874 1 
Dementia 290-290.9 0.777 1 
Diabetes 250-250.3, 250.7 0.239 1 
Diabetes with complications 250.4-250.6 0.44 2 
Moderate/severe liver disease 572.2-572.8 N/A 3 
Moderate/severe renal 
disease 
582-582.9, 583-583.7, 585, 586, 588-588.9 0.678 2 
Myocardial infarction (acute) 410-410.9 0.242 1 
Myocardial infarction (history) 412 0.054 1 
Paralysis 344.1, 342-342.9 0.393 2 
Peptic ulcer disease 531-534.9, 531.4-531.7, 532.4-532.7, 533.4-533.7, 
534.4-534.7 
-0.247 1 
Peripheral vascular disease 443.9, 441, 441.9, 785.4, V43.4, Procedure 38.48 0.359 1 
Rheumatologic disease 710.0, 710.1, 710.4,714.0-714.2, 714.81, 725 0.091 1 
Various cirrhosis 571.2, 571.5, 571.6, 571.4-571.49 N/A 1 
Source: Klabunde et al. 2007 (40), Deyo et al. 1992 (39) 
ICD-9: International Classification of Diseases, 9
th
 Revision 
NCICI: National Cancer Institute Combined Index; CCI: Charlson Comorbidity Index 
 
3.8 Quality of Care Measures 
We used the refined Access to Care for the Elderly Project (ACE-PRO) indicators 
from the Medicare Payment Advisory Commission (MedPAC) to assess use of necessary 
ambulatory care among elderly Medicare beneficiaries (64). The MedPAC, an independent 
Congressional agency, advises the US Congress on issues affecting the Medicare program. 
The ACE-PRO indicators were originally developed for MedPAC by researchers from the 
RAND Corporation in 2000 (34). MedPAC has used the ACE-PRO indicators to study the 
access to and quality of care associated with various geographic and socioeconomic factors, 
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and has used the results of these analyses in their reports to Congress (64). The ACE-PRO 
indicators were updated in 2006 to reflect changes in performance measurement and 
clinical practice. The refined ACE-PRO indicators have been tested and validated on 
Medicare claims by MedPAC (64). 
The refined ACE-PRO indicators consist of 40 items for medical conditions covering 
anemia, angina, breast cancer, colorectal cancer, chronic obstructive pulmonary disease, 
congestive heart failure, coronary artery disease, depression, diabetes, gastrointestinal 
bleeding, hypertension, and stroke or transient ischemic attack. Six indicators were 
excluded from our analysis because they were developed specifically either for women or 
for other cancers. Based on the suggestion of MedPAC, the remaining 34 indicators (Table 
5) were categorized into five groups by their type of care (i.e., Clinical Assessment in 
Chronic Conditions, Management of Chronic Conditions, Follow-up after Hospitalization, 






Table 5. Indicators for the Refined Access to Care for the Elderly Project 
Clinical Assessment for Chronic Conditions 
Two outpatient visits every year for patients with diabetes mellitus 
Two outpatient visits every year for patients with coronary artery disease 
Two outpatient visits every year for patients with stroke or transient ischemic attack 
Two outpatient visits every year for patients with chronic obstructive pulmonary disease 
Two outpatient visits every year for patients with heart failure 
One outpatient visit every year for all elderly Medicare beneficiaries 
Management of Chronic Conditions 
Comprehensive eye exam every two year for patients with diabetes mellitus 
Hemoglobin A1C test every year for patients with diabetes mellitus 
Lipid profile every year for patients with diabetes mellitus 
Lipid profile every year for patients with coronary artery disease 
Measurement of electrolytes and renal function every year for patients with heart failure 
Follow-up after Hospitalization 
At least one non-emergent ambulatory visit within 4 weeks following discharge of patients hospitalized for diabetes mellitus 
At least one non-emergent ambulatory visit within 4 weeks following discharge of patients hospitalized for acute myocardial infarction 
At least one non-emergent ambulatory visit within 4 weeks following discharge of patients hospitalized for stroke or transient ischemic attack 
At least one non-emergent ambulatory visit within 4 weeks following discharge of patients hospitalized for heart failure 
At least one ambulatory visit within 4 weeks following discharge of patients hospitalized for gastrointestinal bleeding 
At least one hemoglobin or hematocrit test within 4 weeks following discharge of patients hospitalized for gastrointestinal bleeding 






Table 5. Indicators for the Refined Access to Care for the Elderly Project (continued) 
Avoidable Adverse Outcomes 
  Hospitalization for diabetic, hyperosmolar, ketotic coma, and uncontrolled diabetes mellitus among patients with a history of diabetes mellitus 
  Hospitalization for renal, ophthalmologic, neurologic, and circulatory complications of diabetes mellitus and non-traumatic lower extremity 
amputation in patient with a history of diabetes mellitus 
  Three or more emergency department visits for coronary artery disease in patients with a history of coronary artery disease 
  Hospitalization for heart failure in patients with a history of heart failure 
  Hospitalization for chronic obstructive pulmonary disease in patients with a history of chronic obstructive pulmonary disease 
  Hospitalization for malignant hypertension in patients with a history of hypertension 
Work-up at Initial Diagnosis 
  Electrocardiography or Holter monitor within 2 days of initial diagnosis of transient ischemic attack 
  Carotid angiogram or non-invasive carotid imaging procedure within 2 weeks of initial diagnosis in patients hospitalized for carotid artery 
stroke 
  Carotid imaging to carotid endarterectomy interval less than 2 months, in patients with a hospitalization for stroke or transient ischemic attack 
prior to the carotid endarterectomy 
  Diagnostic ultrasound, radionuclide ventriculography, or left ventriculogram within 3 months, before or after, initial diagnosis of heart failure 
  Diagnostic ultrasound, radionuclide ventriculography, or left ventriculogram within 3 months, before or after, hospitalization for heart failure 
  Electrocardiography within one month before or three months after initial diagnosis of heart failure 
  Chest X-ray within one month before or three months after initial diagnosis of heart failure 
  At least one inpatient or outpatient visit, within four weeks following initial diagnosis of gastrointestinal bleeding in an outpatient setting 
  Colonoscopy or barium enema within one month before or three months after initial diagnosis of iron deficiency anemia 
  Hemoglobin or hematocrit test within one to six months after initial diagnosis or anemia 
Source: MedPAC Report (64); publicly-available at: http://www.medpac.gov/publications/contractor_reports/MACIEFeb1206Final.pdf
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The ACE-PRO indicators were originally developed for analysis using two years of 
data (64). Many indicators use the first year of observation to determine individuals who are 
qualified to be part of denominators and use the second year of observation to identify 
numerators. In this study, we made some adjustments to the ACE-PRO method for our ten-
year study timeframe. For indicators of clinical assessment, management of chronic 
conditions, and avoidable adverse outcomes, an individual became qualified for the 
denominator after the year when he was first diagnosed with a chronic condition. For 
indicators of follow-up after hospitalization, we used the first event in each time period 
without another event within four weeks following the discharge of the previous event. For 
the indicators of work-up at initial diagnosis, we examined the care at the first diagnosis in 
the entire time frame, rather than the first diagnosis in each time period. Our ten years of 
follow-up allows us to identify the initial diagnosis more precisely than the conventional 
ACE-PRO method using only two years of data. 
We estimated use of necessary care in each two-year time period (64). For each 
indicator, we first used the ICD-9 codes to identify the number of individuals who were 
qualified for it (i.e., the denominator). We then used the CPT codes to identify the number of 
qualified individuals who met the requirement of the indicator (i.e., the numerator). The ratio 
of numerator to denominator represents the proportion of individuals who used the 
necessary care. For example, we assessed the eye care indicator by calculating the 







indicatorcareeye   
For each person, we also calculated composite scores for (1) clinical assessment for 
chronic condition, (2) management of chronic condition, (3) follow-up after hospitalization, (4) 
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possible adverse outcomes avoided, and (5) work-up at initial diagnosis. Finally, we 
calculated an overall composite score by dividing the sum of numerators by the sum of 
denominators to measure the proportion of eligible care that was received by each person 


















3.9 Competing-risk Survival Analysis 
Prostate cancer and other causes are competing risks for cancer patients’ mortality 
because a patient who dies from one of these causes cannot die from the other. Typically, 
cancer survivorship studies use Cox proportional hazard (PH) model (75) when cancer-
specific mortality is the outcome of interest (26, 27, 29-31). Patients who die from causes 
other than cancer are treated as censored cases, which implicitly assumes that the risks of 
dying from cancer and other causes are independent. At present, there is no valid 
mathematic method to examine whether the competing risks are indeed independent (76). 
However, these risks are very likely dependent because the presence of prostate cancer 
(i.e., the risk of dying from cancer) may change the risk of dying from other comorbidities. 
For example, prostate cancer treatments may have negative effects on survivors’ 
cardiovascular disease and mental health (22, 23, 59). In addition, the presence of 
comorbidities also may complicate treatment management and further affect the risk of 
dying from cancer. If the competing-risk relationship just described differs by race, the 
hazard ratio of race directly obtained from a PH model would be biased.  
To account for the competing risks in our survival analysis, we use the cumulative 
incidence curve method developed by Fine and Gray (77). Their competing-risk model 
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allows the dependence of competing risks in the Cox PH model and estimates hazard ratios 
of independent variables for competing risks (i.e., cancer and non-cancer deaths) 
separately. We compared the hazard ratios of black race obtained from the Cox PH and 
competing-risk models to evaluate whether we have consistent findings for racial disparity. 
3.10 Analysis Plans 
3.10.1 Aim 1 
The cumulative prevalence rates were measured as of December 31st in 1999, 2001, 
2003, 2005, and 2007 (Figure 2). At each time point, we calculated the proportion of patients 
alive with a disease history of COPD, diabetes, depression, hypercholesterolemia, or 
hypertension. To confirm a comorbid condition, we required a patient to have at least one 
inpatient or two outpatient visits with the disease diagnosis codes within 12 months (See 
Table 4). Chi-squared tests were conducted to compare the crude prevalence rates between 
the cancer and comparison groups (78). We also used modified Poisson regression analysis 
to compare comorbidity prevalence rates between cancer and comparison groups adjusting 















Figure 2. Analytic plan to compare comorbidity prevalence pre- and post-cancer 
diagnosis 
                  
 
We measured the changes over time in individual patient’s overall comorbidity 
severity by CCI (38, 39). At each time point, crude comorbidity scores for both cancer and 
non-cancer groups were compared using Student’s t tests (78). To account for repeated 
measures, we also estimated a generalized estimating equations (GEE) model (80, 81). The 
effects of cancer on CCI at various time points were of primary interest. The sum of 
coefficients between cancer indicator and its interaction term with time was tested by Wald 
test at each time point (80, 81). Other factors, including age, race, registry site, education, 
and income, which might be associated with comorbidities and prostate cancer, were 
controlled for in the model. For prostate cancer survivors, we used the NCICI to measure 
their comorbidity severity. At each time point, we compared the NCICI scores between black 
and white survivors using Student’s t test (78). A GEE model was conducted to investigate 









































the longitudinal relationship between race and comorbidity severity (80, 81). Wald tests were 
conducted to further examine the relationship between race and NCICI at various time 
points. Age, race, registry site, education, income, marital status, and cancer treatment also 
were controlled for in the GEE model. 
In addition, we examined the number of physician visits over time. The average 
number of office visit to PCPs, prostate cancer specialists, and other specialists were 
calculated in each two-year period. Student’s t tests were conducted to analyze whether 
cancer survivors made more visits to prostate cancer specialists and fewer visits to PCPs 
than they did before cancer diagnosis (78). We further examined the relationship between 
types of provider and newly diagnosed comorbidities. Specifically, we focused on newly 
diagnosed diabetes and hypertension, which are prevalent conditions among the elderly. 
The first diagnosis code of a new condition after cancer was linked to the diagnosing health 
care provider. Cases of newly diagnosed diabetes or hypertension between 2000 and 2001 
were stratified by the type of health care provider. We used a Chi-square test (78) to 
examine whether the new conditions were more likely to be diagnosed by prostate cancer 
specialists than by PCPs. 
3.10.2 Aim 2 
The use of necessary care for each ACE-PRO indicator was measured during five 
time periods (Figure 3). Period 0 measured the baseline use of care in 1998 and 1999 (i.e., 
two years before the index date (i.e., cancer diagnosis or 2000). Data from Period 1 
evaluate whether patients received necessary care for their comorbidities right after cancer 
diagnosis (i.e., between 2000 and 2001). Periods 2 and 3 focused on the use of care 
between 2002 and 2003 and between 2004 and 2005, respectively. Data in the last period, 
Period 4 (between 2006 and 2007), measured the use of care after patients had survived 
prostate cancer for more than five years. The result from this final period can be directly 
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compared with the findings from previous studies evaluating the use of care in other types of 
cancer (35, 36). 
 
 
Figure 3. Analytic plan to compare the use of care pre-and post-cancer 
                  
For each indicator, we first compared the ratios of numerators to denominators 
between cancer and non-cancer groups during different time periods. Chi-square tests (78) 
were conducted to examine whether prostate cancer survivors received the same level of 
care for their comorbid conditions as the comparison group did. For different types of care, 
we conducted Student’s t tests to compare composite scores between cancer and 
comparison groups in different time periods. 
Multivariate GEE regression models (80, 81) were conducted to analyze the 
association between prostate cancer diagnosis and overall use of necessary care. The 
effects of cancer on use of necessary care during various time periods were of primary 
interest. The sum of coefficients between cancer indicator and its interaction term with time 
was tested by Wald test in each time period (80, 81). Other factors, including age, race, 
registry site, education, income, and comorbidities, which might be associated with use of 


























Period 0 Period 2 Period 3 Period 4 Period 1 
Non-cancer 
Group 
Use of care t0 Use of care t2 Use of care t3 Use of care t4 
Use of care t0 Use of care t1 Use of care t2 Use of care t3 Use of care t4 
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care and prostate cancer diagnosis, were controlled for in the models. We also conducted a 
subgroup GEE analysis for cancer survivors only to examine whether racial differences in 
use of care changed after cancer diagnosis. Wald tests were conducted to assess the 
relationship between race and use of necessary care during various time periods. In addition 
to the independent variables in the previous GEE model, we also controlled for marital 
status, primary cancer treatment, tumor grade, and type of care provider, which were 
available only for the cancer group. 
3.10.3 Aim 3 
This aim examined racial disparity in survival among prostate cancer survivors. 
Kaplan-Meier survival curves (82) were used to compare the unadjusted survival (measured 
in months) by race and cancer stage. Log-rank tests were conducted to evaluate whether 
black patients have different survival rates as compared with white patients. We then 
assessed adjusted racial disparity in overall mortality using Cox PH models (75). We also 
examined the racial disparity in cancer or non-cancer mortality using the competing-risk 
models (77), which allow for the dependence of competing risks in the PH model and 
estimates hazard ratios (HRs) of independent variables for competing risks (i.e., cancer and 
non-cancer deaths) separately. We compared the HRs of black race after controlling for 
factors which have been shown to be potentially responsible for racial disparity, such as a 
patient’s age, registry site, marital status, SES, and cancer disease information (i.e., stage, 
grade, and treatment). Subsequently, we evaluated the effect of additional adjustment for 
time-varying NCICI score and use of care on racial disparity in overall survival. 
Finally, we identified the risk factors for overall, cancer, and non-cancer mortality 
among men with prostate cancer. A patient’s demographic information, cancer disease 
information, SES, comorbidity, and use of care were examined in the regression models. We 
first compared the results of Cox PH models controlling for static or time-varying comorbidity 
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scores. The PH assumption was tested by both graphical and goodness-of-fit approaches 
for each variable (83). Finally, we compared the models using the Cox PH (i.e., the 
approach commonly used in the current literature) or competing-risk methods to identify risk 





CHAPTER 4. ASSOCIATION BETWEEN CANCER AND THE DETECTION OF 
COMORBID HEALTH CONDITIONS AMONG ELDERLY MEN WITH PROSTATE 
CANCER IN THE UNITED STATES 
 
4.1 Abstract 
Background: Prostate cancer is a highly survivable disease, but coexisting comorbidities 
are the major threat to life for its survivors. This study examined whether more comorbidities 
were detected after cancer diagnosis. 
Methods: Patients diagnosed with localized/regional prostate cancer at ages 67-84 in 2000 
(n=9,053) were identified from the Surveillance, Epidemiology, and End Results-Medicare 
Program. A comparison group of Medicare beneficiaries with no history of cancer was also 
included (n=43,926). Patients’ claims from 1998 through 2007 were examined. The 
prevalence rates of chronic obstructive pulmonary disease (COPD), diabetes, depression, 
hypercholesterolemia, and hypertension and overall comorbidity score as measured by 
Charlson Comorbidity Index (CCI) and National Cancer Institute Combined Index (NCICI) 
were calculated in two-year intervals. We also compared the number of office visits by 
specialty across time. Poisson regression and generalized estimating equations models 






Results: Comorbidities were more likely to be diagnosed after prostate cancer. The 
prevalence rate of COPD in the cancer group was significantly lower than non-cancer group 
before cancer diagnosis (prevalence ratio [PR]=0.94, 95% confidence interval [95%CI]:0.89-
0.99, p=0.05). However, COPD was marginally more prevalent among cancer group after 
diagnosis (PR=1.08, 95%CI: 1.04-1.13, p<0.001). Similar trends were observed in other 
comorbidities. In addition, the overall comorbidity score of cancer group increased 
significantly more than control group across time. Survivors made more visits to both 
prostate cancer specialists and primary care physicians after cancer diagnosis, especially 
among black survivors. 
Conclusions: Survivors visit health care providers more frequently after cancer diagnosis, 
which may lead to discovery of previously underdiagnosed chronic conditions. 
 
Keywords: prostate cancer, comorbidities, SEER-Medicare, prevalence, outpatient visit 
 
4.2 Introduction 
Cancer is a prevalent disease affecting the elderly population in the United States, 
with approximately two-thirds of new malignancies diagnosed among patients at least 65 
years of age (73). It is estimated that more than 10 million Americans currently live with a 
history of cancer diagnosis, and the number of survivors is expected to continue to grow 
with more early detection, effective treatments, and the aging of the population (73). From 
2000 to 2050, the absolute number of patients aged 65 and older diagnosed with cancer is 
expected to double (41). Since the majority of elderly cancer survivors eventually die from 
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causes other than cancer (73), health problems related to non-cancer conditions also have 
become very important for this population. 
Comorbidities (i.e., additional coexisting health conditions) are commonly observed 
in cancer survivors, especially among the elderly population (1, 6, 46, 47). Previous studies 
have found that cancer survivors are at a higher risk for other comorbidities than the non-
cancer population (6, 46, 47). These increased risks may be the result of the side effects or 
late effects of cancer treatment, genetic predisposition, diet, or common lifestyle factors. A 
population-based study found that 69% of cancer patients aged 40 to 84 have at least one 
chronic condition other than cancer (1). The presence of comorbidities may not only 
complicate treatment management, but may negatively affect prognosis and post-treatment 
health-related quality of life (3-6). Previous studies also reported that prostate cancer 
patients are more likely to die from causes other than cancer (7, 32), demonstrating the 
potential influence of comorbidities and other factors on mortality. However, these previous 
studies primarily focused on the effect of comorbidities at cancer diagnosis on patients’ 
cancer-related outcomes (3-6, 32). The longitudinal association between cancer and 
comorbidities has yet to be fully investigated. 
A cancer diagnosis has the potential to have mixed effects on the diagnosis or 
management of other comorbidities. On one hand, cancer diagnosis may represent “a 
teachable moment” for risk factor reduction because patients tend to be more aware of their 
other health problems after cancer diagnosis (48-50). To prevent cancer recurrence and to 
increase the likelihood of survival, cancer survivors often attempt to quit smoking, to eat 
healthier, and to engage in regular exercise (48-56). Previous studies have found a positive 
effect of these lifestyle changes on health-related outcomes (51, 57, 58). In addition, 
patients may receive more medical services after diagnosis because cancer follow-up may 
provide regular contact with the health care system, increasing the chance of receiving 
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appropriate medical care (35). Health care providers also may identify some chronic 
conditions that were underdiagnosed prior to the cancer diagnosis. Therefore, it is possible 
that comorbidities would be better controlled after cancer diagnosis.  
On the other hand, comorbidities may worsen after cancer diagnosis. Long-term and 
late effects of cancer treatments are commonly observed among cancer survivors. For 
example, chemotherapy and radiation therapy may have negative effects on erectile 
function, cardiovascular disease, or mental health (22, 23, 59). In addition, cancer patients 
may not think that the continued management of other comorbidities is as important after 
their cancer diagnosis. Survivors may receive less care for comorbidities because their care 
may consist primarily of specialty care provided by specialist physicians, with little attention 
to primary care needs (36). Insufficient primary care may lead to development of other 
comorbidities or the worsening of existing comorbidities. 
The purpose of this study is to investigate whether diagnosis of prostate cancer 
creates an opportunity to detect other comorbid conditions. We selected prostate cancer 
survivors as our study sample for several reasons. First, prostate cancer is the most 
prevalent cancer in men, and patients with a history of prostate cancer comprise 
approximately one-fifth of total cancer survivors (second only to breast cancer survivors) 
(73). Second, prostate cancer is predominantly survivable and the majority of its survivors 
are aged 65 and older (73). The majority of elderly prostate cancer survivors die from 
causes other than cancer (7, 32), implicating the importance of comorbidities for this 
population. Finally, to our knowledge there has been no published study examining the 
prevalence and severity of comorbidities longitudinally among prostate cancer patients. 
We first estimated the prevalence of chronic obstructive pulmonary disease (COPD), 
depression, diabetes, hypercholesterolemia, and hypertension before and after the prostate 
cancer diagnosis. These comorbid conditions were selected because they are both common 
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and associated with non-cancer mortality but often are underdiagnosed among the elderly 
population (84-90). These occult diseases may remain undetected for many years, and 
some patients are first identified at an advanced stage during emergency room visit or 
hospitalization (90). Early detection of these comorbidities may lead to better disease control 
by appropriate medical treatments. In addition, we used the Deyo modification of the 
Charlson Comorbidity Index (CCI) (38, 39) and National Cancer Institute Combined Index 
(NCICI) (40) to assess the severity of comorbidities longitudinally. Since a cancer diagnosis 
may create a chance for survivors to have more contact with the health care system (35), we 
expected to observe increases in the prevalence and severity of comorbidities after cancer. 
To indentify the main health care provider for prostate cancer survivors, we examined the 
number of office visits by physician specialty. After cancer diagnosis, we expected the 
number of office visits to prostate cancer specialists and primary care physicians (PCPs) 
would increase and decrease, respectively. We further examined whether the new chronic 
conditions (i.e., those conditions diagnosed after the cancer diagnosis) tend to be identified 
by prostate cancer specialists or by PCPs. We hypothesized that new chronic conditions are 
more likely to be diagnosed by prostate cancer specialists, who tend to be the main 
providers of care to patients after a cancer diagnosis. Finally, we conducted subgroup 
analyses to examine whether the findings are different by race. Previous studies reported 
that black patients generally have more comorbidities than white patients (32, 91, 92), but 
that comorbid conditions are more likely to be underdiagnosed among black patients (67). 






This study used the data from the Surveillance, Epidemiology, and End Results 
registry (SEER)-Medicare Program. The SEER-Medicare data are population-based data 
that combine SEER cancer registry information with Medicare enrollment and claims files 
(70, 72). The SEER Program of the National Cancer Institute (NCI) is an authoritative 
program collecting information on cancer incidence and survival statistics, serving as one of 
very few comprehensive sources of population-based cancer information in the United 
States (68). The SEER Program is considered the standard for quality among cancer 
registries around the world. It routinely collects data on patient demographics, primary tumor 
site, stage at diagnosis, primary course of treatment, and cause of death. The SEER 
Program also collects socioeconomic status (SES) information including median household 
economic and educational status (69, 70). These SES variables are aggregate measures 
from the US Census Bureau that reflect the characteristics of the census tracts and zip 
codes in which patients resided during the year of their first diagnosis (69). We used the 
data from the SEER-17 registries, which cover Arizona native Americans, Alaska Natives, 
nine states (California, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New 
Mexico, and Utah), and seven regions (Atlanta, Detroit, rural Georgia, Los Angeles, San 
Francisco, San Jose, and Seattle).  
Medicare is the primary health insurer for 97% of the US population aged 65 years 
and older (70). All Medicare beneficiaries receive Part A benefits, which are generally paid 
for by payroll taxes collected from workers. Approximately 99% of Medicare beneficiaries 
pay no premium for Part A services because they have at least 40 quarters of Medicare-
covered employment (71). Medicare Part A benefits cover inpatient care in hospitals, 
including critical access hospitals, and skilled nursing facilities (but not custodial or long-term 
care), hospice care and some home health care services. Among Medicare Part A 
beneficiaries, 95% of them also pays a monthly premium for the Part B benefits (70). 
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Medicare beneficiaries pay premiums for Part B benefits which cover physician services, 
outpatient care, durable medical equipment, some of the services of physical and 
occupational therapists, and home health in some cases. A beneficiary’s disease diagnoses, 
treatments, and services received are available in the Medicare claims. However, data are 
missing for health maintenance organization (HMO) enrollees, services not covered by 
Medicare (i.e., outpatient prescription drugs and long term care), and services provided by 
Veterans Affairs or Medicaid, or by Medicare supplement programs (i.e., Medigap policies) 
(70). 
Cohort Selection 
Patients diagnosed with localized or regional prostate cancer (i.e., Stage I, II, and III) 
in 2000 were included in this study. These patients are not likely to die from prostate cancer 
because their five-year relative overall survival rate is approximately 100% as compared 
with the non-cancer population (73). Patients diagnosed with distant prostate cancer were 
excluded because their five-year relative survival rate is only 32% (73) and the presence of 
some comorbidities (e.g., cardiovascular diseases) may be associated with hormonal 
treatment for distant prostate cancer (59). A patient’s claims were examined for up to ten 
years, beginning from January 1, 1998 through December 31, 2007. To be eligible for 
inclusion in the study, patients must have been continuously enrolled in Medicare Part A and 
Part B during the study period. To observe the presence of comorbidities for at least two 
years before cancer diagnosis, we included only patients who were diagnosed with prostate 
cancer at age 67 or older as of January 1, 2000, thus allowing for two years of observation 
prior to diagnosis following their enrollment in Medicare at age 65. Medicare beneficiaries 
who are eligible for Medicare because of disability or the presence of end-stage renal 
disease before age 65 were excluded from the analyses. HMO enrollees also were excluded, 
as services provided by HMOs are not included in the SEER–Medicare data. Other 
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exclusion criteria included: prior cancer history, diagnosis with a second cancer within six 
months, noninvasive tumors (i.e., carcinoma in situ), unstaged prostate cancer, diagnosis 
after age 84, diagnosis at death or via autopsy, and missing income and education 
information. Finally, patients of races other than black and white were excluded from the 
analyses because of the small sample size and unreliable classification of the race groups 
(69). 
We also included a comparison group from the 5-percent random sample of 
individuals without cancer in the SEER-Medicare data. Inclusion criteria for the comparison 
group were: male gender; qualified for Medicare benefit because of age; age between 67 
and 84 years as of January 1, 2000; continuously enrolled in Medicare Part A and Part B 
and never enrolled in the HMO program during the study period; and living in areas covered 
by the SEER-17 registry. 
Variable Definitions 
Covariates 
A cancer patient’s age, race, and date of death are available from both SEER and 
Medicare data. Demographic information from these two sources is highly consistent.(69) 
Since the demographic data for the comparison group are available only in the Medicare 
enrollment file, we employed Medicare’s Enrollment Database as our primary source to 
identify age, race, and vital status for both groups. We controlled for median household 
income and percentage of residents with less than a high school degree at zip code level 
from the 2000 Census for both groups in our analyses. 
The type of care provider was classified based on the specialty information in the 
Medicare Carrier Claims (36). Prostate cancer specialists were defined as sub-specialists in 
urology (code 34), hematology oncology (code 83), medical oncology (code 90), surgical 
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oncology (code 91), or radiation oncology (code 92). Primary care physicians were defined 
as physicians in general practice (code 01), family practice (code 08), internal medicine 
(code 11), geriatric medicine (code 38), or multi-specialty group practices (code 70). 
Primary cancer treatment 
The type of primary treatment for prostate cancer was identified from the SEER data 
and Medicare claims within six months of cancer diagnosis. Previous studies suggested that 
surgery and radiation therapy (XRT) are consistently reported in SEER and Medicare claims 
data (>90% agreement) (93, 94). Surgery was defined as procedures performed with 
curative intent or in anticipation of a subsequent curative procedure (27). We used: (1) the 
SEER indicator for whether a cancer-directed surgery was performed; and (2) International 
Classification of Diseases, 9th Revision, (ICD-9) procedure codes 60.5 and 60.6; Healthcare 
Common Procedure Coding System (HCPCS) codes 55810, 55812, 55815, 55840, 55842, 
55845, and 55866 from Medicare claims to identify radical prostatectomy and procedures 
performed on regional lymph nodes. XRT is defined as external beam therapy, 
brachytherapy, or therapeutic isotope radiation therapy as listed in the SEER data (63). We 
used: (1) the SEER indicator for whether a cancer-directed XRT was performed; and (2) 
ICD-9 procedure codes 92.2x, V58.0, V66.1, V67.1, HCPCS codes 77301, 77400–77499, 
and 77750-77799 from Medicare claims to identify XRT. Men who receive both surgery and 
XRT were be classified as having surgery because some patients may receive XRT after an 
incomplete or unsuccessful surgery (27, 63). 
Comorbidities 
We measured comorbidity prevalence within the prostate cancer and non-cancer 
groups using ICD-9 diagnosis codes from the Medicare inpatient, outpatient, and physician 
claims. The codes to identify COPD, diabetes, hypertension, depression, and 
hypercholesterolemia are listed in Table 4. In addition, we used the CCI and the NCICI to 
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assess the severity of comorbidities at different time points. The CCI is a commonly used 
measure of comorbidity in epidemiologic and outcomes research (27, 38, 39, 63, 74). 
Researchers can accumulate the weighted comorbidities to establish a single index and to 
compare the severity of comorbidities across patients. A higher comorbidity score 
represents more severe health problems. The NCICI was developed specifically for the use 
with SEER-Medicare data to adjust for the risk of dying from causes other than cancer (40). 
The NCICI adapts the comorbid conditions from CCI but weights them differently and the 
comorbidity weights vary by cancer site. Compared with the CCI, the NCICI performed 
better in predicting non-cancer mortality among cancer survivors (40). The comorbidities and 
their ICD-9 codes and weights for CCI and NCICI are listed in Table 4. 
Statistical Analyses 
The cumulative comorbidity prevalence rates were measured as of December 31st in 
1999, 2001, 2003, 2005, and 2007 (Figure 2). At each time point, we calculated the 
proportion of patients alive with a disease history of COPD, diabetes, depression, 
hypercholesterolemia, or hypertension. To confirm a comorbid condition, we required a 
patient to have at least one inpatient or two outpatient visits with the relevant disease 
diagnosis codes within 12 months. Chi-squared tests were conducted to compare the crude 
prevalence rates between cancer and non-cancer groups (78). We also conducted Poisson 
regressions with robust error variances to compare the prevalence ratios between cancer 
and non-cancer groups adjusting for age, race, registry site, income, and education (79). 
We measured the changes over time in individual patient’s overall comorbidity 
severity by CCI (38, 39). At each time point, crude comorbidity scores for both cancer and 
non-cancer groups were compared using Student’s t tests (78). To account for repeated 
measures, we used a generalized estimating equations (GEE) model (80, 81). The effects of 
cancer on CCI at various time points were of primary interest. The sum of coefficients of 
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cancer indicator and its interaction term with time was examined by Wald test at each time 
point (80, 81). Other factors, including age, race, registry site, education, and income, which 
might be associated with comorbidities and prostate cancer, were controlled for in the model. 
For prostate cancer patients, we also used the NCICI to measure their comorbidity severity. 
We conducted subgroup analysis by race. In addition, we examined the number of physician 
visits over time. We further examined the relationship between types of provider and newly 
diagnosed comorbidities. Specifically, we focused on newly diagnosed diabetes and 
hypertension, which are prevalent conditions among the elderly.  
4.4 Results 
Study Sample 
A total of 43,150 prostate cancer cases were initially identified in 2000 from the 
SEER-Medicare data (Figure 4). Employing the inclusion and exclusion criteria described 




Figure 4. Procedures to generate the study sample of prostate cancer patients 
 
 
Prostate cancer cases 
diagnosed between 
01/01/2000 and 12/31/2000, 
n=43,150 
 
 Diagnosed at age < 67 or >84, 
 With prior cancer history 
 Enrolled in Medicare not 
because of age, n=21,507 





cancer within 6 
months, n=424 





With HMO coverage, 
n=7,354 
Qualified prostate cancer 
patients, n=21,643 
 
Any non-enrollment in 
Parts A & B, n=2,195 
No 2
nd
 cancer within 6 
months, n=21,219 
Continuously enrolled in 
Parts A & B, n=19,024 
Without HMO coverage, 
n=11,770 
With in situ carcinoma, 
or diagnosed at death 
or via autopsy, n=369 
 
Other races, n=594 
With localized/regional 
prostate cancer, n=10,182 
Black or white patients, 
n=9,588 
With income and 
education data, n=9,053 
Without Income or 
education data, n=535 
HMO: health maintenance organization 
Non-cancer group 
following the same 
inclusion/exclusion 




Table 6 presents the baseline characteristics of the study sample. Compared with 
individuals without cancer, prostate cancer survivors were generally younger and had longer 
follow-up (p<0.001). Individuals with prostate cancer tend to live in areas with higher median 
household income and lower proportions of residents with less than a high school degree. 
Compared with individuals without cancer, cancer survivors are more likely to be black 
(9.0% vs. 5.6%, p<0.001). Among white men, cancer survivors were more likely to be 
younger and to have longer follow-up (p<0.001). Compared with the white comparison group, 
members of the white cancer group were less likely to live in areas in which fewer people 
have a high school degree (p<0.001), and with higher median household income (p<0.001). 
Similar findings were observed among black patients. However, except for the length of 
follow-up (p<0.01) and registry site (p<0.001), none of the differences in baseline 
characteristics between the black cancer and non-cancer groups was statistically significant. 
At the time of cancer diagnosis, black survivors were less likely to be married than white 
survivors (74.0% vs. 82.5%, p<0.001) (Table 7). In addition, prostate cancer grades were 
not significantly different between black and white survivors. Compared with white survivors, 





Table 6. Comparison of baseline characteristics between cancer & non-cancer groups 
Sociodemographic 
Characteristics 

























Age (years) on 01/01/2000, % 
67-69 19.1 19.2 <0.001  22.1 20.4 0.52  18.8 19.1 <0.001 
70-74 37.5 33.2 
 
 35.9 35.4 
  
37.7 33.1 
 75-79 29.6 29.6  27.9 28.1 29.8 29.7 
80-84 13.8 18.0  14.2 16.1 13.8 18.1 
Mean age, year 74.0 74.4 <0.001  73.7 74.1 0.08  74.0 74.5 <0.001 
Mean follow-up 
time, month 
105.7 102.8 <0.001  100.6 97.3 <0.01  106.2 103.1 <0.001 
Alive as of 
12/31/2007, % 
65.7 64.1 <0.01  56.0 54.6 0.49  66.6 64.7 <0.001 
Registry site, % 
San Francisco 3.0 2.9 <0.001  2.7 3.3 <0.001  3.1 2.9 <0.001 
Connecticut 7.6 6.9 
 





Detroit 11.7 8.2  33.1 20.4 9.7 7.5 
Hawaii 0.4 0.4  0.1 0.1 0.5 0.5 
Iowa 8.7 8.3  0.9 0.9 9.5 8.7 
New Mexico 2.1 2.6  0.3 0.7 2.3 2.7 
Seattle 5.9 5.3  1.1 1.3 6.4 5.6 
Utah 3.7 3.1  0.4 0.3 4.0 3.2 
Atlanta 3.1 3.1  6.7 7.7 2.7 2.8 
San Jose 1.9 2.1  0.9 0.6 2.0 2.2 
Los Angeles 6.0 6.4  8.0 8.6 5.8 6.3 
Rural Georgia 0.2 0.3  0.5 1.1 0.2 0.2 
Greater California 14.7 17.3  4.1 6.5  15.7 17.9 
Kentucky 5.8 9.0  2.8 5.8  6.1 9.2 
Louisiana 7.0 7.0  17.1 19.6  6.0 6.3 
New Jersey 18.3 17.2  18.3 19.4  18.3 17.1 
Percent persons age 25+ of same race with less than a high school education 
Mean, % 16.2 16.5 0.02  28.2 28.9 0.17  15.0 15.8 <0.001 
Annual household income 





Table 7. Baseline characteristics of black and white cancer survivors 
 Black White p-value 
Marital status at cancer diagnosis (%)  
Ever married 74.0 82.5 <0.001 
Never married 13.7 5.2  
Unknown or missing 12.3 12.3 
Prostate cancer grade (%)  
1 (well differentiated) 3.2 4.8 0.053 
2 (Moderately differentiated) 68.4 69.0  
3 (Poorly differentiated) 22.8 22.0 
4 (Undifferentiated) 0.7 0.3 
Unknown or missing 4.8 3.9 
Primary cancer treatment (%)  
Radiation therapy 43.7 51.2 <0.001 
Surgery 24.0 25.8 
 
Watchful waiting 32.3 23.0 
 
Comorbidity Prevalence 
As expected, more comorbid conditions were diagnosed among cancer survivors 
than among individuals without cancer after 2000 (i.e., the year when prostate cancer was 
diagnosed among survivors) (Table 8). On December 31st, 1999, the prevalence rate of 
COPD was significantly lower in cancer group than in non-cancer group. After 2000, the 
COPD prevalence rate became significantly higher among cancer group than among non-
cancer group. A similar time trend of prevalence rate was observed in diabetes. Compared 
with individuals without cancer, prostate cancer patients were less likely to be diagnosed 
with diabetes before cancer (15.3% vs. 17.6%, p<0.001). However, the prevalence rates of 
diabetes were significantly higher in the cancer group after 2000. Although 
hypercholesterolemia and hypertension were always more prevalent among cancer patients 
than among individuals without cancer, the differences in prevalence increased over time. 
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Finally, we conducted subgroup analyses by race. For both black and white patients, the 
prevalence rate of each condition increased more in the cancer group than in non-cancer 
group after 2000. 
 
Table 8. Unadjusted comorbidity prevalence rate (%) 
Race Condition Group 
Prevalence time point 
Pre-diagnosis  Post-diagnosis 
12/31/99  12/31/01 12/31/03 12/31/05 12/31/07 
Both 
Hypertension 
Cancer 51.8†  69.1¶ 76.9¶ 83.4¶ 85.3¶ 
Non-cancer 50.4  63.3 71.4 77.1 79.9 
Hypercholesterolemia 
Cancer 18.9‡  29.9¶ 38.9¶ 48.4¶ 52.7¶ 
Non-cancer 17.5  27.2 35.2 43.2 47.7 
COPD 
Cancer 16.4¶  24.8‡ 28.8‡ 32.9¶ 33.4¶ 
Non-cancer 17.9  23.4 27.1 29.9 30.8 
Diabetes 
Cancer 15.3¶  20.9 24.7 33.4¶ 34.5¶ 
Non-cancer 17.6  21.2 24.1 27.6 29.5 
Depression 
Cancer 2.2¶  4.7 6.6 8.2 8.5 
Non-cancer 3.0  4.9 6.7 7.9 8.5 
Black 
Hypertension 
Cancer 61.0†  79.2¶ 84.8¶ 88.8¶ 90.7¶ 
Non-cancer 56.4  69.4 75.6 80.4 81.4 
Hypercholesterolemia 
Cancer 13.3‡  22.5‡ 31.0‡ 40.4‡ 44.1† 
Non-cancer 9.5  17.6 24.9 32.7 37.3 
COPD 
Cancer 18.6  28.8‡ 34.4¶ 38.6¶ 40.7¶ 
Non-cancer 17.8  23.7 26.5 29.4 29.8 
Diabetes 
Cancer 21.8  30.2 35.5 45.0¶ 48.0¶ 
Non-cancer 24.4  28.8 32.2 36.6 39.1 
Depression 
Cancer 1.7  3.6 5.7 5.8 6.2 
Non-cancer 2.3  4.3 4.8 5.3 6.2 
White 
Hypertension 
Cancer 50.9  68.1¶ 76.2¶ 83.0¶ 84.9¶ 
Non-cancer 50.0  63.0 71.2 77.0 79.8 
Hypercholesterolemia 
Cancer 19.4‡  30.6¶ 39.6¶ 49.1¶ 53.4¶ 
Non-cancer 17.9  27.8 35.8 43.8 48.2 
COPD 
Cancer 16.2¶  24.4† 28.3 32.5¶ 32.8‡ 
Non-cancer 17.9  23.4 27.2 29.9 30.9 
Diabetes 
Cancer 14.6¶  20.0 23.7 32.4¶ 33.4¶ 
Non-cancer 17.2  20.8 23.7 27.2 29.0 
Depression 
Cancer 2.3¶  4.8 6.7 8.4 8.7 
Non-cancer 3.1  5.0 6.8 8.0 8.6 
COPD: Chronic pulmonary disease 
Chi-squared tests were conducted between cancer and non-cancer groups: Significance denoted as: †: p<0.05; 




Consistent with the previous analyses, Poisson regression models indicated that the 
prevalence rates of COPD, diabetes, and depression were lower among cancer survivors 
than among individuals without cancer before 2000 (Table 9). However, COPD and diabetes 
were more prevalent among the cancer group after 2000. Individuals with diagnosis of 
cancer were more likely to be diagnosed with hypercholesterolemia or hypertension at each 
time point and the magnitude of the prevalence ratios (PR) was higher after 2000, 
suggesting that some of the previously underdiagnosed conditions might be found after 
prostate cancer diagnosis. The racial subgroup analysis suggested that the magnitude of 
increase in PR was larger among black men. 
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Table 9. Adjusted disease prevalence ratios in cancer vs. non-cancer groups 
Race Condition 
Prevalence time point 




(1.00 – 1.05) 
 
1.09 ¶ 
(1.07 – 1.11) 
1.07 ¶ 
(1.06 – 1.09) 
1.08 ¶ 
(1.07 – 1.09) 
1.07 ¶ 
(1.05 – 1.08) 
Hypercholesterolemia 
1.07 ‡ 
(1.02 – 1.12) 
 
1.09 ¶ 
(1.05 – 1.13) 
1.09 ¶ 
(1.06 – 1.13) 
1.11 ¶ 
(1.08 – 1.14) 
1.09 ¶ 
(1.07 – 1.12) 
COPD 
0.94 † 
(0.89 – 0.99) 
 
1.08 ¶ 
(1.04 – 1.13) 
1.08 ¶ 
(1.03 – 1.12) 
1.11 ¶ 
(1.07 – 1.16) 
1.10 ¶ 
(1.04 – 1.14) 
Diabetes 
0.86 ¶ 
(0.81 – 0.90) 
 
0.97 
(0.93 – 1.01) 
1.01 
(0.96 – 1.05) 
1.19 ¶ 
(1.15 – 1.23) 
1.15 ¶ 
(1.11 – 1.20) 
Depression 
0.77 ‡ 
(0.67 – 0.90) 
 
1.00 
(0.90 – 1.11) 
1.04 
(0.95 – 1.14) 
1.08 
(0.99 – 1.17) 
1.03 




(1.00 – 1.14) 
 
1.12 ¶ 
(1.07 – 1.18) 
1.11 ¶ 
(1.07 – 1.16) 
1.11 ¶ 
(1.06 – 1.15) 
1.11 ¶ 
(1.07 – 1.16) 
Hypercholesterolemia 
1.39 ‡ 
(1.12 – 1.73) 
 
1.27 ‡ 
(1.08 – 1.50) 
1.24 ‡ 
(1.08 – 1.43) 
1.22 ‡ 
(1.08 – 1.38) 
1.18 † 
(1.04 – 1.33) 
COPD 
1.04 
(0.88 – 1.23) 
 
1.20 ‡ 
(1.05 – 1.37) 
1.27 ¶ 
(1.12 – 1.45) 
1.27 ¶ 
(1.12 – 1.45) 
1.33 ¶ 
(1.16 – 1.53) 
Diabetes 
0.86 † 
(0.74 – 1.00) 
 
1.01 
(0.89 – 1.15) 
1.07 
(0.94 – 1.21) 
1.18 ‡ 
(1.05 – 1.32) 
1.19 ‡ 
(1.06 – 1.33) 
Depression 
0.79 
(0.44 – 1.43) 
 
0.90 
(0.59 – 1.39) 
1.30 
(0.89 – 1.89) 
1.24 
(0.84 – 1.85) 
1.04 




(1.00 – 1.04) 
 
1.08 ¶ 
(1.07 – 1.10) 
1.07 ¶ 
(1.06 – 1.09) 
1.08 ¶ 
(1.07 – 1.09) 
1.06 ¶ 
(1.05 – 1.08) 
Hypercholesterolemia 
1.06 † 
(1.01 – 1.11) 
 
1.08 ¶ 
(1.04 – 1.12) 
1.08 ¶ 
(1.05 – 1.12) 
1.10 ¶ 
(1.07 – 1.13) 
1.09 ¶ 
(1.06 – 1.12) 
COPD 
0.93 ‡ 
(0.88 – 0.98) 
 
1.07 ‡ 
(1.03 – 1.12) 
1.06 ‡ 
(1.02 – 1.10) 
1.10 ¶ 
(1.06 – 1.15) 
1.08 ¶ 
(1.03 – 1.12) 
Diabetes 
0.85 ¶ 
(0.81 – 0.90) 
 
0.96 
(0.92 – 1.01) 
1.00 
(0.96 – 1.05) 
1.19 ¶ 
(1.15 – 1.24) 
1.15 ¶ 
(1.10 – 1.20) 
Depression 
0.77 ‡ 
(0.66 – 0.90) 
 
1.00 
(0.90 – 1.12) 
1.03 
(0.93 – 1.13) 
1.07 
(0.98 – 1.17) 
1.03 
(0.94 – 1.13) 
95% confidence intervals are listed in parentheses; Significance denoted as: †: p<0.05;  ‡: p<0.01;  ¶: p<0.001 
COPD: Chronic pulmonary disease 
Patients without cancer is the reference group 




We compared the unadjusted severity of comorbidities between cancer and 
individuals without cancer by CCI Index (Table 10). The cancer group tended to be healthier 
than the non-cancer group before cancer diagnosis (CCI score 0.76 vs. 0.93, p<0.001). 
However, after survivors were diagnosed with prostate cancer in 2000, the difference 
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between groups diminished by the first time point (i.e., 12/31/01), and disappeared by the 
second time point (i.e., 12/31/03). At the last two time points, the CCI scores were 
significantly higher among cancer group than among non-cancer group. Similar findings 
were observed in subgroup analysis by race. In black men, the CCI score before cancer was 
significantly lower among cancer patients as compared with individuals without cancer (1.01 
vs. 1.17, p<0.05). Although there were no significant differences at the first two time points 
after diagnosis, black cancer patients had significantly higher CCI scores at the 3rd and 4th 
time points (2.43 vs. 2.15 on 12/31/05 and 2.73 vs. 2.38 on 12/31/07, respectively). In white 
men, the CCI scores of cancer patients were significantly lower than of individuals without 
cancer at the first three time points (0.73 vs. 0.91, p<0.001; 1.20 vs. 1.27, p<0.001; 1.50 vs. 
1.56, p<0.05). However, white cancer group had significantly higher CCI scores than white 
non-cancer group at the last two time points (1.91 vs. 1.80, p<0.001; 2.04 vs. 1.98, p<0.05). 
We also used the NCICI to compare racial differences in comorbidity severity for prostate 
cancer patients. The NCICI scores increased with time in both black and white cancer 
survivors. However, black patients consistently had significantly higher NCICI scores than 
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95% Confidence intervals are listed in parentheses; Significance denoted as: †: p<0.05;  ‡: p<0.01;  ¶: p<0.001 
NCICI: National Cancer Institute Combined Index; CCI: Charlson Comorbidity Index 





The results from the GEE models are listed in Table 11. Variables with positive 
coefficients are associated with higher comorbidity severity. In general, comorbidity severity 
increased over time because all four time variables are strong predictors for higher CCI 
score. In addition, elder age, living in area with lower median household income, and living 
in area with higher proportion of persons without high school degree are associated with a 
higher CCI score.  
A series of Wald tests was conducted to assess the time effect on difference in CCI 
score between men with and without cancer and between black and white men (Table 12). 
At baseline, the CCI score of cancer patients was significantly lower than the score of 
individuals without cancer (-0.158, p<0.001). However, this difference became smaller after 
2000 and was no longer statistically significant at the last two time points. In addition, the 
CCI score was not different between black and white men at baseline (0.042, p=0.24), but it 
increased more among black men over time, signifying an increase in diagnosed 
comorbidity. Black men had significantly higher CCI score than white men between Time 1 
and Time 4. 
Another GEE analysis was conducted for prostate cancer survivors only to 
investigate the factors associated with comorbidity severity as measured by NCICI (Table 
11). The significantly positive time indicators suggest that severity of comorbidity increased 
over time. Elder age was also predictors for higher NCICI score. Higher median household 
income and receiving XRT were associated with lower NCICI score. The NCICI score was 
not significantly different between black and white cancer survivors before cancer diagnosis 
after adjusting for other factors (0.011, p=0.70). However, the results from Wald tests 
indicate that black survivors had significantly higher NCICI scores after cancer diagnosis 
than white survivors and the magnitude of the difference increased over time (Table 12).
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Table 11. Results of generalized estimating equations (GEE) analysis of comorbidity 
index score 
Variables All subjects Cancer survivors 
only Outcome CCI score NCICI score 
Cancer (non-cancer is the reference) -0.158 (0.020) ¶  
Black race (white race is the reference) 0.042 (0.036) 0.011 (0.029) 
Demographic information   
Age (as of 01/01/00) 0.061 (0.001) ¶ 0.027 (0.002) ¶ 
Median annual household income in $1,000 -0.003 (0.000) ¶ -0.002 (0.000) ¶ 
Percent persons with  a high school diploma 0.005 (0.001) ¶ 0.002 (0.001) † 
Time point (12/31/99 is the reference)   
  Time 1 (12/31/01) 0.434 (0.007) ¶ 0.212 (0.006) ¶ 
  Time 2 (12/31/03) 0.805 (0.007) ¶ 0.361 (0.007) ¶ 
  Time 3 (12/31/05) 1.148 (0.007) ¶ 0.564 (0.007) ¶ 
  Time 4 (12/31/07) 1.444 (0.007) ¶ 0.651 (0.007) ¶ 
Interaction terms   
Black * Case 0.046 (0.064)  
Cancer * Time 1 0.063 (0.015) ¶  
Cancer * Time 2 0.056 (0.016) ¶  
Cancer * Time 3 0.190 (0.017) ¶  
Cancer * Time 4 0.132 (0.017) ¶  
Black * Time 1 0.116 (0.025) ¶ 0.064 (0.022) ‡  
Black * Time 2 0.164 (0.026) ¶ 0.114 (0.023) ¶ 
Black * Time 3 0.234 (0.027) ¶ 0.112 (0.024) ¶ 
Black * Time 4 0.338 (0.029) ¶ 0.186 (0.026) ¶ 
Marital status (ever married is the reference)   
Never married  -0.000 (0.029) 
Unknown  -0.026 (0.023) 
Cancer grade (well differentiated is the reference)   
Moderately differentiated  -0.161 (0.032) ¶ 
Poorly differentiated  -0.166 (0.034) ¶ 
Undifferentiated  -0.154 (0.116) 
Unknown or missing  -0.148 (0.046) ‡  
Primary cancer treatment (watchful waiting is the reference) 
Surgery  -0.031 (0.021) 
Radiation therapy  -0.046 (0.018) † 
Constant -3.315 (0.112) ¶ -1.328 (0.135) ¶ 
Number of observations (n) 218,472 38,209 
Standard error is listed in parentheses; Significance denoted as: †: p<0.05;  ‡: p<0.01;  ¶: p<0.001 
CCI: Charlson Comorbidity Index; NCICI: National Cancer Institute Combined Index 
A survivor’s registry site is also controlled in the model (results not shown) 
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 Table 12. Time trend of group difference in comorbidity severity  
Outcomes CCI score NCICI score 
Comparison 
Cancer survivors vs. 
individuals without cancer 
Black men vs.  
white men 
Black survivors vs.  
white survivors 
Time point 
   
0 (12/31/99) -0.158 ¶             0.042                 0.011 
1 (12/31/01)* -0.095 ¶ 0.158 ¶ 0.075 † 
2 (12/31/03)* -0.102 ¶ 0.206 ¶ 0.125 ¶ 
3 (12/31/05)*                 0.032 0.276 ¶ 0.123 ¶ 
4 (12/31/07)*                -0.026 0.380 ¶ 0.197 ¶ 
*Difference between groups is the sum of baseline difference and time interaction from the corresponding GEE 
model. Wald test is conducted to evaluate whether there was group difference at each time point. 
Significance denoted as: †: p<0.05;  ‡: p<0.01;  ¶: p<0.001 
CCI: Charlson Comorbidity Index; NCICI: National Cancer Institute Combined Index 
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Physician Visits 
Before 2000, the total number of office visits by cancer patients was not different 
from the number by the individuals without cancer (Figure 5). Cancer patients had 
significantly more total office visits than individuals without cancer right after cancer 
diagnosis, but the difference in total office visits diminished in later time periods. Before 
cancer diagnosis in 2000, cancer survivors had more visits to prostate cancer specialists but 
fewer visits to PCPs than the individuals without cancer. As we expected, survivors’ made 
more office visits to prostate cancer specialists after cancer diagnosis. However, their visits 
to PCPs and other specialists also increased after cancer diagnosis. The average number of 
visit to urologists increased substantially from 0.8 in 1999 to 3.8 in 2000. Although the 
number of visits to prostate cancer specialists decreased after 2000, survivors still made 
more visits to their prostate cancer specialists than individuals without cancer. In addition, 
survivors made more visits to their PCPs after their cancer diagnosis (from 3.0 in 1999 to 3.8 
in 2000), especially among black survivors (from 3.2 in 1999 to 4.1 in 2000). Due to the data 
error in physician claims, the average number of office visit by survivors might be 





Eight weeks after the dissertation was defended on 12/04/2009, the SEER-Medicare Program Reported an error 
in 2004 physician claims data.http://healthservices.cancer.gov/seermedicare/seermed_2004_data_letter.pdf  
Therefore, the number of office visit might be underestimated in 2004. 










1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
year
Number of visit









1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
year
Number of visit









1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
year
Number of visit
Urologist Oncologist PCP Other








1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
year
Number of visit









1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
year
Number of visit
Urologist Oncologist PCP Other








1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
year
Number of visit
Urologist Oncologist PCP Other
PCP: primary care physician 
 70 
We also examined whether diabetes and hypertension newly diagnosed after cancer 
were more likely to be identified by prostate cancer specialists, rather than by PCPs. The 
prevalence rate of diabetes in cancer survivors changes from 15.3% on 12/31/1999 to 
20.9% on 12/31/2001. The provider specialty was unknown in 16.1% of the new diabetes 
cases diagnosed between 2000 and 2001. Approximately 40.6% of the new diabetes cases 
were diagnosed by PCPs but only 4.4 % of the cases were diagnosed by prostate cancer 
specialists (p<0.001). The rest of the new cases were identified by other specialists (38.8%). 
Similar findings were observed among new hypertension cases diagnosed between 2000 
and 2001. The proportion of cases diagnosed by unknown specialty was 20.0%. The new 
hypertension cases diagnosed by prostate cancer specialists and PCPs were 3.1% and 
47.2%, respectively (p<0.001). Other specialists diagnosed 29.7% of the new hypertension. 
4.5 Discussion 
As survivorship issues continue to grow, identification and treatment of comorbidities 
becomes increasingly relevant for cancer survivors. The existence of comorbidities may not 
only influence the choice of cancer treatment, but also may affect the health-related quality 
of life, morbidity, and mortality of cancer survivors (3-6). Although measurement of 
comorbidity is commonly included in regression analyses of cancer survivorship studies, it is 
usually measured cross-sectionally, rather than treated as a time-variant variable. 
To our knowledge, the current study is the first one to examine the longitudinal 
relationship between prostate cancer and diagnosis of other comorbidities. We selected a 
cohort of prostate cancer cases who were diagnosed in 2000 and examined their claims for 
up to ten years. We also included a comparison group of Medicare beneficiaries without 
cancer to eliminate the effect of aging on comorbidity. In our study, we found that more 
comorbid conditions were identified after cancer diagnosis. The prevalence rates of 
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comorbidities and overall comorbidity scores of prostate cancer survivors increased at a 
faster rate after their cancer diagnosis than those observed of individuals without cancer 
during the same time periods. Although the increases in the prevalence rates of depression, 
diabetes, and hypertension may be caused by the side effects of hormonal and radiation 
therapy (22, 23, 59), the same pattern was observed for COPD which has not been found to 
be associated with cancer treatment. In addition, similar findings were found in the GEE 
models controlling for cancer treatments. Moreover, we controlled for receiving hormonal 
therapy as an additional covariate in sensitivity analysis and still found similar results (result 
not shown). Therefore, it is possible that these changes were associated with more contact 
with the health care system because cancer survivors visited their health care providers 
more often after cancer diagnosis. We found that cancer survivors made more office visits 
not only to their prostate cancer specialists (including urologists) but also to their PCPs after 
the cancer diagnosis. This phenomenon was especially true among black cancer survivors. 
In addition, we expected prostate cancer specialists to become the main health care 
provider for cancer survivors and to supplant some of the responsibilities of care provided by 
PCP. However, it seems that cancer survivors still received their primary care for other 
health conditions from PCPs because the majority of newly diagnosed comorbid conditions 
after cancer were identified by PCPs, not by prostate cancer specialists. Therefore, a 
diagnosis of prostate cancer may provide a chance for some patients who were not 
previously engaged in the health care system to have regular contact with their PCPs, which 
increases the likelihood of finding other health conditions. 
In our study, racial differences were observed in comorbidity severity and the 
differences varied across time. Black cancer survivors consistently had higher NCICI scores 
than white survivors, meaning that they had a risk to die from causes other than cancer than 
white cancer survivors. Although black patients generally have more comorbidities than 
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white patients (32, 91, 92), it is also likely that more underdiagnosed comorbid conditions 
among black patients were found after the cancer diagnosis. In addition, black cancer 
patients made more visits to PCPs and other specialists than black individuals without 
cancer during the same time period. However, the numbers of office visits to PCPs and 
other specialists were not different between white cancer and white non-cancer groups. 
Although black patients tend to have more comorbidities than white patients, they tend to 
use less medical care possibly because of limited access to care and less trust in their 
physicians. Thus, a diagnosis of prostate cancer may represent a golden opportunity for 
black men to gain access to care for other comorbidities. 
Many other cancer studies controlled comorbidity as a time-invariant variable in their 
survival analyses (27, 32, 63). Methodologically, this approach may be inappropriate 
because we found the CCI and NCICI scores increased significantly across time. Future 
studies may want to control for a time-variant comorbidity score which could better reflect 
the risk for dying from causes other than cancer. In addition, our study found that black 
patients had consistently higher comorbidity scores than white patients and the magnitude 
of difference increased over time. Thus, previous survival analyses controlling for a time-
invariant baseline comorbidity index score may under estimate the racial differences in 
comorbidity. We suggest that future studies to use time-variant comorbidity index scores 
which may be more appropriate to adjust for racial differences in mortality among prostate 
cancer survivors. 
The main limitations of this study were similar to those observed in observational 
studies using administrative datasets. The results of this study may not be generalizable to 
non-SEER regions because Medicare beneficiaries living in the SEER regions are less likely 
to be white, live in poverties, reside in rural areas, and enroll in managed care plans (70). 
Medicare beneficiaries who were diagnosed with cancer before age 67 were excluded from 
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our analyses because we were unable to obtain their claims data before Medicare 
enrollment. Therefore, the findings from our study may not be generalized to younger 
prostate cancer survivors. The results from our study may not be generalized to HMO 
enrollees who were excluded from our analyses because information about their medical 
care was not available. Since risk factors, treatment options, and survival rates vary by types 
of cancer, different cancers may have different influence on the rates of and severity 
associated with various comorbidities. Therefore, the results from our study may not be 
generalizable to other types of cancer survivors. Due to data limitations, we were unable to 
observe the diagnosis of comorbidities before a patient enrolled in the Medicare program. 
Thus, it is likely that our study underestimated the true prevalence of each chronic condition. 
However, we expected that this problem has a similar influence on both the cancer and non-
cancer groups. We did not consider cure function for comorbid conditions when we 
measured cumulative comorbidity prevalence and severity. This assumption may be more 
appropriate for some diseases (e.g., COPD and diabetes) than others (e.g. peptic ulcer and 
hypertension). However, we expected the influence of this assumption to be similar among 
both cancer and non-cancer groups.  
In addition, the CCI and NCICI scores were the aggregated weight of chronic 
conditions observed in insurance claims. Although the severity of a disease may vary across 
patients, the severity of patients diagnosed with same type of diseases is weighted in the 
same way. Without a detailed review of patient medical records, we were unable to 
differentiate the severity of the disease among individuals. In addition, we measured the 
comorbidity prevalence and severity among individuals who remained alive at different time 
points. A “survivor effect” might exist in the time trend of diagnosis. In other words, those 
who remain alive at a time point may be healthier (i.e., fewer comorbidities) than those who 
die before that point. Since individuals with localized or regional prostate cancer and the 
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general non-cancer population have very similar survival rates (9), we expected the survivor 
effect to be similar between them. In sensitivity analysis, we restricted our samples to those 
who survive until the end of study (results not shown). The results from this approach did not 
differ from our primary findings. We selected patients diagnosed with prostate cancer in 
2000 because they are the most recent cohort to fulfill our longitudinal study design. In 
sensitivity analysis (results not shown), we used patients who were diagnosed with prostate 
cancer in 1997 and applied the same study design. The findings were unchanged. 
4.6 Conclusion 
The benefit of prostate cancer screening remains controversial because most the 
prostate cancer patients are diagnosed at early stage (9). Previous studies did not find 
evidence to support that a reduction in cancer mortality rate from the early diagnosis of 
prostate cancer (18, 21, 95). In addition, prostate cancer treatments may cause adverse 
effects, such as incontinence and erectile dysfunction (22, 23). Therefore, some researchers 
have criticized the overdiagnosis and overtreatment of the low-risk prostate cancer patients 
(15-17). However, a diagnosis of prostate cancer at early stage may have some unexpected 
positive effects on other health conditions. Our study found that a diagnosis of prostate 
cancer may be associated with detection of previously underdiagnosed comorbid conditions. 
Identifying occult diseases at their early stages may lead to effective intervention and 
ultimately to better health outcomes. We also found that survivors had more contact with 
their health care providers after their cancer diagnosis, which might increase their chances 
of receiving appropriate management for comorbidities. Survivorship programs should 
incorporate management of comorbidities as one of their focuses for cancer survivors, since 






CHAPTER 5. ASSOCIATION BETWEEN CANCER AND USE OF NECESSARY CARE 
FOR COMORBID HEALTH CONDITIONS AMONG ELDERLY MEN WITH PROSTATE 




Background: Since prostate cancer survivors are more likely to die from non-cancer causes 
than from their cancer, coexisting comorbidities are important health issues for this 
population. This study examined whether patients are more likely to receive necessary 
ambulatory care after their prostate cancer diagnosis. 
Methods: Patients diagnosed with localized/regional prostate cancer at age 67-84 in 2000 
(n=9,053) were identified from the Surveillance, Epidemiology, and End Results-Medicare 
Program. A comparison group of Medicare beneficiaries with no history of cancer also were 
included (n=43,926). Indicators from the refined Access to Care for the Elderly Project were 
used to examine the use of necessary care for non-cancer comorbidities. The proportion of 
eligible patients receiving necessary care for each indicator was calculated every two years 
from 1998 through 2007. Composite scores were calculated for indicators of clinical 
assessment for chronic conditions, management of chronic conditions, follow-up after 
hospitalization, preventable adverse outcomes avoided, work-up at initial diagnosis, and 
overall use of necessary care. A generalized estimating equations (GEE) model was used to 





Results: After 2000, the cancer group was more likely to receive more necessary care for 
their comorbid conditions than the non-cancer group, especially for clinical assessment and 
management of chronic conditions. Results from the GEE analysis indicate that black 
survivors tend to use less care than white survivors, but the difference diminished after their 
cancer diagnosis. 
Conclusions: A diagnosis of prostate cancer may represent an opportunity for survivors to 
improve their use of necessary care for other comorbidities, especially for black survivors. 
Further studies are necessary to examine whether the improvement is associated with better 
health outcomes.  
 
Keywords: prostate cancer, comorbidities, use of care, SEER-Medicare, 
 
5.2 Introduction 
Prostate cancer is the most often diagnosed cancer among men in the United States. 
The incidence of prostate cancer has increased dramatically as a result of prostate-specific 
antigen (PSA) testing, which substantially increased since the mid-1990s (14). However, the 
use of the PSA screening is controversial and equivocal (15-17). At present, more than 90% 
of prostate cancer patients are diagnosed with localized or regional stage cancer, which are 
highly survivable (9). Results from the randomized Prostate, Lung, Colorectal, and Ovarian 
(PLCO) Cancer Screening Trial showed that the mortality rates from prostate cancer did not 
differ between patients who received annual PSA screening or usual care (18). Previous 
studies also found potential psychological harms by prostate screening (15, 21) and adverse 
effects, such as incontinence and erectile dysfunction, caused by cancer treatments (15, 22, 
23). Therefore, researchers have questioned whether it is necessary to diagnose and treat 
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patients with early stage prostate cancer (15-17). For many survivors, prostate cancer and 
its treatment may constitute only a fraction of medical history. Other comorbid conditions 
may play a more important role in a survivor’s health, longevity, and physical function. 
However, the quality of care for other comorbid conditions has not been the focus of 
previous cancer survivorship research. 
Although a diagnosis of prostate cancer at early stage may not reduce the risk of 
cancer mortality, it may have some effects on the management of other comorbid conditions. 
Cancer diagnosis may represent “a teachable moment” for risk factor reduction because 
patients tend to be more aware of their other health problems after cancer diagnosis (48-50). 
To prevent cancer recurrence and to increase the likelihood of survival, cancer survivors 
often attempt to quit smoking, to eat healthier, and to engage in regular exercise (48-50, 52, 
53, 55, 56). These behavioral changes are associated with better health-related outcomes 
(51, 57, 58). In a previous study, we found that prostate cancer survivors made more visits 
not only to their oncology specialists but also to their primary care physicians (PCPs) and 
other specialists after their cancer diagnosis (Chapter 4). This regular contact with the health 
care system may increase the chance of receiving appropriate medical care. We also found 
that some chronic conditions that were potentially underdiagnosed prior to the cancer 
diagnosis were identified after a diagnosis of prostate cancer. Therefore, the cancer 
diagnosis may provide an opportunity to better control comorbidities. 
However, comorbidities may worsen after cancer diagnosis. Long-term and late 
effects of cancer treatments are commonly observed among cancer survivors. For example, 
chemotherapy and radiation therapy may have negative effects on erectile function, 
cardiovascular disease, or mental health (22, 23, 59). In addition, cancer patients may not 
think that the continued management of other comorbidities is as important after their cancer 
diagnosis. Survivors may receive less care for comorbidities because their care may consist 
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primarily of specialty care provided by specialist physicians, with little attention to primary 
care needs (36). Insufficient primary care may lead to development of other comorbidities or 
the worsening of existing comorbidities. 
Few studies have investigated the use of care for other comorbid conditions among 
cancer survivors. A previous study found that breast cancer survivors received more 
preventive care than the non-cancer controls (35), suggesting that breast cancer patients’ 
enhanced participation in the health care system may explain better quality of care. 
However, different findings were reported in colorectal cancer patients. Despite the higher 
prevalence of comorbidities, colorectal cancer survivors were more likely to underuse 
necessary care for their comorbid conditions than non-cancer controls (36). Since risk 
factors, treatment options, and survival rates vary by types of cancer, the results from these 
studies may not be generalized to other types of cancer survivors. In addition, both of the 
studies measured the use of care cross-sectionally by following 5-year cancer survivors for 
two years. Although the authors examined the use of care among long term survivors, they 
did not analyze whether the same patterns of care use exist even before the cancer 
diagnosis. To our knowledge, no published study has examined the use of care for other 
comorbid conditions longitudinally among prostate cancer patients. 
The purpose of this study is to investigate whether diagnosis of prostate cancer 
creates an opportunity to improve use of necessary care among Medicare beneficiaries. We 
used the refined Access to Care for the Elderly Project (ACE-PRO) indicators to examine 
the receipt of care of prostate cancer patient for a maximum of ten years. We first measured 
the use of care for each indicator in two-year intervals. Indicators with similar nature were 
grouped together and compared across time. We expected an increase in the proportion of 
patients receiving necessary care after cancer diagnosis. In addition, we conducted 
subgroup analyses to examine whether the findings differ by race. Finally, we used 
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regression analyses to examine whether black survivors used less necessary care for their 
comorbid conditions after controlling for other confounders. 
5.3 Methods 
Data Sources 
Our data were obtained from the Surveillance, Epidemiology, and End Results 
registry (SEER)-Medicare Program. The SEER-Medicare data are population-based data 
that combine SEER cancer registry information with Medicare enrollment and claims files 
(70, 72). The SEER Program is a national cancer registry which covers more than 25% of 
the US population. It routinely collects data on patient demographics, tumor site, stage at 
diagnosis, primary course of treatment and aggregate measures of social economic status 
(SES) information including regional median household economic and educational status 
(69, 70). We used the data from the SEER-17 which provides the latest data available for 
our longitudinal follow-up. The SEER-17 includes cancer registries of the Arizona Native 
American, Alaska Natives, nine states (California, Connecticut, Hawaii, Iowa, Kentucky, 
Louisiana, New Jersey, New Mexico, and Utah), and seven regions (Atlanta, Detroit, rural 
Georgia, Los Angeles, San Francisco, San Jose, and Seattle). Medicare is the primary 
health insurer for 97% of the US population ages 65 years and older. A beneficiary’s 
disease diagnoses, treatments, and services received are available in the Medicare claims. 
However, data are not available for health maintenance organization (HMO) enrollees, 
services not covered by Medicare (i.e., outpatient prescription drugs and long term care), 
and services provided by Veterans Affairs or Medicaid, or by Medicare supplement 




Patients diagnosed with localized or regional (i.e., Stage I, II, or III) prostate cancer in 
2000 were included in this study. Compared with non-cancer population, these cancer 
patients’ five-year relative survival rate is approximately 100% (9). We excluded patients 
who were diagnosed with distant (i.e., Stage IV) prostate cancer because their five-year 
relative survival rate is only 32% (9). The claims of each patient were examined for up to ten 
years, beginning from January 1, 1998 through his death or December 31, 2007. To be 
eligible for inclusion in the study, patients must have been continuously enrolled in Medicare 
Part A and Part B and never enrolled in HMO during the study period. To observe the use of 
necessary care before cancer diagnosis, we included only patients were at age 67 or older 
as of January 1, 2000, thus allowing for two years of observation prior to diagnosis. 
Medicare beneficiaries who are eligible for Medicare because of disability or the presence of 
end-stage renal disease before age 65 were excluded from the analyses as well. Other 
exclusion criteria included: age 84 and over as of January 1, 2000; prior cancer history; 
diagnosis with a second cancer within six months; noninvasive tumors (i.e., carcinoma in 
situ); unstaged prostate cancer; diagnosis at death or via autopsy; or missing; race other 
than black or white; or missing SES variables. 
To control for the effect of aging, we selected a comparison group from the 5-percent 
random sample of patients without cancer in the SEER-Medicare data. Inclusion criteria for 
the non-cancer group were: male gender; qualified for Medicare benefit because of age; age 
between 67 and 84 years as of January 1, 2000; continuously enrolled in Medicare Part A 
and Part B and never enrolled in the HMO program during the study period; and living in 
areas covered by the SEER-17 registry. We did not to use matching technique to further 
narrow down the non-cancer group. Instead, we used all of the non-cancer patients who are 
qualified for our inclusion/exclusion criteria. Since the non-cancer group, by definition, had 
never been diagnosed with any cancer in the study timeframe, it would be arbitrary and 
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potentially biased to assign an index date (i.e., date of cancer diagnosis) to them by 
matching technique. We used regression analyses to adjust for the influence caused by 
baseline differences between cancer and non-cancer. 
Variable Definitions 
A cancer patient’s age, race, and date of death are available from both SEER and 
Medicare data. Demographic information from these two sources is highly consistent (69). 
Since the demographic data for the comparison group are available only in the Medicare 
enrollment file, we employed Medicare’s Enrollment Database as our primary source to 
identify age, race, and vital status for both groups. Empirically, data aggregated at the 
census tract level are more likely to reflect a patient’s socioeconomic status (SES) than are 
zip code level data (69). However, the SES information for the comparison group is 
available only at the zip code level; hence we controlled for median household income and 
percentage of residents with less than a high school degree at zip code level from the 2000 
Census for both groups in our analyses. We also used the Charlson Comorbidity Index (CCI) 
to assess the severity of comorbidities at different time points. The CCI is a commonly used 
measure of comorbidity in epidemiologic and outcomes research (27, 38, 39, 63, 74). A 
higher comorbidity score represents more severe health problems. For the subgroup 
analysis for prostate cancer survivors, we used the National Cancer Institute Combined 
Index (NCICI) to measure comorbidity severity. The NCICI, which adapts the comorbid 
conditions from the CCI, was developed specifically for the use with SEER-Medicare data by 
weighing comorbidity differently by cancer site (40). As with the CCI, higher NCICI scores 
indicate greater comorbidity severity. 
We used both SEER indicator and Medicare claims within six months of cancer 
diagnosis to identify primary cancer treatment. Surgery and radiation therapy (XRT) are 
consistently reported in SEER and Medicare claims data (>90% agreement) (93, 94). 
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Surgery was defined as procedures performed with curative intent or in anticipation of a 
subsequent curative procedure (27). We used: (1) the indicator for whether a cancer-
directed surgery was performed; (2) International Classification of Diseases, 9th Revision, 
(ICD-9) procedure codes 60.5 and 60.6; Current Procedural Terminology (CPT) codes 
55810, 55812, 55815, 55840, 55842, 55845, 55866 from Medicare claims; and (3) site-
specific surgery codes 30–90 from the SEER data to identify radical prostatectomy and 
procedures performed on regional lymph nodes. XRT was defined as external beam therapy, 
brachytherapy, or therapeutic isotope radiation therapy as listed in the SEER data.(63) We 
used: (1) the indicator for whether a cancer-directed XRT was performed; (2) ICD-9 
procedure codes 92.2x, V58.0, V66.1, V67.1, CPT codes 77301, 77400–77499; revenue 
center codes 0330–0339 from Medicare claims; and (3) site-specific radiation codes 1–5 in 
the SEER data to identify XRT. Men who receive both surgery and XRT were classified as 
having surgery because some patients may receive XRT after an incomplete or 
unsuccessful surgery (27, 63). 
The type of care provider was classified based on the specialty information in the 
Medicare Carrier Claims (36). Oncology specialists were defined as sub-specialists in 
urology (code 34), hematology oncology (code 83), medical oncology (code 90), surgical 
oncology (code 91), or radiation oncology (code 92). Primary care physicians were defined 
as physicians in general practice (code 01), family practice (code 08), internal medicine 
(code 11), geriatric medicine (code 38), or multi-specialty group practices (code 70). 
Quality of Care Measures 
We used the refined Access to Care for the Elderly Project (ACE-PRO) indicators 
from the Medicare Payment Advisory Commission (MedPAC) to assess use of necessary 
ambulatory care among elderly Medicare beneficiaries (64). The MedPAC, an independent 
Congressional agency, advises the US Congress on issues affecting the Medicare program. 
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The ACE-PRO indicators were originally developed for MedPAC by researchers from the 
RAND Corporation in 2000 (34). MedPAC has used the ACE-PRO indicators to study the 
access to and quality of care associated with various geographic and socioeconomic factors, 
and has used the results of these analyses in their reports to Congress (64). The ACE-PRO 
indicators were updated in 2006 to reflect changes in performance measurement and 
clinical practice. The refined ACE-PRO indicators have been tested and validated on 
Medicare claims by MedPAC (64). 
The refined ACE-PRO indicators consist of 40 indicators for medical conditions 
covering anemia, angina, breast cancer, colorectal cancer, chronic obstructive pulmonary 
disease, congestive heart failure, coronary artery disease, depression, diabetes, 
gastrointestinal bleeding, hypertension, and stroke or transient ischemic attack. Six 
indicators were excluded from our analysis because they were developed specifically either 
for women or for other cancers. Based on the suggestion of MedPAC, the remaining 34 
indicators were categorized into five groups by their type of care (Table 5) (64). 
We estimated the use of necessary care in every two-year time period (64). For each 
indicator, we first used the ICD-9 codes to identify the number of individuals who were 
qualified for it (i.e., denominator). We then used the CPT codes to identify the number of 
qualified individuals who met the requirement of the indicator (i.e., numerator). The ratio of 
numerator to denominator represents the proportion of individuals used the necessary care. 
For example, we assessed the eye care indicator by calculating the proportion of individuals 
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For each person, we also calculated composite scores for clinical assessment in 
chronic condition, management of chronic condition, follow-up after hospitalization, possible 
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adverse outcomes avoided, and work-up at initial diagnosis. Finally, we calculated an overall 
composite score by dividing the sum of numerators to the sum of qualified denominators to 



















The use of necessary care for each indicator was measured during five time periods 
(Figure 3). Period 0 measured the baseline use of care in 1998 and 1999 (i.e., two years 
before the index date (i.e., cancer diagnosis or 2000). Period 1 evaluated whether patients 
receive necessary care for their comorbidities right after cancer diagnosis (i.e., between 
2000 and 2001). Periods 2 and 3 focused on the use of care between 2002 and 2003 and 
between 2004 and 2005, respectively. The last period, Period 4 (between 2006 and 2007), 
measured the use of care after patients have survived from prostate cancer for more than 
five years. The result from this period can be directly compared with the findings from 
previous studies evaluating the use of care in other types of cancer (35, 36). 
The ACE-PRO indicators were originally developed for analysis using two years of 
data (64). Many indicators use the first year of observation to determine individuals who are 
qualified for denominators and use the second year to identify numerators. In this study, we 
made some adjustments to the ACE-PRO method for our ten-year study timeframe. For 
indicators of clinical assessment, management of chronic conditions, and avoidable adverse 
outcomes, an individual became qualified for denominator after the year when he was first 
diagnosed with a chronic condition. For example, if a person was diagnosed with diabetes in 
1998 and survived through 2007, he was qualified for the denominator of clinical 
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assessment indicator for diabetic patient in Period 0, Period 1, Period 2, Period 3, and 
Period 4. This patient would need at least two outpatient visits per year during a time period 
to meet the requirements of the indicator. For indicators of follow-up after hospitalization, we 
used the first event in each time period without another event within 4 weeks following the 
discharge of the previous event. For the indicators of work-up at initial diagnosis, we 
examined the care at the first diagnosis in the entire time frame, rather than the first 
diagnosis in each time period. Our ten years of follow-up allows us to identify the initial 
diagnosis more precisely than the conventional ACE-PRO method using only two years of 
data. 
Statistical Analyses 
For each indicator, we first compared the ratios of numerators to denominators 
between cancer and non-cancer groups at different time periods. Chi-square tests (78) were 
conducted to examine whether prostate cancer survivors received the same level of care for 
their comorbid conditions as the comparison group did. For different types of care, we 
conducted Student’s t tests to compare composite scores between cancer and comparison 
groups in different time periods. 
A multivariate generalized estimating equations (GEE) regression model (80, 81) 
was conducted to analyze the association between prostate cancer diagnosis and overall 
use of necessary care. Identity link and normal residuals were used in the GEE model. The 
effects of cancer on use of necessary care during various time periods were of primary 
interest. The sum of coefficients of cancer indicator and its interaction term with time was 
tested by Wald test in each time period (80, 81).  Other factors, including age, race, registry 
site, education, income, and comorbidities, which might be associated with use of care and 
prostate cancer diagnosis, were controlled for in the model. In addition, we conducted a 
separate GEE analysis for cancer survivors only to examine whether racial differences in 
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use of care changed after cancer diagnosis. The sum of coefficients of race and interaction 
terms between race and time was further examined by Wald test (80, 81). In addition to the 
independent variables in the previous GEE model, we also controlled for marital status, 
primary cancer treatment, tumor grade, and type of care provider, which were only available 
for the cancer group. 
5.4 Results 
Study Sample 
Figure 6 presents a flow chart of the sample selection process. A total of 43,150 
prostate cancer cases were initially identified in 2000 from the SEER-Medicare data. 
Employing the inclusion and exclusion criteria described earlier, 9,053 prostate cancer 




Figure 6. Procedures to generate the study sample of prostate cancer patients 
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Age (years) on 01/01/2000, % 
67-69 19.1 19.2 <0.001  22.1 20.4 0.52  18.8 19.1 <0.001 
70-74 37.5 33.2 
 
 35.9 35.4 
  
37.7 33.1 
 75-79 29.6 29.6  27.9 28.1 29.8 29.7 
80-84 13.8 18.0  14.2 16.1 13.8 18.1 
Mean age, year 74.0 74.4 <0.001  73.7 74.1 0.08  74.0 74.5 <0.001 
Mean follow-up 
time, month 
105.7 102.8 <0.001  100.6 97.3 <0.01 
 
106.2 103.1 <0.001 
Alive as of 
12/31/2007, % 
65.7 64.1 <0.01  56.0 54.6 0.49  66.6 64.7 <0.001 
Registry site, % 
San Francisco 3.0 2.9 <0.001  2.7 3.3 <0.001  3.1 2.9 <0.001 
Connecticut 7.6 6.9 
 





Detroit 11.7 8.2  33.1 20.4 9.7 7.5 
Hawaii 0.4 0.4  0.1 0.1 0.5 0.5 
Iowa 8.7 8.3  0.9 0.9 9.5 8.7 
New Mexico 2.1 2.6  0.3 0.7 2.3 2.7 
Seattle 5.9 5.3  1.1 1.3 6.4 5.6 
Utah 3.7 3.1  0.4 0.3 4.0 3.2 
Atlanta 3.1 3.1  6.7 7.7 2.7 2.8 
San Jose 1.9 2.1  0.9 0.6 2.0 2.2 
Los Angeles 6.0 6.4  8.0 8.6 5.8 6.3 
Rural Georgia 0.2 0.3  0.5 1.1 0.2 0.2 
California 14.7 17.3  4.1 6.5  15.7 17.9 
Kentucky 5.8 9.0  2.8 5.8  6.1 9.2 
Louisiana 7.0 7.0  17.1 19.6  6.0 6.3 
New Jersey 18.3 17.2  18.3 19.4  18.3 17.1 
Percent persons age 25+ of same race with less than a high school education 
Mean, % 16.2 16.5 0.02  28.2 28.9 0.17  15.0 15.8 <0.001 
Annual household income 
Mean, $ 51,281 49,140 <0.001  35,544 35,465 0.89  52,829 49,954 <0.001 
Charlson Comorbidity Index Score 
12/31/1999 0.76 0.93 <0.001  1.01 1.17 0.02  0.73 0.91 <0.001 
12/31/2001 1.24 1.29 0.01  1.63 1.59 0.58  1.20 1.27 <0.001 
12/31/2003 1.54 1.57 0.24  2.01 1.84 0.07  1.50 1.56 0.02 
12/31/2005 1.95 1.81 <0.001  2.43 2.15 0.01  1.91 1.80 <0.001 




Table 13 presents the baseline characteristics of the study sample. Compared with 
the comparison group, prostate cancer survivors were generally younger and had longer 
follow-up (p<0.001). The proportions of individuals coming from specific registry sites were 
different between the cancer and comparison groups (p<0.001). The cancer group lived in 
areas with higher median household income and a lower proportion of residents with less 
than a high school degree. Before 2000, the cancer group had a lower average CCI score 
than the comparison group did (0.76 vs. 0.93, p<0.001). Compared with the non-cancer 
comparison group, cancer survivors were more likely to be black (9.0% vs. 5.6%, p<0.001). 
Among white men, cancer survivors were more likely to be younger, to have longer follow-up, 
and to have fewer comorbidities (i.e., a lower CCI score). In addition, white cancer survivors 
were less likely to live in an area with higher educational attainment (p<0.001) and higher 
median household income (p<0.001). Similar findings were observed among black patients. 
However, except for the length of follow-up (p<0.01), registry site (p<0.001), and comorbidity 
score (p=0.02), none of the differences in baseline characteristics between the black cancer 
and comparison groups was statistically significant. 
Receipt of Necessary Care 
Clinical Assessment of Chronic Conditions 
Table 14 shows results of the indicators for clinical assessment and management of 
chronic conditions. In Period 0, cancer survivors with coronary artery disease (CAD), chronic 
obstructive pulmonary disease (COPD), and congestive heart failure (CHF) were more likely 
to have regular visits to their physicians than individuals without cancer having the same 
conditions. No difference was observed between the cancer and comparison groups with 
respect to diabetes or stroke/transient ischemic attack (TIA). Regardless of comorbid 
conditions, cancer survivors were more likely to have at least one office visit per year to their 
physician than were individuals without cancer (84.1% vs. 81.4%, p<0.001). For all of the 
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clinical assessment indicators, cancer patients were more likely to have regular outpatient 
visits than the non-cancer patients after 2000. Surprisingly, the use of care dropped among 
cancer group in Period 3, and cancer survivors were less likely to have regular office visits to 
their physicians than were individuals without cancer. However, the receipt of care as 
measured by most of the indicators was significantly higher among cancer survivors than 
among individuals without cancer in the last time period. A similar time trend was observed 
in subgroup analyses by race. However, the difference in receipt of care between the cancer 
and non-cancer groups after 2000 was larger among black patients. 
Management of Chronic Conditions 
Similar findings were observed for the management of chronic condition indicators. 
After prostate cancer diagnosis, survivors with a history of diabetes were more likely to 
receive an eye exam but less likely to receive a hemoglobin A1C test. Except for Period 3, 
cancer survivors with a history of CAD were more likely to receive annual lipid testing than 
were individuals without cancer. In the period immediately following cancer diagnosis or 
index date, cancer survivors with CHF were more likely to have had a regular exam for 







Table 14. Comparison of indicators for clinical assessment and management of chronic conditions 2 
  Sample size (n) Proportion of patients reaching the goal (%) 
  Both Both Black White 
Indicator Period (year) Cancer Non-Cancer Cancer Non-cancer Cancer Non-cancer Cancer Non-cancer 
Clinical assessment in chronic disease 
Two outpatient visits per 
year in patients with 
diabetes mellitus 
P0 (1998-1999) 855 5,162 96.8 96.0 94.8 92.4 97.2 96.4 
P1 (2000-2001) 1,302 6,511 98.0 92.6 ¶ 94.6 89.4 † 98.5 92.9 ¶ 
P2 (2002-2003) 1,416 6,940 96.3 91.2 ¶ 92.4 87.7 96.9 91.5 ¶ 
P3 (2004-2005) 1,924 7,070 85.8 92.0 ¶ 80.4 88.1 ‡ 86.4 92.3 ¶ 
P4 (2006-2007) 1,831 6,977 94.5 92.0 ¶ 92.1 86.6 94.7 92.4 ‡ 
Two outpatient visits per 
year in patients with 
coronary artery disease 
P0 (1998-1999) 1,507 8,129 97.8 96.4 ‡ 94.4 92.4 98.0 96.5 ‡ 
P1 (2000-2001) 2,468 11,599 98.3 93.6 ¶ 97.7 87.0 ¶ 98.3 93.9 ¶ 
P2 (2002-2003) 2,783 12,845 97.2 92.4 ¶ 95.9 89.3 ‡ 97.3 92.5 ¶ 
P3 (2004-2005) 3,041 13,127 81.8 92.3 ¶ 81.6 89.4 ‡ 81.9 92.4 ¶ 
P4 (2006-2007) 2,859 12,696 95.1 91.9 ¶ 93.0 85.1 ‡ 95.3 92.4 ¶ 
Two outpatient visits per 
year in patients with 
stroke / transient 
ischemic attack 
P0 (1998-1999) 333 2,126 95.2 95.2 92.9 92.1 95.4 95.4 
P1 (2000-2001) 730 3,968 98.5 93.2 ¶ 95.2 86.2 † 98.8 93.7 ¶ 
P2 (2002-2003) 943 5,022 97.5 92.4 ¶ 98.5 87.6 ‡ 97.4 92.6 ¶ 
P3 (2004-2005) 1,224 5,631 85.2 92.3 ¶ 86.7 86.2 85.1 92.6 ¶ 
P4 (2006-2007) 1,250 5,814 94.6 91.8 94.2 85.7 † 94.6 92.2 ‡ 
Two outpatient visits per 
year in patients with 
COPD / Asthma 
P0 (1998-1999) 653 3,693 96.3 94.1 † 95.7 87.5 96.4 94.5 
P1 (2000-2001) 1,261 5,707 97.5 91.3 ¶ 95.4 87.5 † 97.8 91.6 ¶ 
P2 (2002-2003) 1,486 6,538 96.0 90.5 ¶ 93.4 85.5 † 96.3 90.8 ¶ 
P3 (2004-2005) 1,782 6,845 82.8 90.4 ¶ 77.4 86.3 † 83.3 90.7 ¶ 
P4 (2006-2007) 1,676 6,758 94.9 91.1 ¶ 94.2 84.8 ‡ 94.9 91.4 ¶ 
Two outpatient visits per 
year in patients with 
congestive heart failure 
P0 (1998-1999) 364 2,467 98.4 96.2 † 98.1 92.2 98.4 96.5 
P1 (2000-2001) 785 4,126 98.2 94.8 ¶ 96.2 86.2 ‡ 98.5 95.4 ¶ 
P2 (2002-2003) 989 4,904 96.7 94.2 ‡ 94.3 88.9 96.9 94.5 ‡ 
P3 (2004-2005) 1,325 5,319 86.8 93.5 ¶ 83.3 88.3 87.2 93.9 ¶ 
P4 (2006-2007) 1,304 5,396 96.0 93.9 ‡ 94.7 86.2 † 96.2 94.3 † 
One outpatient visits per 
year in Medicare 
beneficiaries 
P0 (1998-1999) 9,053 43,926 84.1 81.4 ¶ 72.4 66.9 ‡ 85.2 82.2 ¶ 
P1 (2000-2001) 8,599 39,953 96.2 83.4 ¶ 90.1 68.8 ¶ 96.8 84.3 ¶ 
P2 (2002-2003) 7,747 35,981 95.4 85.6 ¶ 87.8 72.9 ¶ 96.1 86.3 ¶ 
P3 (2004-2005) 6,865 32,223 83.8 87.3 ¶ 79.2 75.1 84.2 88.0 ¶ 
P4 (2006-2007) 5,945 28,176 94.2 88.5 ¶ 87.2 75.4 ¶ 94.8 89.1 ¶ 
 ___________________________ 
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Eight weeks after the dissertation was defended on 12/04/2009, the SEER-Medicare Program Reported an error in preparing 2004 physician 
claims data. http://healthservices.cancer.gov/seermedicare/seermed_2004_data_letter.pdf Therefore, the use of necessary care might be 




Table 14. Comparison of indicators for clinical assessment and management of chronic conditions (continued) 
Management of Chronic Conditions 
Comprehensive eye 
exam every 2 years in 
patients with diabetes 
P0 (1998-1999) 855 5,162 64.3 62.2 53.9 56.7 64.9 62.7 
P1 (2000-2001) 1,302 6,511 63.1 63.3 50.3 54.7 64.9 64.0 
P2 (2002-2003) 1,416 6,940 68.6 65.5 † 58.1 56.3 70.1 66.2 ‡ 
P3 (2004-2005) 1,924 7,070 74.0 66.6 ¶ 69.1 58.2 ‡ 74.5 67.2 ¶ 
P4 (2006-2007) 1,831 6,977 70.7 67.8 † 60.5 55.4 71.8 68.7 † 
Hemoglobin A1C test 
every year in patients 
with diabetes 
P0 (1998-1999) 855 5,162 72.3 69.8 67.8 57.9 73.0 70.9 
P1 (2000-2001) 1,302 6,511 66.7 66.0 59.9 54.5 67.7 66.9 
P2 (2002-2003) 1,416 6,940 65.0 65.3 54.1 60.7 66.6 65.6 
P3 (2004-2005) 1,924 7,070 45.3 65.8 ¶ 51.5 55.1 44.6 66.6 ¶ 
P4 (2006-2007) 1,831 6,977 51.3 66.7 ¶ 54.8 58.0 51.0 67.3 ¶ 
Lipid profile every year 
in patients with 
diabetes 
P0 (1998-1999) 855 5,162 63.3 57.1 ¶ 58.3 44.4 ‡ 64.1 58.2 ‡ 
P1 (2000-2001) 1,302 6,511 57.2 54.7 49.1 38.8 ‡ 58.4 56.0 
P2 (2002-2003) 1,416 6,940 63.2 59.7 † 48.8 51.2 65.2 60.4 ‡ 
P3 (2004-2005) 1,924 7,070 61.0 63.4 47.9 53.0 62.5 64.2 
P4 (2006-2007) 1,831 6,977 63.3 65.7 54.8 51.1 64.2 66.7 
Lipid profile every year 
in patients with 
coronary artery 
disease 
P0 (1998-1999) 1,507 8,129 68.5 63.3 ¶ 56.7 46.2 69.2 64.0 ¶ 
P1 (2000-2001) 2,468 11,599 62.2 58.6 ¶ 47.7 39.3 63.3 59.4 ¶ 
P2 (2002-2003) 2,783 12,845 63.2 59.8 ¶ 52.3 44.5 64.0 60.4 ¶ 
P3 (2004-2005) 3,041 13,127 56.9 61.9 ¶ 44.7 46.7 57.9 62.6 ¶ 
P4 (2006-2007) 2,859 12,696 63.0 62.4 56.7 50.4 63.5 62.8 
Measurement of 
electrolytes and renal 
function every year in 
patients with heart 
failure 
P0 (1998-1999) 364 2,467 23.1 25.4 35.8 25.4 20.9 25.4 
P1 (2000-2001) 785 4,126 81.0 76.8 ‡ 81.1 68.1 † 81.0 77.4 † 
P2 (2002-2003) 989 4,904 81.0 79.2 82.1 73.6 80.9 79.5 
P3 (2004-2005) 1,325 5,319 78.6 79.9 72.7 74.7 79.3 80.2 
P4 (2006-2007) 1,304 5,396 83.4 81.3 83.2 77.0 83.5 81.6 
COPD: chronic obstructive pulmonary disease 
Significance denoted as: †: p<0.05; ‡: p<0.01;  ¶: p<0.001 
Dashed line differentiates pre- and post-cancer era
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Follow-up after Hospitalization 
Indicators of follow-up after diagnosis and having avoidable adverse outcomes are 
listed in Table 15. In general, the use of necessary care for follow-up after hospitalization 
was not different between cancer and comparison groups. However, cancer survivors 
received less care than individuals without cancer in four and two indicators in Period 3 and 
Period 4, respectively. As compared with blacks without cancer, black cancer survivors were 
more likely to have a follow-up visit after discharge from the hospital for complications of 
diabetes in Period 2 (86.2% vs. 72.1%, p<0.05). Black cancer survivors also were more 
likely to have follow-up visit after hospitalization for acute myocardial infarction in Period 1 
(88.2% vs. 54.5%, p<0.05).  
Experiencing Avoidable Adverse Outcomes 
Cancer survivors were less likely to have been hospitalized for short-term or long-
term complications of diabetes, CHF, and COPD than individuals without cancer in Period 0. 
Cancer survivors with history of diabetes also were less likely to be hospitalized for their 
diabetic complications than non-cancer patients in Periods 3 and 4. However, most of the 
above findings were only observed in white patients. The proportions of patients having 
avoidable adverse outcomes were not different between black cancer and black non-cancer 
patients. Since having at least three emergency department visits for CAD and 
hospitalization for malignant hypertension were rare events, we were unable to detect 






Table 15. Comparison of indicators for follow-up after hospitalization and having avoidable outcomes 3 
  Sample size (n) Proportion of patients reaching the goal (%) 
  Both Both Black White 
Indicator Period (year) Cancer Non-cancer Cancer Non-cancer Cancer Non-cancer Cancer Non-cancer 
Follow-up outpatient after hospitalization 
At least one office visit ≤ 4 
weeks after discharge of 
hospitalization for diabetes 
P0 (1998-1999) 332 2,558 79.8 76.9 73.1 73.3 81.1 77.3 
P1 (2000-2001) 659 2,522 76.5 79.6 77.4 70.4 76.3 80.4 † 
P2 (2002-2003) 511 2,502 83.0 79.7 86.2 72.1 † 82.5 80.4 
P3 (2004-2005) 519 2,570 71.3 81.1 ¶ 70.0 70.5 71.5 82.1 ¶ 
P4 (2006-2007) 474 2,482 78.9 79.8 74.1 64.9 79.5 80.9 
At least one office visit ≤ 4 
weeks after discharge of 
hospitalization for acute 
myocardial infarction 
P0 (1998-1999) 121 960 85.1 81.5 66.7 64.8 86.1 82.5 
P1 (2000-2001) 164 869 86.0 84.1 88.2 54.5 † 85.7 85.7 
P2 (2002-2003) 166 798 81.9 85.3 83.3 80.0 81.8 85.6 
P3 (2004-2005) 136 718 73.5 85.8 ¶ 55.6 77.5 74.8 86.3 ‡ 
P4 (2006-2007) 114 650 76.3 86.2 ‡ 72.7 74.2 76.7 86.8 ‡ 
At least one office visit ≤ 4 
weeks after discharge of 
hospitalization for stroke/ 
transient ischemic attack 
P0 (1998-1999) 297 1,999 74.4 72.1 52.2 67.4 76.3 72.5 
P1 (2000-2001) 360 1,915 78.6 74.7 63.6 64.2 80.1 75.5 
P2 (2002-2003) 346 1,779 80.6 76.6 74.3 68.4 81.4 77.2 
P3 (2004-2005) 309 1,573 74.8 78.4 60.0 75.2 76.1 78.6 
P4 (2006-2007) 301 1,512 72.4 78.2 † 67.7 66.3 73.0 79.0 † 
At least one office visit ≤ 4 
weeks after discharge of 
hospitalization for 
congestive heart failure 
P0 (1998-1999) 270 2,272 85.6 81.4 79.5 72.2 86.7 82.2 
P1 (2000-2001) 480 2,338 82.3 83.3 78.8 69.7 82.9 84.4 
P2 (2002-2003) 424 2,356 86.8 84.5 80.8 80.6 87.6 84.8 
P3 (2004-2005) 469 2,422 76.3 85.7 ¶ 73.3 75.5 76.8 86.4 ¶ 
P4 (2006-2007) 454 2,300 84.4 85.6 79.5 76.2 84.9 86.1 
At least one office visit ≤ 4 
weeks after discharge of 
hospitalization for 
gastrointestinal bleeding 
P0 (1998-1999) 109 698 84.4 81.4 64.3 72.7 87.4 82.3 
P1 (2000-2001) 175 672 84.6 82.0 81.5 75.0 85.1 82.6 
P2 (2002-2003) 192 695 82.3 81.0 75.0 64.2 83.5 82.4 
P3 (2004-2005) 161 624 78.3 84.0 90.0 68.4 76.6 85.0 † 
P4 (2006-2007) 146 630 82.9 83.5 61.5 79.0 85.0 83.8 
At least one office visit ≤ 2 
weeks after discharge of 
hospitalization for 
depression 
P0 (1998-1999) 71 566 50.7 60.4 62.5 53.8 49.2 60.7 
P1 (2000-2001) 144 642 55.6 60.7 27.3 48.8 57.9 61.6 
P2 (2002-2003) 135 650 60.7 63.8 58.3 43.5 61.0 64.6 
P3 (2004-2005) 125 647 45.6 64.5 ¶ 50.0 46.2 45.4 64.8 ¶ 
P4 (2006-2007) 130 612 63.1 64.7 33.3 51.6 64.5 65.4 
 ___________________________ 
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Table 15. Comparison of indicators for follow-up after hospitalization and having avoidable outcomes (continued) 
  Sample size (n) Proportion of patients reaching the goal (%) 
  Both Both Black White 
Indicator Period (year) Cancer Non-cancer Cancer Non-cancer Cancer Non-cancer Cancer Non-cancer 
At least one hemoglobin 
or hematocrit test ≤ 4 
weeks after discharge of 
hospitalization for 
gastrointestinal bleeding 
P0 (1998-1999) 109 698 43.1 37.4 21.4 30.3 46.3 38.1 
P1 (2000-2001) 175 672 38.3 37.8 37.0 25.0 38.5 39.0 
P2 (2002-2003) 192 695 49.5 47.2 25.0 41.5 53.7 47.7 
P3 (2004-2005) 161 624 50.3 56.6 50.0 36.8 50.4 57.8 
P4 (2006-2007) 146 630 56.2 52.9 38.5 32.6 57.9 54.3 
Having Avoidable Adverse Outcomes 
Hospitalization for 
serious short term 
complications of diabetes 
in patient with diabetic 
history 
P0 (1998-1999) 855 5,162 3.6 6.2 ‡ 5.2 12.0 3.3 5.7 ‡ 
P1 (2000-2001) 1,302 6,511 3.3 3.6 6.6 4.9 2.8 3.5 
P2 (2002-2003) 1,416 6,940 3.1 3.0 4.0 5.6 3.0 2.8 
P3 (2004-2005) 1,924 7,070 1.7 3.0 ‡ 3.1 6.0 1.6 2.8 ‡ 
P4 (2006-2007) 1,831 6,977 2.0 3.1 ‡ 2.8 4.9 1.9 3.0 † 
Hospitalization for 
serious long term 
complications of diabetes 
in patient with diabetic 
history 
P0 (1998-1999) 855 5,162 7.6 11.5 ¶ 18.8 14.7 5.9 11.2 ¶ 
P1 (2000-2001) 1,302 6,511 8.9 9.3 13.0 13.7 8.3 9.0 
P2 (2002-2003) 1,416 6,940 7.3 8.7 12.1 12.0 6.6 8.4 † 
P3 (2004-2005) 1,924 7,070 6.4 7.8 † 9.7 12.2 6.1 7.5 † 
P4 (2006-2007) 1,831 6,977 4.7 7.7 ¶ 7.3 9.8 4.5 7.6 ¶ 
Hospitalization for heart 
failure in patients with a 
history of heart failure 
P0 (1998-1999) 364 2,467 13.5 23.0 ¶ 17.0 28.5 12.9 22.6 ¶ 
P1 (2000-2001) 785 4,126 14.5 15.7 23.6 16.7 13.1 15.6 
P2 (2002-2003) 989 4,904 10.3 11.9 11.3 15.0 10.2 11.7 
P3 (2004-2005) 1,325 5,319 9.3 10.8 12.9 13.9 8.9 10.6 
P4 (2006-2007) 1,304 5,396 8.0 10.2 † 12.2 13.8 7.5 10.1 ‡ 
Hospitalization for COPD 
in patients with a history 
of COPD 
P0 (1998-1999) 653 3,693 16.8 25.3 ¶ 14.5 30.7 ‡ 17.1 24.9 ¶ 
P1 (2000-2001) 1,261 5,707 12.4 13.3 13.7 19.3 12.2 13.0 
P2 (2002-2003) 1,486 6,538 9.0 9.5 8.6 11.9 9.1 9.4 
P3 (2004-2005) 1,782 6,845 7.8 8.9 10.7 13.7 7.5 8.6 
P4 (2006-2007) 1,676 6,758 7.4 8.0 12.8 10.1 6.8 7.9 
COPD: chronic obstructive pulmonary disease 
Significance denoted as: †: p<0.05; ‡: p<0.01;  ¶: p<0.001 ; Dashed line differentiates pre- and post-cancer diagnosis era 
Since the proportion of patients with “hospitalization for malignant hypertension” or “emergency room visit for coronary artery disease” are very rare. The 
results of these two indicators are not shown. 
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Work-up at Initial Diagnosis 
Mixed findings were observed in the use of care for work-up at initial diagnosis 
(Table 16). Cancer survivors were more likely to receive colonoscopy or barium enema after 
their initial diagnosis of iron deficiency anemia. A potential explanation is that cancer 
survivors were more aware of their health condition, which may be associated with the 
second cancer. However, prostate cancer patients generally received less care than 
individuals without cancer for other indicators, especially in Period 3. 
Use of Care by Composite 
Comparison of a composite score for indicators with similar nature is presented in 
Table 16. In period 0, cancer survivors were more likely to have regular office visits to 
physician, to have better management of their chronic conditions, and not to have avoidable 
adverse outcomes than individuals without cancer. After Period 0, cancer survivors had 
significantly higher composite scores for clinical assessment, management of chronic 
condition, not having avoidable adverse outcomes, and work-up at initial diagnosis of 
comorbidities, except for in Period 3. However, cancer survivors had lower composite scores 






Table 16. Comparison of indicators for work-up at initial diagnosis 4 
  Sample size Proportion of patients reaching the goal (%) 
  Both Both Black White 
Indicator Period (year) Cancer Non-cancer Cancer Non-cancer Cancer Non-cancer Cancer Non-cancer 
Work-up at Initial Diagnosis   
Electrocardiography or Holter 
Monitor within 2 days of initial 
diagnosis of TIA 
P0 (1998-1999) 359 1,899 44.3 45.6 60.6 47.6 42.6 45.5 
P1 (2000-2001) 425 2,002 32.5 37.9 † 31.6 41.7 32.6 37.7 
P2 (2002-2003) 349 1,746 35.2 37.3 33.3 44.7 35.4 36.8 
P3 (2004-2005) 407 1,413 31.7 37.6 † 29.4 34.9 31.9 37.7 † 
P4 (2006-2007) 231 1,210 39.8 37.3 60.0 36.8 37.9 37.3 
Carotid angiogram or non-
invasive carotid imaging within 
2 weeks of initial 
hospitalization for carotid 
artery stroke 
P0 (1998-1999) 65 451 63.1 74.5 75.0 86.4 62.3 73.9 
P1 (2000-2001) 108 555 50.0 53.5 50.0 36.4 50.0 53.9 
P2 (2002-2003) 85 456 48.2 46.9 100.0 50.0 47.0 46.9 
P3 (2004-2005) 71 389 49.3 51.9 50.0 62.5 49.3 51.7 
P4 (2006-2007) 86 371 50.0 57.1 87.5 63.6 46.2 56.9 
Carotid imaging within two 
months prior to carotid 
endarterectomy in patients 
hospitalized for stroke / TIA 
P0 (1998-1999) 69 375 97.1 95.5 100.0 100.0 97.0 95.4 
P1 (2000-2001) 90 371 91.1 89.2 100.0 100.0 90.9 89.1 
P2 (2002-2003) 61 315 86.9 92.7 100.0 100.0 86.7 92.6 
P3 (2004-2005) 41 229 92.7 87.3 100.0 100.0 92.1 87.2 
P4 (2006-2007) 40 159 82.5 86.2 100.0 50.0 82.1 86.6 
Diagnostic ultrasound, 
radionuclide ventriculography, 
or left ventriculogram within 3 
months, before or after, initial 
diagnosis of heart failure 
P0 (1998-1999) 943 5,924 58.7 56.0 58.3 51.6 58.8 56.3 
P1 (2000-2001) 929 3,729 57.6 60.0 65.6 56.9 56.7 60.2 
P2 (2002-2003) 646 2,978 59.1 64.0 ‡ 56.9 59.9 59.4 64.2 † 
P3 (2004-2005) 1,194 2,582 46.6 62.7 ¶ 52.4 62.0 46.1 62.7 ¶ 
P4 (2006-2007) 371 2,176 61.2 64.2 56.5 66.7 61.5 64.1 
Diagnostic ultrasound, 
radionuclide ventriculography, 
or left ventriculogram within 3 
months, before or after, 
hospitalization for heart failure 
P0 (1998-1999) 240 1,994 83.3 83.2 88.1 84.5 82.3 83.1 
P1 (2000-2001) 397 1,775 75.8 76.1 75.6 71.4 75.9 76.4 
P2 (2002-2003) 278 1,586 78.1 78.5 80.0 75.9 77.8 78.7 
P3 (2004-2005) 290 1,530 69.0 78.4 ¶ 69.7 81.7 68.9 78.2 ‡ 
P4 (2006-2007) 263 1,314 77.9 79.3 66.7 85.2 78.8 79.0 
 ___________________________ 
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one month before or three 
months after initial diagnosis 
of heart failure 
P0 (1998-1999) 966 6,177 68.5 68.1 65.5 67.3 69.1 68.1 
P1 (2000-2001) 929 3,729 68.5 67.0 75.6 67.2 67.7 67.0 
P2 (2002-2003) 646 2,978 73.2 68.6 † 67.7 62.3 73.8 68.9 † 
P3 (2004-2005) 1,194 2,582 59.4 70.3 ¶ 60.0 63.6 59.4 70.6 ¶ 
P4 (2006-2007) 371 2,176 67.7 68.0 87.0 65.6 † 66.4 68.1 
Chest X-Ray within one month 
before or three months after 
initial diagnosis of heart failure   
P0 (1998-1999) 937 6,092 64.5 64.5 64.3 64.7 64.5 64.5 
P1 (2000-2001) 929 3,729 67.7 65.4 73.3 65.9 67.1 65.4 
P2 (2002-2003) 646 2,978 60.7 66.2 ‡ 56.9 64.7 61.1 66.3 † 
P3 (2004-2005) 1194 2,582 56.8 64.9 ¶ 64.6 62.8 56.2 65.0 ¶ 
P4 (2006-2007) 371 2,176 64.7 64.5 60.9 63.4 64.9 64.5 
At least one inpatient or 
outpatient visit, within four 
weeks following initial 
diagnosis of gastrointestinal 
bleeding 
P0 (1998-1999) 569 2,806 77.7 80.0 80.0 80.5 77.4 79.9 
P1 (2000-2001) 821 2,518 71.6 68.7 73.8 73.9 71.4 68.3 
P2 (2002-2003) 771 2,101 70.8 71.5 66.7 74.8 71.2 71.3 
P3 (2004-2005) 590 1,567 71.5 75.7 † 67.4 66.3 71.8 76.2 † 
P4 (2006-2007) 280 1,391 72.5 76.3 72.0 78.2 72.5 76.2 
Colonoscopy or barium 
enema within one month 
before or three months after 
initial diagnosis of iron 
deficiency anemia 
P0 (1998-1999) 1,450 7,203 47.0 49.5 53.1 49.4 45.9 49.5 † 
P1 (2000-2001) 1,803 5,188 46.3 36.8 ¶ 43.9 35.1 46.5 36.9 ¶ 
P2 (2002-2003) 1,020 4,047 51.3 45.4 ¶ 55.8 39.9 † 50.9 45.7 ‡ 
P3 (2004-2005) 1,146 3,098 57.4 53.0 ‡ 52.1 42.9 57.8 53.6 † 
P4 (2006-2007) 379 2,674 49.3 50.5 58.6 45.3 48.6 50.7 
Hemoglobin or hematocrit test 
within one to six months after 
initial diagnosis of anemia 
P0 (1998-1999) 339 1,999 33.3 29.2 28.3 26.3 34.1 29.5 
P1 (2000-2001) 713 2,070 25.9 22.9 27.7 28.1 25.7 22.5 
P2 (2002-2003) 580 1,989 32.6 24.1 ¶ 32.8 26.1 32.6 24.0 ¶ 
P3 (2004-2005) 686 1,655 21.1 25.9 † 16.7 30.8 21.5 25.5 † 
P4 (2006-2007) 322 1,660 27.6 24.9 34.5 24.7 27.0 24.9 
TIA: transient ischemic attack 
Significance denoted as: †: p<0.05; ‡: p<0.01;  ¶: p<0.001 
Dashed line differentiates pre- and post-cancer diagnosis era 
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claims data. http://healthservices.cancer.gov/seermedicare/seermed_2004_data_letter.pdf Therefore, the use of necessary care might be 




Table 17. Comparison of composite scores between cancer and non-cancer groups 5 
  Sample size Proportion of eligible care was received (%) 
  Both Both Black White 




P0 (1998-1999) 9,053 43,926 83.8 81.0 ¶ 71.7 66.3 ‡ 85.0 81.8 ¶ 
P1 (2000-2001) 8,599 39,953 96.0 82.5 ¶ 89.8 67.8 ¶ 96.6 83.3 ¶ 
P2 (2002-2003) 7,747 35,981 94.9 84.2 ¶ 87.0 70.6 ¶ 95.6 84.9 ¶ 
P3 (2004-2005) 6,865 32,223 80.3 85.8 ¶ 75.6 73.3 80.7 86.4 ¶ 
P4 (2006-2007) 5,945 28,176 92.9 86.9 ¶ 86.2 73.4 ¶ 93.5 87.5 ¶ 
Management of 
chronic condition 
P0 (1998-1999) 2,223 12,245 63.1 59.2 ¶ 55.0 47.5 † 64.0 59.9 ¶ 
P1 (2000-2001) 3,398 16,051 64.2 61.7 ‡ 53.1 48.6 65.3 62.5 ¶ 
P2 (2002-2003) 3,685 17,098 66.2 63.2 ¶ 55.7 53.2 67.1 63.7 ¶ 
P3 (2004-2005) 4,009 17,060 59.4 65.0 ¶ 52.2 53.6 60.1 65.6 ¶ 
P4 (2006-2007) 3,722 16,255 64.8 65.8 59.6 56.4 65.2 66.3 
Follow-up after 
hospitalization 
P0 (1998-1999) 885 6,161 76.4 74.3 68.4 68.3 77.4 74.8 
P1 (2000-2001) 1,441 6,016 74.4 76.8 † 70.4 68.0 74.8 77.5 † 
P2 (2002-2003) 1,236 5,879 79.4 78.1 78.9 70.9 79.4 78.6 
P3 (2004-2005) 1,189 5,732 70.8 79.9 ¶ 69.4 72.3 70.9 80.4 ¶ 
P4 (2006-2007) 1,117 5,471 77.1 79.2 70.3 67.4 77.7 79.8 
Avoidable adverse 
outcomes 
P0 (1998-1999) 3,950 19,975 96.9 94.7 ¶ 95.2 91.8 ‡ 97.0 94.9 ¶ 
P1 (2000-2001) 5,815 25,204 97.4 97.0 † 95.8 95.3 97.5 97.5 † 
P2 (2002-2003) 5,913 25,911 98.1 97.7 † 97.3 96.4 98.1 97.8 † 
P3 (2004-2005) 5,760 25,190 98.1 97.8 † 97.3 96.4 98.2 97.9 
P4 (2006-2007) 5,195 23,337 98.3 97.9 ‡ 96.6 96.9 98.5 98.0 ¶ 
Work-up at initial 
diagnosis 
P0 (1998-1999) 2,640 13,821 55.4 57.0 58.9 55.3 54.9 57.2 † 
P1 (2000-2001) 3,277 11,597 49.8 47.7 † 50.0 47.2 49.8 47.7 † 
P2 (2002-2003) 2,465 9,910 53.0 50.5 † 53.3 48.3 53.0 50.6 † 
P3 (2004-2005) 2,801 8,331 48.9 53.8 ¶ 50.3 47.5 48.8 54.1 ¶ 
P4 (2006-2007) 1,394 7,276 52.6 52.9 61.8 50.9 † 51.9 53.0 
Overall use of care 
P0 (1998-1999) 9,053 43,926 77.4 73.8 ¶ 64.2 58.4 ¶ 78.4 74.5 ¶ 
P1 (2000-2001) 8,599 39,953 85.7 75.6 ¶ 78.5 62.0 ¶ 86.4 76.4 ¶ 
P2 (2002-2003) 7,747 35,981 86.8 78.6 ¶ 79.1 66.0 ¶ 87.5 79.3 ¶ 
P3 (2004-2005) 6,865 32,223 76.0 80.9 ¶ 72.6 69.5 76.3 81.5 ¶ 
P4 (2006-2007) 5,945 28,176 86.4 82.1 ¶ 80.7 71.6 ¶ 86.9 82.6 ¶ 
Significance denoted as: †: p<0.05; ‡: p<0.01;  ¶: p<0.001 ; Dashed line differentiates pre- and post-cancer diagnosis era 
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Overall Use of Care 
Figure 7 shows the time trend for the composite score of overall use of necessary 
care by race. In white men, the composite score of the comparison group improved steadily 
over time. Before 2000, the white cancer survivors received a higher proportion of 
necessary care than the white men who never had cancer. The difference in composite 
score between cancer survivors and individuals without cancer became larger in Period 1 
and diminished across time. However, the composite score of cancer survivors became 
significantly lower than the comparison group’s score in Period 3. Similar time trend was 
observed among black men. Black cancer survivors received higher proportion of necessary 
care than black men without cancer in Period 0. The difference became larger in Period 1 
and diminished over time. However, the composite score of black cancer survivors dropped 





Figure 7. Time trend of overall use of necessary care 
 
The vertical bars represent a 95% confidence interval for each composite score. 
Note:  the drop in use of care might be caused by data error in 2004 physician claims. 
http://healthservices.cancer.gov/seermedicare/seermed_2004_data_letter.pdf  
 










1998-1999 2000-2001 2002-2003 2004-2005 2006-2007
Year
Composite score
Cancer (black) Non-cancer (black) Cancer (white) Non-Cancer (white)
Cancer diagnosis / Index date 
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We used a GEE model to examine whether cancer survivors had a higher composite 
score for overall use of necessary care compared to men without cancer after 2000 
controlling for other factors (Table 18). In the GEE model, variables with positive coefficients 
are associated with more use of necessary care. The result indicates that the use of 
necessary care increased over time because the time indicators were all significantly 
positive as compared with baseline. Elder age, higher income, and higher comorbidity index 
scores were associated with higher use of necessary care. Living in an area with higher 
proportion of persons without high school degree was associated with less use of necessary 
care.  
Wald tests were conducted to further examine the difference between men with and 
without cancer and between black and white men during various time periods (Table 19). In 
general, cancer survivors received more necessary care than men without cancer did. At 
baseline (i.e., Period 0), cancer survivors received significantly more necessary care than 
men without cancer did (3.81, p<0.001). The difference in use of necessary care became 
larger after 2000, and the largest difference was observed in Period 1 (10.08, p<0.001). 
However, cancer survivors used significantly less necessary care than men without cancer 
did in Period 3 (-5.39, p<0.001). In addition, racial disparity in use of necessary care was 
consistently observed among elderly men. Although the racial difference diminished over 
time, black men still received significantly less care than white men did. 
Another GEE analysis was conducted for prostate cancer survivors only to identify 
the factors associated with use of necessary care (Table 18). We found elder age, and 
higher comorbidity index score were associated with less use of necessary care. Higher 
household income, ever having married, and ever receiving surgery or XRT were associated 
with more use of necessary care. We also examined the relationship between type of care 
provider and use of necessary care. Survivors who visited both PCPs and prostate cancer 
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specialists received significantly much more care than those who visited neither of them 
(p<0.001). However, survivors who visited only PCPs or only specialists received 
comparable amount of care than those who visited both types of provider. 
Wald tests were conducted to examine the racial difference in use of necessary care 
across time.  In Period 0, black survivors received significantly less care than white survivors 
did (-5.75, p<0.001), but the difference diminished after cancer diagnosis (Table 19). Black 
survivors still received less care in Period 1 (-2.95, p<0.001) and Period 2 (-2.20, p<0.01). 
However, no such significant difference was observed in Period 3 (1.07, p=0.23) and Period 




Table 18. Results of generalized estimating equations (GEE) analyses of use of 
necessary care 
Variables All patients Cancer group only 
Cancer (non-cancer is the reference) 3.81 (0.36) ¶  
Black race (white race is the reference) -13.77 (0.62) ¶ -5.75 (0.75) ¶ 
Age (as of 01/01/00) 0.11 (0.02) ¶ -0.06 (0.03) † 
Median annual household income in $1,000 0.03 (0.01) ¶ 0.01 (0.01) 
Percent persons with less than a high school diploma -0.27 (0.01) ¶ -0.02 (0.01) 
Comorbidity Index score 1.64 (0.05) ¶ -1.40 (0.15) ¶ 
Time indicators (1998 – 1999 is the reference)   
Period 1 (2000 - 2001) 1.07 (0.17) ¶ -0.81 (0.32) † 
Period 2 (2002 - 2003) 3.24 (0.17) ¶ 1.16 (0.32) ¶ 
Period 3 (2004 - 2005) 4.71 (0.18) ¶ -1.86 (0.33) ¶ 
Period 4 (2006 - 2007) 5.22 (0.20) ¶ 2.27 (0.35) ¶ 
Interaction terms   
Black * cancer 4.29 (1.00) ¶  
Cancer * Period 1 6.27 (0.39) ¶  
Cancer * Period 2 4.20 (0.40) ¶  
Cancer * Period 3 -9.22 (0.42) ¶  
Cancer * Period 4 0.02 (0.44)  
Black * Period 1 2.93 (0.62) ¶ 2.80 (0.99) ‡ 
Black * Period 2 3.83 (0.65) ¶ 3.55 (1.03) ‡ 
Black * Period 3 5.90 (0.68) ¶ 6.82 (1.08) ¶ 
Black * Period 4 6.13 (0.73) ¶ 5.12 (1.15) ¶ 
Marital status (ever married is the reference)   
Never married  -0.85 (0.51) 
Unknown   1.28 (0.41) ‡ 
Cancer grade (well differentiated is the reference)   
Moderately differentiated  -0.64 (0.55) 
Poorly differentiated  -1.09 (0.59) 
Undifferentiated  -1.06 (2.15) 
Unknown or missing  -1.02 (0.80) 
Cancer-related treatment (watchful waiting is the reference)   
Surgery (no surgery is the reference)  1.41 (0.37) ¶ 
Radiation therapy (no radiation therapy is the reference)  2.57 (0.32) ¶ 
Type of care provider (visit both PCP or specialist is the reference) 
Visit PCP only  -0.84 (0.31) ‡ 
Visit specialist only  -0.09 (0.39) 
Visit neither PCP nor specialist  -53.95 (0.35) ¶ 
Constant 68.52 (1.77) ¶ 93.81 (2.38) ¶ 
Number of observations (n) 218,472 38,209 
Standard error is listed in parentheses; Significance denoted as: †: p<0.05; ‡: p<0.01;  ¶: p<0.001 
Note: A survivor’s registry site is also controlled in the model (results not shown)  
Note: comorbidity index score and type of care provider are time-variant variables. Charlson Comorbidity Index 
was used for the GEE model using the entire sample. National Cancer Institute Combined Index was used for 
the subgroup analysis using prostate cancer survivors only. 




Table 19. Time trend of group difference in overall use of necessary care 
 
All subjects Cancer group only 
Cancer survivors vs. 
individuals without cancer 
Black men vs.  
white men 
Black survivors vs.  
white survivors 
Time period 
   
0 (1998 - 1999) 3.81 ¶ -13.77 ¶ -5.75 ¶ 
1 (2000 - 2001)* 10.08 ¶ -10.84 ¶ -2.95 ¶ 
2 (2002 - 2003)* 8.01 ¶ -9.94 ¶ -2.20 ‡ 
3 (2004 - 2005)* -5.39 ¶ -7.87 ¶                  1.07 
4 (2006 - 2007)* 3.83 ¶ -7.64 ¶                 -0.63 
*Difference between groups is the sum of baseline difference and time interaction from the corresponding GEE 
model. Wald test is conducted to evaluate whether there was group difference at each time point. 
Significance denoted as: †: p<0.05; ‡: p<0.01; ¶: p<0.001 
 
5.5 Discussion 
Previous studies have criticized the overdiagnosis and overtreatment of low-risk 
prostate cancer patients (15-17). Since prostate cancer is a latent disease, approximately 
23% to 42% of screen-detected cases would not have been diagnosed before death in the 
absence of PSA screening (15, 96). Although it is unclear whether cancer treatment can 
improve survival among patients with localized or regional prostate cancer, previous studies 
found that cancer treatments often cause adverse effects, such as incontinence and erectile 
dysfunction (15, 22, 23). However, prostate cancer and its treatment may constitute only a 
fraction of medical history for many survivors. Other comorbid conditions may play a more 
important role for a survivor’s health, longevity, and physical function. However, the 
diagnosis and management of other comorbid conditions have not been the focuses of 
previous cancer survivorship research. 
 106 
 
In this study, we found that prostate cancer survivors consistently used more 
necessary care than individuals without cancer did. Although the difference in use of 
necessary care existed even before cancer diagnosis, the magnitude of difference became 
larger after diagnosis. It is possible that prostate cancer was diagnosed because cancer 
survivors already had more contact with their health care providers before their cancer 
diagnosis than individuals without cancer had. After cancer diagnosis, more survivors 
started to make regular visits to their care providers and received better care from them. 
Therefore, a diagnosis of prostate cancer may represent “a wake-up call” for elderly men to 
be engaged in the health care system. 
Black patients are traditionally a vulnerable population experiencing poor quality of 
care (34-36). As we expected, black patients consistently received less necessary care for 
their comorbid conditions, regardless of whether they were cancer survivors or not. 
Interestingly, we found that a cancer diagnosis created an opportunity to reduce this racial 
disparity. After their cancer diagnosis, black prostate cancer survivors increased their overall 
use of necessary care. This main reason for this finding was because more black patients 
began to have regular office visits to their physicians after cancer diagnosis. Therefore, a 
prostate cancer diagnosis may create an opportunity for this population to be more aware of 
their health and to further improve their quality of care. 
Among cancer survivors, the use of necessary care surprisingly dropped between 
2004 and 2005 but increased back between 2006 and 2007. Although this finding might be 
partly explained by the data error in 2004 physician claims, another potential explanation is 
the enactment of Medicare Prescription Drug, Improvement, and Modernization Act of 2003 
(MMA). The MMA reduced the reimbursements for Medicare Part B chemotherapy drugs 
from 95% of average wholesale prices in 2003 to 80-85% in 2004 (97). In 2005, the 
reimbursements were further reduced to 106% of average selling prices which tend to be 
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substantially lower than the average wholesale prices (97). To compensate the potential 
loss, the MMA also increased the reimbursements for administration services of 
chemotherapy provided by oncologists substantially (97, 98). However, the increases in 
reimbursements for corresponding services provided by urologists were much smaller (97, 
98). Therefore, it is possible that some urologists may limit the number of Medicare patients 
they see and send their patients to hospital. Since some patients may feel inconvenient to 
receive their care from hospital, their adherence to therapy could decrease (98). Therefore, 
the implementation of MMA may limit a survivor’s access to urologists, who tend to provide a 
large proportion of health care for prostate cancer survivors (Chapter 4). In 2006, urologists 
were allowed to obtain chemotherapy drugs for their patients from a third party contractor 
through a process called competitive acquisition (97, 98). This policy change may explain 
the improvement in use of necessary care from 2004-2005 to 2006-2007. Further studies 
are necessary to examine the impact of MMA on quality of care and health outcomes on 
prostate cancer survivors. 
This study, which is the first to examine a wide range of quality of care indictors for 
non-cancer conditions among prostate cancer survivors, has several strengths. Although the 
ACE-PRO indicators have been used to study the access to and quality of care associated 
with various geographic and socioeconomic factors, they have never been used to assess 
the care among prostate cancer survivors. Our longitudinal study design allows us to 
measure the use of necessary care pre- and post-cancer diagnosis, instead of measuring it 
cross-sectionally. Therefore, we are able to examine the time trend of care and the potential 
effect of cancer diagnosis. In this study, we included all of the 5-percent Medicare qualified 
patients in our non-cancer group and did not to use a matched control group. Results from 
our non-cancer group allow us to have a clear picture about the use of necessary care in the 
general population without cancer. 
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The main design issues of this observational study results from the limitations of 
administrative datasets. The overall population covered by SEER is comparable to the 
general US population with regard to measures of poverty and education (68). However, the 
results of this study may not be generalizable to non-SEER regions because Medicare 
beneficiaries living in SEER regions are less likely to be white, reside in rural areas, and 
enroll in managed care plans (70). Medicare beneficiaries who were diagnosed with cancer 
before age 67 were excluded from our analyses because we were unable to obtain their 
claims data before Medicare enrollment. Therefore, the findings from our study may not be 
generalized to younger prostate cancer survivors. In addition, the results from our study may 
not be generalized to HMO enrollees because information about their use of care was not 
available. Since risk factors, treatment options, and survival rates vary by types of cancer, 
different cancers may have different influence on comorbidities. Therefore, the results from 
our study may not be generalized to other types of cancer survivors. The time of a disease’s 
first diagnosis is critical for many of the refined ACE-PRO indicators, especially for initial 
work-up indicators. Due to data limitations, we were unable to observe the diagnosis of 
comorbid condition before age of 65. The first diagnosis of a comorbid condition that we 
observed in the Medicare claims may not be the true initial diagnosis. However, we 
expected that this type 1 error has a similar effect on the cancer and non-cancer groups. 
When we calculated composite scores to evaluate the use of care, the indicators of 
necessary care were not weighted. However, some indicators may play more important 
roles for a patient’s health than others. 
For each ACE-PRO indicator, only patients who remained alive during the entire two-
year time frame were included. Therefore, we were unable to fully examine the use of care 
for those who died during a time period. Since we only included survivors in our analyses, 
we might observe a “survivor effect” in the time trends of use of care. That is, those 
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individuals who remained alive at a time point may be healthier than those individuals who 
died before that time. We assumed that cancer and non-cancer patients who died during the 
study periods were un-informatively censored (i.e., death during follow up is independent 
with use of care). The issues of uninformative censoring assumption should be minor 
because the five-year relative survival rate of localized or regional prostate cancer patients 
is approximately 100% as compared with the non-cancer population (9). Therefore, we 
expected the survivor effect to be similar between cancer and non-cancer groups. In 
sensitivity analysis, we restricted our samples to those individuals who survived during the 
entire study time frame and obtained similar results as the findings our primary analyses 
(results not shown). 
The ACE-PRO indicators were originally developed to measure underuse of 
necessary care. Fulfilling the requirement of an indicator does not guarantee optimal use of 
care. Further studies are necessary to develop measurements for detecting overuse or 
misuse of necessary care. In addition, the majority of the ACE-PRO quality of care indicators 
measure whether a patient visited his care providers when necessary. Other indicators 
measure whether a patient received necessary examinations or treatment for his comorbid 
conditions. However, none of them measures the quality of care by evaluating a patient’s 
health outcomes. Since results from laboratory report are generally unavailable in claims 
data, further studies are necessary to assess a survivor’s quality of care using his medical 
record. 
5.6 Conclusion 
In our previous study, we found that black cancer patients consistently had higher 
comorbidity index scores than white cancer patients did (Chapter 4). We also found that the 
racial difference in comorbidity became larger after cancer diagnosis. One explanation is 
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that more previously underdiagnosed comorbid conditions were detected after cancer 
diagnosis among black survivors than among white survivors. In this study, we found that 
cancer patients increased their use of necessary care after cancer diagnosis. The 
magnitude of improvement was more substantial among black patients than among white 
patients. Therefore, a diagnosis of prostate cancer may represent an opportunity to 
eliminate racial disparity in quality of care. In the next chapter, we examine whether racial 
disparity in mortality of prostate cancer survivors remains after we control for time-variant 







CHAPTER 6. RACIAL DISPARITY IN SURVIVAL AMONG ELDERLY MEN DIAGNOSED 




Background: Racial disparity in survival is consistently observed among prostate cancer 
survivors. This study compared various methods to examine racial disparity and other risk 
factors for overall, cancer, and non-cancer mortality. 
Methods: The sample consisted of 882 black and 6,613 white patients diagnosed with 
stage 1-4 prostate cancer between the ages of 67-84 in 2000 from the Surveillance, 
Epidemiology, and End Results-Medicare Program. The claims of each patient were 
examined from the cancer diagnosis until his death or December, 2007. Proportional 
hazards (PH) models were conducted to examine racial disparity in overall mortality 
controlling for time-varying comorbidity and use of necessary care, neither of which have 
been controlled for in previous studies. PH and competing-risk models were conducted 
subsequently to identify risk factors for cancer and non-cancer mortality. 
Results: After controlling for age, registry site, marital status, and socioeconomic status, 
black survivors had a significant higher risk for overall mortality than white survivors (hazard 
ratio [HR]=1.24; 95% confidence interval [CI]: 1.10-1.41). The HR decreased after additional 
adjustment for cancer stage, grade, and treatment (HR=1.15, 95%CI: 1.01-1.30). The racial 




of care (HR=1.07, 95%CI: 0.95-1.22). Although PH and competing-risk models yielded 
similar results for cancer-specific mortality, their findings were somewhat different for non-
cancer mortality. Use of care, a potentially modifiable factor, was consistently associated 
with lower risks of mortality. 
Conclusion: Racial disparities in prostate cancer survival are due to differences in SES, 
stage, grade, primary treatment, comorbidities, and use of care. Efforts to increase early 
diagnosis, appropriate treatment, and post-diagnosis use of care among black survivors 
may be necessary to improve their survival and further eliminate racial disparities in prostate 
cancer survival. 
 




Racial disparity in health outcomes of prostate cancer survivors has been observed 
in many previous studies (8, 24-27). Prostate cancer incidence and mortality rates for black 
men are approximately twice the rates for white men (9). Black survivors are more likely to 
be diagnosed with advanced prostate cancer (31) and also have a lower survival rate than 
white survivors (26, 27, 29-31). Various studies have tried to identify the factors that may 
explain the racial differences in overall and cancer mortality rates. A study using California 
cancer registry data found that racial disparities in survival were completely explained by 
treatment option, stage, grade, year of diagnosis, and socioeconomic status (SES) (30). 
However, other studies using data from national registries found that even after controlling 
for SES, treatment options and pre-existing comorbidities, black survivors diagnosed with 
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localized prostate cancer still had worse overall and prostate cancer survival rates than 
those observed in white men (27, 29). A meta-analysis found that black survivors had higher 
rate of cancer recurrence, prostate cancer mortality, and overall mortality than white 
survivors (33). After controlling for comorbidity, type of prostate cancer screening, or access 
to health care, racial differences diminished for overall mortality but still existed for cancer 
recurrence and prostate cancer mortality. 
Comorbidity is an important predictor for mortality rates among cancer survivors (27, 
29, 33, 40). However, previous cancer studies usually controlled only for the pre-existing 
comorbidity before the cancer diagnosis in their survival analyses (27, 29, 33). In a previous 
study, we found that comorbidity index score (i.e., comorbidities) increased after prostate 
cancer diagnosis, especially among black survivors (Chapter 4). Not only did the black 
prostate cancer survivors continuously have a higher average comorbidity score than white 
survivors, the magnitude of difference increased after cancer diagnosis. Therefore, allowing 
comorbidities to vary over time (i.e., with a time-varying comorbidity index score) may better 
reflect the longitudinal racial difference in risks of dying from causes other than cancer. In 
another study, we found that black prostate cancer survivors consistently underutilized 
necessary care for their comorbidities than the white survivors (Chapter 5), but the 
difference diminished after cancer diagnosis. Therefore, a diagnosis of prostate cancer may 
create an opportunity not only to identify previously underdiagnosed comorbidities among 
black patients but also to improve their quality of care. Effective control of comorbidity in 
black cancer patients may help improve life expectancy and lead to a reduction in survival 
disparities (37). However, the use of necessary care for comorbidities has never been 
controlled for in previous cancer survival analyses. 
Although the majority of prostate cancer survivors die from causes other than cancer 
(9), most of previous cancer survivorship studies focused on overall or cancer-specific 
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mortality (26, 27, 29-31, 33), rather than non-cancer mortality. Since prostate cancer is 
highly survivable, it also is very important to identify the risk factors for non-cancer mortality 
with appropriate methodology. Typically, cancer survivorship studies used proportional 
hazard (PH) model (75) to identify risk factors for cancer-specific mortality (26, 27, 29-31). 
Patients who died from causes other than cancer were treated as censored cases, which 
implicitly assumed the risks of dying from cancer and other causes are independent.  
The purpose of this study is to adopt various methods to assess racial disparity and 
other risk factors for mortality among prostate cancer survivors. We used the data from the 
Surveillance, Epidemiology, and End Results registry (SEER)-Medicare Program to identify 
the prostate cancer patients who were diagnosed in 2000. Each patient’s claims were 
examined from diagnosis until death or December 31st, 2007, whichever came first. We first 
examined whether a racial disparity in survival remained after controlling for time-varying 
comorbidity and use of necessary care, neither of which have been controlled for in previous 
studies. We then investigated the effect of controlling for static or time-varying comorbidity 
on overall mortality. Finally, we compared the findings from PH and competing-risk models 
examining risk factors for cancer and non-cancer mortality. 
6.3 Methods 
Data Sources 
The SEER-Medicare data are population-based data that combine SEER cancer 
registry information with Medicare enrollment and claims files (70, 72). We used the latest 
data from the SEER-17 cancer registries, including Arizona Native Americans, Alaska 
Natives, nine states (California, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, 
New Mexico, and Utah), and seven regions (Atlanta, Detroit, rural Georgia, Los Angeles, 
San Francisco, San Jose, and Seattle). The SEER Program routinely collects data on 
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patient demographics, marital status, primary tumor site, stage at diagnosis, primary course 
of treatment, and cause of death. It also collects SES information measured from the US 
Census Bureau that reflect the characteristics of a census tract in which a patient resided 
(69). The aggregated SES variables include median household income, percentage of 
residents living under poverty level, and educational status at census tract level (69, 70). 
SEER registry data are linked with Medicare claims and include a beneficiary’s disease 
diagnoses, treatments, and services received. However, these health care data are 
unavailable for health maintenance organization (HMO) enrollees, services not covered by 
Medicare (e.g., long term care), services provided by Veterans Affairs or Medicaid, or by 
Medicare supplement programs (i.e., Medigap policy) (70).  
Cohort Selection 
Men diagnosed with localized, regional, and distant prostate cancer in 2000 were 
included in this study. The data of each survivor were examined for up to eight years, 
beginning from the month of cancer diagnosis through his death or December, 2007, 
whichever came first. To be eligible for inclusion in the study, survivors must have been 
continuously enrolled in Medicare Part A and Part B during the entire study period. To 
observe baseline comorbidity severity and use of necessary care, we included only patients 
who were diagnosed with prostate cancer at age 67 or older as of January 1, 2000, thus 
allowing for two years of observation prior to diagnosis. Medicare beneficiaries who were 
eligible for Medicare because of disability or the presence of end-stage renal disease before 
age 65 were excluded from the analyses. HMO enrollees also were excluded, as services 
provided by HMOs are not included in the SEER–Medicare data. Other exclusion criteria 
included: prior cancer history, diagnosis with a second cancer within six months of diagnosis, 
noninvasive tumors (i.e., carcinoma in situ), unstaged prostate cancer, diagnosis after age 
84, diagnosis at death or via autopsy, and missing income and education information. 
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Survivors of other races were excluded from the analyses because we focused on the racial 
difference between black and white survivors, who have the largest survival disparity. Finally, 
we excluded registries with fewer or equal than 10 black prostate cancer cases in 2000 
because black race only consists of a very small proportion of their populations. 
Variable Definitions 
Demographic variables are available from both SEER and Medicare data, and the 
information found in the two sources is highly consistent (69). Since a patient’s comorbidity 
and use of care are measured from the Medicare data, we employed Medicare Enrollment 
Database as our primary source to identify age, race, and vital status when observing 
inconsistencies between these two data sources. Empirically, data aggregated at the census 
tract level are more likely to reflect a patient’s SES than are zip code level data (69). 
Therefore, we included median household income, percentage of residents living below 
poverty level, percentage of residents with less than a high school degree at census tract 
level from the 2000 Census in our analyses. We identified cancer stage, tumor grade, and 
marital status from the SEER data.  
The date of death is available in both Medicare and SEER data, but is derived from 
different sources and covers different time periods. The Medicare death date was obtained 
from Medicare Enrollment Database, which is updated nightly by the Social Security 
Administration; and includes death data through December, 2007. The SEER death date is 
primarily obtained from state death certificates, but it is sometimes acquired from the 
Medicare Enrollment Database when state data are unavailable, whereas SEER Program 
has this information only until December, 2005. We used Medicare as the primary source to 
identify time of death for overall mortality because it allows us to have a longer observation 
timeframe (i.e., up to eight years). However, since the cause of death is only available from 
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the SEER Program, a patient’s data was examined only until December, 2005, when we 
disaggregated mortality by cause. 
The type of primary treatment for prostate cancer was identified from the SEER data 
and Medicare claims within six months of cancer diagnosis. Surgery is defined as 
procedures performed with curative intent or in anticipation of a subsequent curative 
procedure (27). To identify radical prostatectomy and procedures performed on regional 
lymph nodes, we used: (1) the SEER indicator for whether a cancer-directed surgery was 
performed; (2) procedure codes from Medicare claims (International Classification of 
Diseases, 9th Revision, [ICD-9] 60.5 and 60.6; Current Procedural Terminology [CPT] codes 
55810, 55812, 55815, 55840, 55842, 55845, 55866); and (3) site-specific surgery codes 30–
90 from the SEER data. Radiation therapy (XRT) is defined as external beam therapy, 
brachytherapy, or therapeutic isotope radiation therapy as listed in the SEER data (63). 
Specifically, we used: (1) the SEER indicator for whether cancer-directed radiotherapy was 
performed; (2) ICD-9 procedure codes 92.2x, V58.0, V66.1, V67.1, CPT codes 77301, 
77400–77499; revenue center codes 0330–0339 from Medicare claims; and (3) site-specific 
radiation codes 1–5 from the SEER data to identify XRT. Men who receive both surgery and 
XRT will be classified as having surgery because some patients may receive XRT after an 
incomplete or unsuccessful surgery (27, 63). 
We measured comorbidity severity using the National Cancer Institute Combined 
Index (NCICI), which was developed specifically for the use with SEER-Medicare data to 
adjust for the risk of dying from causes other than cancer (40). We applied the weighting 
scheme for prostate cancer and accumulated the weighted comorbidities to establish a 
single index. A higher NCICI score represents more severe health problems. A patient’s 
NCICI score was measured as of December 31st in each of 1999, 2001, 2003, and 2005. 
The procedures used to calculate NCICI score are described in Chapter 3.  
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The use of necessary care for non-cancer comorbidities was measured by the 
refined Access to Care for the Elderly Project (ACE-PRO) indicators from the Medicare 
Payment Advisory Commission (MedPAC) (64). The refined ACE-PRO indicators evaluate 
the use of care for clinical assessment and management of chronic condition, follow-up after 
hospitalization, avoidable adverse outcomes, and work-up at initial diagnosis. We used 34 
indicators to examine the use of ambulatory care for medical conditions including anemia, 
angina, chronic obstructive pulmonary disease, congestive heart failure, coronary artery 
disease, depression, diabetes mellitus, gastrointestinal bleeding, hypertension, and stroke 
or transient ischemic attack. A composite score for overall use of care was calculated for the 
proportion of qualified necessary care that was received in each two-year period (64). The 
sum of the number of indicators for necessary care received and possible adverse 
outcomes avoided was divided by the total number of eligible indicators during each time 
period. Additional details are provided in Chapter 5. 
Statistical Analyses 
Kaplan-Meier survival curves (82) were used to compare the unadjusted survival 
(measured in months) by race and cancer stage. Log-rank tests were conducted to evaluate 
whether black patients have different survival rates as compared with white patients. We 
then assessed adjusted racial disparity in overall mortality using Cox proportional hazards 
(PH) models (75). We compared the hazard ratio (HR) of black race after controlling for 
factors which have been shown to be potentially responsible for racial disparity, such as a 
patient’s age, registry site, marital status, SES, cancer disease information (i.e., stage, 
grade, and treatment). Finally, we evaluated the effect of additional adjustment for time-
varying NCICI score and use of care on racial disparity in overall survival. 
Since prostate cancer is highly survivable, the majority of prostate cancer survivors 
die from causes other than cancer (9). Prostate cancer and other causes are competing 
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risks for cancer patients’ mortality because a patient who dies from one of these causes can 
never die from the other. At present, there is no valid mathematic method to examine 
whether the competing risks are independent (76). However, these risks are very likely 
dependent because the presence of prostate cancer (i.e., the risk of dying from cancer) may 
change the risk of dying from other comorbidities. For example, prostate cancer treatments 
may have negative effects on survivors’ cardiovascular disease and mental health (22, 23, 
59). In addition, the presence of comorbidities also may complicate treatment management 
and further affect the risk of dying from cancer. If the competing-risk relationship just 
described differs by race, the hazard ratio of race directly obtained from a PH model would 
be biased. To account for the competing risks in our survival analysis, we use the 
Cumulative Incidence Curve method developed by Fine and Gray (77). Their competing-risk 
model allows the dependence of competing risks in the PH model and estimates hazard 
ratios of independent variables for competing risks (i.e., cancer and non-cancer deaths) 
separately. 
In addition, we identified the risk factors for overall, cancer, and non-cancer mortality 
among men with prostate cancer. A patient’s demographic information, cancer disease 
information, SES, comorbidity, and use of care were examined in the regression models. We 
first compared the results of PH models controlling for static or time-varying comorbidity 
scores. The PH assumption was assessed using both graphical and goodness-of-fit 
approaches for each variable (83). Finally, we compared the models using PH (i.e., the 
approach commonly used in the current literature) or competing-risk regression analyses to 
identify risk factors for dying from cancer or other causes. STATA ® 11.0 (The StataCorp, 





A flow chart of the selection process of study sample is presented in Figure 8. A 
cohort of 43,150 prostate cancer patients was initially identified in 2000 from the SEER-
Medicare data. Employing the inclusion and exclusion criteria described earlier, a total of 




Figure 8. Procedures to Generate the Study Sample 
 
 
Prostate cancer cases diagnosed between 
01/01/2000 and 12/31/2000 
n=43,150 
 
 Diagnosed at age < 67 or >84, 
 With prior cancer history 
 Enrolled in Medicare because 
of disability or end-stage renal 
disease,n=21,507 





within 6 months, n=424 




HMO: health maintenance organization 
With HMO coverage, 
n=7,354 
Qualified prostate cancer 
patients, n=21,643 
 
Any non-enrollment in 
Parts A & B, n=2,195 
No 2
nd
 cancer within 6 
months, n=21,219 
Continuously enrolled in 
Parts A & B, n=19,024 
Without HMO coverage, 
n=11,770 
With in situ carcinoma, 
or diagnosed at death 
or via autopsy, n=369 
 
Other races, n=626 
With staged prostate 
cancer, n=10,706 
Black or white races, 
n=10,080 
With income and 
education data, n=9,750 
Without Income or 
education data, n=330 
With income and 
education data, n=7,495 
Registries with fewer or 
equal to 10 black cases, 
n: black=41, white=2,214 
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Table 20 describes the characteristics of black and white prostate cancer patients. At 
diagnosis (based on age as of 1/1/2007), both black and white prostate cancer patients 
were approximately 74 years old. Black cancer patients were more likely to have distant 
prostate cancer (p<0.001), grade 3 and 4 tumors (i.e., more serious, p<0.01), and to have 
died by the end of the observation period (p<0.001) than white cancer survivors. White 
cancer patients were more likely to have received radiation therapy or surgery (p<0.001) 
than black patients. In terms of comorbidities, black cancer patients had more comorbidities 
prior to cancer diagnosis and continued to have more post-diagnosis comorbidities than 
white cancer patients (p<0.001). Despite a greater burden of comorbidity, black patients 
were less likely to receive necessary care than white patients at any point in time (p<0.001). 
Demographically black and white cancer patients differed. Compared to white cancer 
patients, black cancer patients were less likely to have been married, live in areas with lower 
socioeconomic status, as measured by income and educational attainment in census tract of 
residence; two-thirds of black cancer patients were obtained from three registries (i.e., 
Detroit, Louisiana, and New Jersey). 
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Table 20. Comparison of baseline characteristics between black and white patients 
 Black (n=882) White (n=6,613) p-value 
Mean Age as of 01/01/2000 73.8 (0.15) 74.1 (0.05) 0.10 
Mean follow-up time (month) 67.1 (1.01) 74.7 (0.32) <0.001 
Alive as of 12/31/2007 (%) 51.4 62.9 <0.001 
Prostate cancer stage (%) 
Localized or regional 90.8 95.7 <0.001 
Advanced 9.2 4.3 
Prostate cancer grade (%) 
1 (well differentiated) 3.0 4.7 <0.01 
2 (Moderately differentiated) 64.6 67.6 
3 (Poorly differentiated) 24.6 22.2 
4 (Undifferentiated) 0.8 0.3 
Unknown or missing 7.0 5.2 
Primary cancer treatment 
Watchful waiting (%) 35.6 22.4 <0.001 
Surgery (%) 24.0 25.2 
Radiation therapy (%) 40.4 52.4 
National Cancer Institute Combined Index 
   01/01/2000 (baseline) 0.42 (0.02) 0.32 (0.01) <0.001 
01/01/2002 0.69 (0.03) 0.53 (0.01) <0.001 
01/01/2004 0.86 (0.04) 0.66 (0.01) <0.001 
01/01/2006 1.04 (0.04) 0.84 (0.01) <0.001 
Composite score for use of necessary care 
1998-1999 (baseline) 62.2 (1.38) 78.3 (0.32) <0.001 
2000-2001 77.8 (1.02) 86.4 (0.26) <0.001 
2002-2003 78.7 (1.08) 87.7 (0.26) <0.001 
2004-2005* 72.7 (1.18) 78.3 (0.35) <0.01 
Socioeconomic status    
Median household income ($) 31,205 (577) 58,790 (347) <0.001 
% of persons living below poverty level 20.9 (0.68) 7.0 (0.10) <0.001 
% of persons without a high school education 29.5 (0.48) 15.5 (0.15) <0.001 
Marital status at cancer diagnosis (%) 
Ever married 73.0 80.9 <0.001 
Never married 14.7 5.9 
Unknown or missing 12.2 13.2 
Registry site, %    
San Francisco 2.8 4.1 <0.001 
Connecticut 3.1 10.0 
Detroit 32.5 12.8 
Atlanta 6.9 3.6 
Los Angeles 8.3 7.9 
Greater California 5.1 21.6 
Kentucky 3.2 8.2 
Louisiana 19.2 8.2 
New Jersey 18.9 23.5 
Standard errors are listed in parentheses 





Unadjusted Comparison of Survival by Race 
Figure 9 presents a series of comparisons of Kaplan-Meier survival curves by race. 
Black patients consistently had a lower probability of overall survival as compared with white 
patients (log-rank test p< 0.001) (Figure 9a). Among those with localized or regional prostate 
cancer, black patients had a significantly lower overall survival rate than white patients 
(p<0.001) (Figure 9b). This racial difference was still statistically significant among those 
with distant prostate cancer (p=0.04). The black cancer patients had significantly higher 
risks for death from both cancer and non-cancer causes than white patients (log-rank tests, 
p<0.001) (Figures 9c and 9d). At the end of observation period (12/31/2005), black patients 
were more likely to die both from cancer (15.6% vs. 10.9%, p<0.001) and from other causes 







Figure 9. Comparison of Kaplan-Meier survival curves by race 
9a. Survival curves for overall mortality by race                                        9b. Survival curves for overall mortality by race and cancer stage 
           
 
9c. Survival curves for cancer mortality by race                                        9d. Survival curves for non-cancer mortality by race 
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Effect of Adjustment for Confounders on Racial Disparity 
A series of time-to-event regression analyses were conducted with the goal of 
identification of the factors that potentially explain the racial disparity (Table 21). After 
adjustment for age only, black survivors had a higher risk for overall mortality than white 
survivors. Although the HR associated with black race was substantially decreased, it was 
still statistically significant after adding a patient’s registry site, marital status, SES, disease 
stage, grade, and treatment to the regression model. However, the racial difference in 
overall mortality was no longer statistically significant after controlling for a time-varying 
NCICI score and use of necessary care, neither of which have been used in previous 
studies. Thus, although cancer stage, grade, treatment, and SES were the primary factors 
responsible for the racial difference in risk of overall mortality, comorbidity and use of 
necessary care can also explain part of this racial disparity. We used similar procedures to 
assess racial disparity in cancer and non-cancer mortality using competing-risk models and 
observed very similar results. 
Table 21. Effect of confounder adjustment on racial difference in overall mortality 
 
Cause of death 











(1.47 – 1.81) 
<0.001 
1.54 
(1.28 – 1.85) 
<0.001 
1.58 
(1.35 – 1.85) 
<0.001 
Age, registry, marital status, SES  
1.24 
(1.10 – 1.41) 
<0.01 
1.32 
(1.05 – 1.66) 
0.02 
1.14 
(0.93 – 1.39) 
0.20 
Age, registry, marital status, SES, 
treatment, stage, grade 
1.15 
(1.01 – 1.30) 
0.03 
1.12 
(0.89 – 1.42) 
0.34 
1.11 
(0.90 – 1.35) 
0.32 
Age, registry, marital status, SES, 
treatment, stage, grade, comorbidity 
1.12 
(0.99 – 1.27) 
0.08 
1.13 
(0.89 – 1.42) 
0.32 
1.06 
(0.87 – 1.29) 
0.57 
Age, registry, marital status, SES, 
treatment, stage, grade, comorbidity, 
use of necessary care 
1.07 
(0.95 – 1.22) 
0.27 
1.09 
(0.86 – 1.37) 
0.49 
1.02 
(0.83 – 1.24) 
0.87 
95% confidence intervals are listed in parentheses. 
SES: socioeconomic status 
Comorbidity (time-varying) is measured by National Cancer Institute Combined Index (40). 




Risk Factors for Overall Mortality 
We used several PH models to identify the risk factors for overall mortality (Table 22) 
Race, age, marital status, SES, stage, grade, treatment, comorbidity, and use of care were 
examined in two PH models. Model 1 adjusted for comorbidity severity at diagnosis, which 
was the common approach in previous cancer survival analyses. Model 2 controlled for a 
time-varying comorbidity score. The HRs of distant stage and moderate differentiated cancer 
grade were not constant over time in Model 2. Thus, the baseline hazard was stratified by 
these two binary variables in Model 2 to fulfill the PH model assumption.  
Table 22. Different Cox PHs models examining risk factors for overall mortality 
Variable 
Model 1 Model 2 
HR p value HR p value 
Demographic information     
Black race (white race is the reference) 1.08 (0.95 – 1.23) 0.22 1.07 (0.95 – 1.22) 0.28 
Age as of 01/01/2000 1.09 (1.08 – 1.10) <0.001 1.08 (1.07 – 1.09) <0.001 
Socioeconomic status     
Median annual household income in $1,000 1.00 (1.00 – 1.00) 0.02 1.00 (1.00 – 1.00) 0.05 
% living below poverty level 1.00 (1.00 – 1.00) 0.81 1.00 (1.00 – 1.00) 0.88 
% without a high school education 1.00 (1.00 – 1.01) 0.06 1.00 (1.00 – 1.01) 0.09 
Marital status (ever married is the reference)    
Never married 1.08 (0.94 – 1.25) 0.27 1.09 (0.95 – 1.25) 0.23 
Unknown or missing 1.00 (0.88 – 1.13) 0.99 1.03 (0.91 – 1.18) 0.60 
Cancer grade (well differentiated is the reference)    
Poorly differentiated 2.03 (1.63 – 2.52) <0.001 2.14 (1.72 – 2.66) <0.001 
Undifferentiated 3.81 (2.34 – 6.21) <0.001 3.88 (2.38 – 6.32) <0.001 
Unknown or missing 2.16 (1.69 – 2.77) <0.001 2.21 (1.72 – 2.83) <0.001 
Cancer treatment (watchful waiting is the 
reference) 
    
Surgery 0.80 (0.72 – 0.90) <0.001 0.77 (0.69 – 0.86) <0.001 
Radiation 0.65 (0.59 – 0.72) <0.001 0.66 (0.60 – 0.72) <0.001 
Comorbidity index score     
Static NCICI at baseline 1.81 (1.71 – 1.92) <0.001   
Time-varying NCICI   1.77 (1.70 – 1.85) <0.001 
Proportion of necessary care received 0.57 (0.49 – 0.66) <0.001 0.53 (0.46 – 0.61) <0.001 
95% confidence intervals are in parenthesis. 
HR: hazard ratio; NCICI: National Cancer Institute Combined Index 
A survivor’s registry site is also controlled in the model (results not shown). 




The results from both models indicate that racial disparity in overall mortality was 
completely explained by other covariates (Model 2 in Table 22 is the final model shown in 
Table 21). Elder age and lower family income were predictors for higher mortality rates. In 
Model 1, the mortality risk of patients with distant prostate cancer was approximately four 
times of the risk of patients with localized or regional cancer. In addition, higher cancer 
grade was associated with higher risk of mortality. Patients receiving XRT were more likely 
to survive than those who did not have XRT. The use of necessary care, which has not been 
controlled for in previous cancer survival analysis, was a strong predictor for lower mortality 
rate. An increase in the proportion of necessary care received from 0% to 100% was 
associated with a reduction in overall mortality rate by half.  
Risk Factors for Cancer and Non-cancer Mortality 
We also identified the risk factors for cancer (Table 23) and non-cancer (Table 24) 
mortality using both Cox PH and competing-risk models. We used a PH model and treated 
survivors who died from other causes as censored cases (i.e., the approach currently used 
in the literature). Since distant stage cancer violated the PH assumption, it was treated as 
stratification variables in Model 3 to fulfill the model assumption. We compared these results 
to a competing-risk model that incorporates the dependence between the risks of cancer 
and non-cancer mortality. Both models indicated that elder age, distant cancer stage, higher 
tumor grade, and higher comorbidity score were associated with higher cancer mortality 










Table 23. Comparison of results from proportional hazards and competing-risk 
regression models examining cancer mortality 
Variable 
Model 3 Model 4 
Proportional hazards Competing-risks 
HR p value HR p value 
Demographic information     
Black race (white race is the reference) 1.10 (0.88 – 1.38) 0.38 1.09 (0.86 – 1.37) 0.49 
Age as of 01/01/2000 1.05 (1.04 – 1.07)  <0.001 1.04 (1.03 – 1.06) <0.001 
Socioeconomic status     
Median annual household income in $1,000 1.00 (0.99 – 1.00) 0.17 1.00 (0.99 – 1.00) 0.16 
% living below poverty level 1.00 (0.99 – 1.01) 0.83 1.00 (0.99 – 1.01) 0.98 
% without a high school education 1.00 (0.99 – 1.01) 0.92 1.00 (0.99 – 1.01) 0.69 
Marital status (ever married is the reference)     
Never married 0.92 (0.71 – 1.19) 0.52 0.88 (0.66 – 1.17) 0.37 
Unknown or missing 1.04 (0.82 – 1.32) 0.73 1.02 (0.80 – 1.30) 0.89 
Distant stage (local/regional stage is the reference)  7.48 (6.17 – 9.08) <0.001 
Cancer grade (well differentiated is the reference)     
Moderately differentiated 1.86 (1.09 – 3.17)  0.02 1.86 (1.08 – 3.21) 0.03 
Poorly differentiated 4.60 (2.23 – 6.76) <0.001 4.41 (2.55 – 7.63) <0.001 
Undifferentiated 9.84 (4.42 – 21.89) <0.001 11.12 (5.19 – 23.83) <0.001 
Unknown or missing 4.52 (2.57 – 7.96) <0.001 4.28 (2.41 – 7.61) <0.001 
Cancer treatment (watchful waiting is the reference) 
Surgery 0.93 (0.77 – 1.14) 0.49 0.96 (0.78 – 1.19) 0.73 
Radiation 0.83 (0.70 – 0.99) 0.04 0.92 (0.76 – 1.11) 0.38 
Time-varying comorbidity measured by NCICI 1.24 (1.13 – 1.35) <0.001 1.14 (1.03 – 1.25) 0.008 
Proportion of necessary care received 0.56 (0.44 – 0.71) <0.001 0.63 (0.49 – 0.80) <0.001 
95% confidence intervals are in parenthesis. 
HR: hazard ratio; NCICI: National Cancer Institute Combined Index 
A survivor’s registry site is also controlled in the model (results not shown). 
Distant stage is stratified in Model 3 to fulfill the PH assumptions 
 
We also compared PH and competing-risk models for non-cancer mortality. In these 
models, elder age and higher comorbidity were associated with higher risks for non-cancer 
mortality, whereas receiving surgery and more necessary care are related to lower risks. PH 
and competing-risk models yielded different results for prostate cancer stage. Although 
stage was a predictor for dying from causes other than cancer in the PH model, it was 




Table 24. Comparison of results from proportional hazards and competing-risk 
regression models examining non-cancer mortality 
Variable 
Model 5 Model 6 
Proportional hazards Competing-risks 
HR p value HR p value 
Demographic information     
Black race (white race is the reference) 1.02 (0.84 – 1.23) 0.85 1.02 (0.83 – 1.24) 0.87 
Age as of 01/01/2000 1.09 (1.08 – 1.11) <0.001 1.09 (1.07 – 1.10) <0.001 
Socioeconomic status     
Median annual household income in $1,000 1.00 (0.99 – 1.00) 0.05 1.00 (0.99 – 1.00) 0.08 
% living below poverty level 1.00 (0.99 – 1.01) 0.88 1.00 (0.99 – 1.00) 0.78 
% without a high school education 1.00 (1.00 – 1.01) 0.26 1.00 (1.00 – 1.01) 0.27 
Marital status (ever married is the reference)     
Never married   1.14 (0.91 – 1.44) 0.25 
Unknown or missing 1.16 (0.96 – 1.40) 0.13 1.15 (0.96 – 1.38) 0.14 
Distant stage (local/regional is the reference) 1.31 (1.00 – 1.71) 0.05 0.72 (0.54 – 0.98) 0.04 
Cancer grade (well differentiated is the reference)     
Moderately differentiated 1.13 (0.85 – 1.49) 0.41 1.09 (0.82 – 1.44) 0.56 
Poorly differentiated 1.36 (1.02 – 1.83) 0.04 1.23 (0.91 – 1.66) 0.18 
Undifferentiated 1.70 (0.68 – 4.27) 0.26 1.26 (0.49 – 3.22) 0.63 
Unknown or missing 1.44 (1.02 – 2.04) 0.04 1.28 (0.89 – 1.83) 0.18 
Cancer treatment (watchful waiting is the reference) 
Surgery 0.73 (0.62 – 0.86) <0.001 0.71 (0.60 – 0.83) <0.001 
Radiation   0.58 (0.50 – 0.67) <0.001 
Time-varying comorbidity measured by NCICI 2.14 (2.01 – 2.27) <0.001 2.17 (2.04 – 2.30) <0.001 
Proportion of necessary care received 0.44 (0.35 – 0.55) <0.001 0.50 (0.40 – 0.62) <0.001 
95% confidence intervals are in parenthesis. 
HR: hazard ratio; NCICI: National Cancer Institute Combined Index 
A survivor’s registry site is also controlled in the model (results not shown). 
Never married and radiation therapy are stratified in Mode 5 to fulfill the PH assumptions 
 
6.5 Discussion 
Summary of the findings 
Racial disparity in survival among prostate cancer patients has been previously 
reported in multiple studies (26, 27, 29, 30). Although time-varying comorbidities and use of 
necessary care for non-cancer conditions are potential confounders for racial disparity in 
survivor, neither of them have been controlled in previous cancer survival analyses. In our 
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study, we found that these two variables may explain part of racial disparity in mortality, 
especially in non-cancer mortality. Although the racial disparity in overall mortality was 
largely explained by racial differences in cancer disease stage, grade, treatment and SES at 
diagnosis, this racial disparity disappeared after further adjustment for a survivor’s time-
varying comorbidity score and use of necessary care. We suggest future cancer studies 
measure these two variables and control them in their survival analyses examining racial 
disparity in survival. 
In our main analysis, a time-varying NCICI score was used to control for comorbidity, 
but the results from models using a static NCICI at baseline yielded similar results. However, 
since a time-varying comorbidity score may better reflect the racial difference in risk of non-
cancer death than a static score (Chapter 4), future cancer survivorship studies should still 
consider controlling for dynamic comorbidity in their analytic models. In addition, we 
measured a patient’s comorbidity using the Charlson Comorbidity Index (CCI), which was 
commonly used in cancer survivorship studies (38). However, measuring comorbidity scores 
by either CCI or NCICI did not change the findings from our regression models. 
Although the majority of prostate cancer survivors die from causes other than cancer 
(9), non-cancer mortality has not been the focus of current cancer survivorship studies. In 
our study, we identified the risk factors for dying from cancer or other causes. Since the risks 
of cancer and non-cancer mortality are likely dependent, a competing-risk model may be 
more appropriate than a PH model. In fact, the results were very similar from PH and 
competing-risk models. The only important difference was that distant prostate cancer stage 
was a risk factor for non-cancer mortality in the PH model but a protective factor in the 
competing-risk model. Future cancer survivorship studies should adopt competing-risk 




MedPAC has used the ACE-PRO indicators to study the access to and quality of 
care among Medicare beneficiaries (64). However, MedPAC has never investigated whether 
more use of necessary care in the ACE-PRO indicators is associated better health 
outcomes. To our knowledge, this study is the first one to control for a patient’s use of 
necessary care in cancer survival analyses. Across different models, we found that more 
use of care is consistently associated with longer survival. Although this variable is intended 
to measure the use of necessary care for non-cancer comorbidities, it may be a good proxy 
for a patient’s quality of cancer care. Therefore, more use of necessary care was associated 
with not only a lower cancer mortality rate but also a lower non-cancer mortality rate. Since 
use of necessary care is a potentially modifiable factor, policy makers and health care 
providers should encourage cancer patients to receive more necessary care for their non-
cancer comorbidities to improve survival. 
Limitations 
The main design issues of this study are related to the limitations of administrative 
datasets. The results of this study may not be generalizable to non-SEER regions because 
Medicare beneficiaries living in the SEER regions are less likely to be white, live in poverties, 
reside in rural areas, and enroll in managed care plans (70). Since we only included prostate 
cancer survivors who were diagnosed in 2000, the results may not be generalized to 
survivors diagnosed in a different year. In addition, Medicare beneficiaries who were 
diagnosed with cancer before age 67 were excluded from our analyses because we are 
unable to obtain their claims data before Medicare enrollment. Thus, the findings from our 
study may not be generalized to younger prostate cancer patients. The results from our 
study may not be generalized to HMO enrollees who are excluded from our analyses 
because information about their medical care is not available. Since risk factors, treatment 
options, and survival rates vary by types of cancer, different cancers may have different 
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influence on comorbidities. Therefore, the results from our study of prostate cancer may not 
be generalized to other types of cancer patients. 
Similar with our previous two studies (i.e., Chapters 4 and 5), we used a fixed time 
frame to measure NCIC score for every patient. For a survival analysis, this approach was 
not as precise as measuring the comorbidities by using individual patient’s cancer diagnosis 
date. For example, the NCICI score on December 31st, 1999 may not fully capture the 
baseline comorbidities of a patient who was diagnosed with prostate cancer on July, 1st, 
2000. In addition, the composite score for use of necessary care was also measured by a 
fixed time frame (i.e., every two calendar years). Therefore, the composite score may not 
truly reflect how care was received right before a patient’s death. Measuring the use of 
necessary care in every two-year interval prior to a patient’s death might be a better 
predictor for mortality than our current approach. Despite the potential limitation related to 
using a fixed time frame for every patient, we believe that the influence of this measurement 
issue should not differ by race. Thus, our findings of racial difference in mortality are still 
robust. 
Due to data limitations, there was potential for omitted variable bias in our analysis 
(99). Health status, a variable that is associated with health care utilization and mortality, is 
not collected in the SEER-Medicare data. A patient with poor health status may be too sick 
to receive necessary ambulatory care and have a high likelihood of dying. Since we were 
not able to control for health status in our analytic model, the observed HR for use of 
necessary care may be inconsistent. However, since race is exogenous and the relationship 
between health status and mortality should not differ by race, we believe that the HR of race 
is still valid. In the future, prospective studies collecting health status information are 




Racial disparity in survival is also observed among survivors with other survivable 
cancers (e.g., breast or colorectal cancer (8, 9)). Future studies are necessary to examine 
whether the racial disparity remains after additional adjustment for time-varying 
comorbidities and use of necessary care. We also suggest future studies to adopt 
competing-risk models, rather than PH models, to identify risk factors for dying from either 




CHAPTER 7. STUDY LIMITATIONS AND FUTURE RESEARCH AGENDA 
 
7.1 Summary of Findings 
This dissertation examined the dynamics of diagnosis and use of necessary care for 
comorbidities in Medicare beneficiaries with prostate cancer, the most prevalent cancer 
among elderly men in the United States. Previous cancer survivorship studies of prostate 
cancer measure comorbidity cross-sectionally, either at the index date or at a certain time 
point after cancer diagnosis. In addition, although the majority of prostate cancer survivors 
die from causes other than cancer, little is known about the use of necessary care for non-
cancer comorbid conditions among this population. This dissertation sought to examine 
whether survivors are more likely to be diagnosed with comorbidities after their prostate 
cancer diagnosis. In addition, to our knowledge, this study is the first one to examine a wide 
range of quality of care indictors for non-cancer conditions among prostate cancer survivors. 
We further examined whether use of necessary care, a potential modifiable factor, is 
associated with mortality rates and whether it changes the relationship between racial and 
survival among prostate cancer survivors. 
In Chapter 4, we found that more comorbid conditions were identified after cancer 
diagnosis. The prevalence rates of comorbidities and overall comorbidity scores of prostate 
cancer survivors increased at a faster rate after their cancer diagnosis than those rates 
observed among individuals without cancer during the same time periods. In addition, we 




cancer diagnosis. Survivors made more office visits not only to their prostate cancer 
specialists (including urologists) but also to their primary care physicians after the cancer 
diagnosis. Although we hypothesized that cancer specialists, by virtue of their increased 
contact with survivors, might provide primary care for other health conditions, the majority of 
newly diagnosed comorbidities after cancer were identified by PCPs, rather than by prostate 
cancer specialists. Therefore, a diagnosis of prostate cancer may provide a chance for 
some patients who were not previously engaged in the health care system to have regular 
contact with their PCPs, which increases the likelihood of finding other health conditions. 
In Chapter 5, we found that prostate cancer survivors consistently used more 
necessary care than individuals without cancer did. Although the difference in use of 
necessary care existed even before cancer diagnosis, the magnitude of difference became 
larger after cancer diagnosis. It is possible that prostate cancer was diagnosed because 
cancer survivors already had more contact with their health care providers before their 
cancer diagnosis than individuals without cancer had. After cancer diagnosis, more 
survivors started to make regular visits to their care providers and received more care from 
them. Therefore, a diagnosis of prostate cancer may represent “a wake-up call” for elderly 
men to be engaged in the health care system. 
Although the use of necessary care among survivors substantially improved after 
cancer diagnosis in 2000, it surprisingly dropped between 2004 and 2005 but increased 
back between 2006 and 2007. Although this finding might be partly explained by the data 
error in 2004 physician claims, a potential explanation is the enactment of Medicare 
Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). The MMA reduced 
the reimbursements for Medicare Part B chemotherapy drugs from 95% of average 
wholesale prices in 2003 to 80-85% in 2004 (97). In 2005, the reimbursements were further 
reduced to 106% of average selling prices which tend to be substantially lower than the 
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average wholesale prices (97). To compensate the potential loss, the MMA also increased 
the reimbursements for administration services of chemotherapy provided by oncologists 
substantially (97, 98). However, the increases in reimbursements for corresponding services 
provided by urologists were much smaller (97, 98). Therefore, it is possible that some 
urologists may limit the number of Medicare patients they see and send their patients to 
hospital. Since some patients may feel inconvenient to receive their care from hospital, their 
adherence to therapy could decrease (98). Therefore, the implementation of MMA may limit 
a survivor’s access to urologists, who tend to provide a large proportion of health care for 
prostate cancer survivors (Chapter 4). In 2006, urologists were allowed to obtain 
chemotherapy drugs for their patients from a third party contractor through a process called 
competitive acquisition (97, 98). This policy change may explain the improvement in use of 
necessary care from 2004-2005 to 2006-2007. 
In Chapters 4 and 5, we found that a diagnosis of prostate cancer may have positive 
effect on both detection and management of non-cancer comorbidities. These findings are 
especially true for black cancer survivors. Black cancer survivors consistently had higher 
prevalence rates of comorbidities and NCICI scores than white survivors, meaning that they 
had a higher risk of dying from causes other than cancer than white cancer survivors. 
However, the racial differences became larger after prostate cancer diagnosis. Although 
black men generally have more comorbidities than white men (32, 91, 92), it is also possible 
that more previously underdiagnosed comorbidities were detected after cancer diagnosis 
among black survivors than among white survivors. However, black patients consistently 
received less necessary care for their comorbid conditions, regardless of whether they were 
cancer survivors or not. Interestingly, we found that this racial disparity decreased after 
cancer diagnosis because black prostate cancer survivors improved their overall use of 
necessary care. The main reason for this finding is likely that more black survivors began to 
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have more regular office visits to their physicians after cancer diagnosis. Therefore, a 
prostate cancer diagnosis may create an important opportunity for black men to be more 
aware of their health and to obtain necessary care for comorbid conditions. 
In Chapter 6, we found that racial differences in comorbidities and use of necessary 
care may explain some of racial disparity observed in mortality, especially in non-cancer 
mortality. Although the disparity in overall mortality was largely explained by racial 
differences in cancer disease information (i.e., stage, grade, and treatment) and SES, racial 
disparity disappeared after further adjustment for comorbidities and use of necessary care. 
In addition, we found that more use of care consistently was associated with longer survival. 
Although this measure of care is intended to evaluate the use of necessary care for non-
cancer comorbidities, it may be a good proxy for a patient’s quality of cancer care. Therefore, 
more use of necessary care was associated with not only a lower cancer mortality rate but 
also a lower non-cancer mortality rate. Further prospective studies are necessary to further 
investigate whether there is causal relationship between use of necessary care and mortality 
among cancer survivors.  
Although the benefit of diagnosing localized or regional prostate cancer at an early 
stage remains controversial, diagnosis of prostate cancer at an early stage may have some 
unexpected positive effects on non-cancer comorbidities. In this study, a diagnosis of 
prostate cancer was associated with not only more detection of comorbidities but also more 
use of necessary care for these conditions. These above findings were especially true 
among black survivors. Therefore, researchers should not only examine the cancer-related 
health outcomes but also consider the relationship between prostate cancer and detection 
and management of comorbidities when they evaluate the overall benefit of prostate cancer 
screening. 
7.2 Study Limitations 
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7.2.1 Data Issues 
The main limitations of this study were similar to those observed in observational 
studies using administrative datasets. The results of this study may not be generalizable to 
non-SEER regions because Medicare beneficiaries living in the SEER regions are less likely 
to be white, live in poverty, reside in rural areas, and enroll in managed care plans (70). 
Medicare beneficiaries who were diagnosed with cancer before age 67 were excluded from 
our analyses because we were unable to obtain their claims data before Medicare 
enrollment. Therefore, the findings from our study may not be generalized to younger 
prostate cancer survivors. The results from our study also may not be generalized to HMO 
enrollees who were excluded from our analyses because information about their medical 
care was not available. Since risk factors, treatment options, and survival rates vary by types 
of cancer, different cancers may have different influence on the rates of and severity 
associated with various comorbidities. Therefore, the results from our study may not be 
generalizable to survivors of other types of cancer. 
In this study, we selected patients diagnosed with prostate cancer in 2000 because 
they are the most recent cohort for which we had sufficient data. In sensitivity analysis, we 
used patients who were diagnosed with prostate cancer in 1997 and applied the same study 
design. The main findings of this dissertation were unchanged, except for the use of 
necessary care between 2004 and 2005. The use of care among the 1997 cancer cohort did 
not drop substantially in Period 3 as what we observed among the 2000 cancer cohort. 
Therefore, this finding supports our explanation that the change in use of care between 
2004 and 2005 might be associated with the data error in 2004 physician claims or the 
implement of MMA.  
Due to data limitations, we were unable to observe the diagnosis of comorbidities 
before a patient enrolled in the Medicare program at age of 65. In Aim 1, it is likely that our 
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study underestimated the true prevalence of each chronic condition. However, we expect 
that this problem has a similar influence on both the cancer and non-cancer groups. In Aim 
2, the time of a disease’s first diagnosis is critical for many of the refined ACE-PRO 
indicators, especially for initial work-up indicators. Since we were unable to observe the 
diagnosis of comorbid condition before age of 65, the first diagnosis of a comorbid condition 
that we observed in the Medicare claims may not be the true initial diagnosis. Our findings 
may be biased if patients receive more/less care for their true initial diagnosis before 65 than 
for their first diagnosis after 65. However, we expected that this type 1 error has a similar 
effect on the cancer and non-cancer groups.  
7.2.2 Design Issues 
The CCI and NCICI scores represent an aggregated weight of chronic conditions 
observed in insurance claims. Specifically, although the severity of a disease may vary 
across patients, the severity of patients diagnosed with same type of diseases is weighted in 
the same way. Without a detailed review of patient medical records, we were unable to 
differentiate the severity of the disease among individuals. In addition, we assumed that 
comorbid conditions were incurable when we measured cumulative comorbidity prevalence 
and severity. This assumption may be more appropriate for some diseases (e.g., COPD and 
diabetes) than others (e.g. peptic ulcer and hypertension). For example, some patients with 
a history of hypertension may have normal blood pressure through diet control or regular 
exercise. Therefore, we might overestimate the comorbidity prevalence and severity. 
However, we expected the influence of this assumption to be similar among both cancer and 
non-cancer groups.  
The ACE-PRO indicators were originally developed to measure underuse of 
necessary care. Fulfilling the requirement of an indicator does not guarantee optimal use of 
care, however. For example, some patients who overused necessary care may still be 
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classified as using appropriate care by the ACE-PRO indicators. Further studies are 
necessary to develop measures for detecting overuse or misuse of necessary care. In 
addition, the majority of the refined ACE-PRO indicators measure quality of care by 
examining whether a patient visited to his care providers when necessary. However, the 
indicators do not evaluate whether this patient received necessary examine or treatment 
during his visit. In addition, none of the refined ACE-PRO indicators measures the quality of 
care by evaluating a patient’s health outcomes. Since results from laboratory tests are 
generally unavailable in claims data, it is not possible to link the results from ACE-PRO 
measure to intermediate health outcomes. Therefore, further studies are necessary to 
assess a survivor’s quality of care using his medical record. Finally, when we calculated 
composite scores to evaluate the use of care, the indicators of necessary care were not 
weighted. However, some indicators may play more important roles for a patient’s health 
than others, and therefore were not reflected in the ACE-PRO composite. 
When we calculated comorbidity prevalence and severity in Aim 1, we only included 
individuals who remained alive at a specific time point. In Aim 2, individuals who died during 
a time period were excluded because the ACE-PRO indicators were developed to measure 
the use of care for those who remained alive during the entire two-year time frame. 
Therefore, we may observe a “survivor effect” in Aims 1 and 2. In other words, those who 
are alive at a time point may be healthier (i.e., fewer comorbidities) than those who die 
before that point. We assumed that cancer and non-cancer patients who died during the 
study periods were un-informatively censored (i.e., death during follow up is independent 
with use of care). The effect of uninformative censoring assumption should be minor 
because the five-year relative survival rate of localized or regional prostate cancer patients 
is approximately 100% as compared with the non-cancer population (9). Therefore, we 
expected the survivor effect to be similar between cancer and non-cancer groups. In 
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sensitivity analyses, we restricted our samples to those who survived during the entire study 
time frame and obtained similar results as the findings from our primary analyses. 
In Aim 3, there was potential for omitted variable bias due to data limitations (99). 
Health status, a variable that is associated with health care utilization and mortality, is not 
collected in the SEER-Medicare data. Patients with poor health status may be too sick to 
receive necessary ambulatory care and be more likely to die than those with good health 
status. Since we were not able to control for health status in our analytic model, the use of 
necessary care may have endogeniety issue (99). Therefore, extra caution is necessary 
when interpreting the observed HR of use of necessary care. However, since our key 
independent variable, race, is exogenous and the relationship between health status and 
mortality should not differ by race, we believe that the potential for omitted variable bias 




7.3 Future Research Agenda 
The findings and the limitations of this dissertation suggest some potential directions 
for future research. Specific directions for future studies are listed in Table 25.  
 
 
Table 25. Directions for future research 
Other cancers  Examine detection of comorbidities longitudinally 
 Examine use of care for comorbidities longitudinally 
 Survival analysis 
 Control for use of care 
 Report proportional hazards assumptions 
 Control for time-varying comorbidities 




 Include younger survivors 
 Identity comorbidities diagnosed prior to 65 
 Differentiate severity among patients with the same disease  
 Identify overuse or misuse of types of care 
 Measure quality of care for other types of care 
 Procedure (e.g., prescription drug) 
 Outcomes (e.g., lab data) 
 
Use of care  Use the refined ACE-PRO indicators  
 Develop a shorter version 
 Evaluate the use of care among patients with a certain disease 
 Examine the influence on other health outcomes 
 Examine the influence on medical expenditures 
 
MMA  Examine the influence MMA on: 
 Services provided by urologist (e.g., workload) 
 Prostate cancer patients’ other treatments (e.g., incontinence) 
 Other patients treated by urologists (e.g., bladder cancer patients) 
ACE-PRO: Access to Care for the Elderly Project 
MMA: Medicare Prescription Drug, Improvement, and Modernization Act of 2003 
 
One of the most important future directions is to conduct similar studies among 
survivors diagnosed with other highly survivable cancers. For example, patients diagnosed 
with localized breast or colorectal cancer have very high 5-year relative survival rates (>90%) 
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(9). Although co-existing comorbidities also play an important role for these survivors’ health, 
the longitudinal relationships between these cancers and the detection and management of 
non-cancer health conditions have not been fully investigated. Applying the study design of 
this dissertation to other cancer survivors allows us to determine whether the potential 
positive effect of cancer diagnosis on non-cancer comorbidities is unique to prostate cancer 
survivors. Similarly, racial disparity in survival is also observed among survivors with breast 
or colorectal cancer (9).  
We have some methodological suggestions for future studies examining racial 
disparity in survival among cancer survivors. First, researchers should always test 
proportional hazard (PH) model assumptions and report their solutions for the violated 
assumptions. In addition, instead of a fixed comorbidity score at cancer diagnosis, future 
studies should control for a time-varying comorbidity score which may better reflect the 
dynamic nature of the risk of dying from causes other than cancer. In addition, future studies 
should control for use of necessary care which is a strong predictor for longer survival in our 
study. Finally, we suggest future studies to adopt competing-risk models, rather than PH 
models, when the outcome of interest is either cancer or non-cancer mortality, since the 
risks of dying from cancer or other causes are likely dependent. 
We also recommend future studies to use medical records to investigate 
comorbidities among cancer survivors. Although studies using medical records generally 
have lower external validity than studies using nationwide claims data, medical records have 
several advantages over Medicare claims. First, researchers will be able to include younger 
survivors and identify comorbidities which were diagnosed before age of 65. Second, 
medical records may provide enough information to differentiate the severity of the same 
disease among individuals. Third, a survivor’s overall quality of care may be examined 
comprehensively through medical records. Researchers may identify not only underuse but 
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also overuse and misuse of necessary care. Fourth, researchers will be able to measure 
whether a patient receives necessary physical exam or treatment (e.g., prescription drug) for 
his comorbidities. Finally, future studies may assess a patient’s health outcomes by 
reviewing his laboratory report in medical record. 
The Medicare Payment Advisory Commission (MedPAC) uses the refined ACE-PRO 
indicators to study the access and the quality of care among Medicare beneficiaries, and 
uses the results of these analyses in their reports to Congress (64). However, no previous 
published studies have used these indicators to examine use of care. Although the ACE-
PRO (40 items) covers broad ranges of disease group and type of care, evaluating each 
indicator and calculating an overall composite score for use of care require a lot of time and 
computing codes, which are not available directly from MedPAC. To promote the use of 
ACE-PRO for future research, efforts are necessary to shorten the measurement without 
hurting its internal validity. In addition, the ACE-PRO is primarily used to examine the 
geographic and socioeconomic variations in use of care (64). Future studies are necessary 
to investigate whether patients with a certain disease (e.g., Alzheimer’s disease) tend to use 
less necessary care than the general Medicare beneficiaries, and to further evaluate 
whether use of care is associated with survival. Finally, we suggest future studies to 
examine the longitudinal relationship between use of necessary care and medical 
expenditures and other health outcomes. 
Future studies are needed to examine the impact of MMA on the services provided 
by urologists who tend to be affected by the new policy the most. It is important to examine 
not only whether urologists saw fewer prostate cancer survivors between 2004 and 2005 but 
also whether prostate cancer survivors received less care for their non-cancer conditions 
(e.g., incontinence) from urologists after MMA. Finally, we suggest future studies to 
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investigate the potential influence of MMA on the quality of care and health outcomes in 
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